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Acquired heart disease, which includes conditions such as coronary artery disease (CAD) 
and heart failure, continues to pose a large impediment on the individuals that suffer 
from it as well as on society in general. CAD is the leading cause of death in the Western 
world, and the burden of CAD continues to rise in developing countries[1]. Heart failure is 
a chronic disease with frequent, costly re-hospitalizations[2]. The majority of heart failure 
cases results from CAD[1].
Overall, it has been estimated that by the year 2020, nearly 20.5 million deaths worldwide 
will be due to cardiovascular disease. Predictive thinking plays a fundamental role in 
prevention of adverse cardiac events, and the improvement of our ability to make accurate 
predictions is one of the driving forces behind clinical research. Focusing on patients with 
acquired heart disease for prevention of recurrent cardiac events and mortality may 
contribute to efficient healthcare, because these patients are at high risk of needing 
medical attention and may benefit most from additional treatment. This thesis overarches 
several disciplines, including methodology of prediction modelling, laboratory assessment 
and cardiovascular imaging, in order to evaluate and improve clinical outcome prediction 
in patients with known, acquired heart disease. 
The purpose of this thesis was three-fold:
I. To perform a critical appraisal  of the methodology behind existing prediction models 
for both fatal and non-fatal adverse cardiac events in patients with CAD.
 Multiple prediction models have previously been developed for patients with CAD, 
However, statements on a patient’s individual prognosis remain challenging. We 
investigated the following research questions:
• Which are the limitations of existing prediction models?
• How could existing prediction models be improved?
II. To investigate novel predictors for both fatal and non-fatal adverse cardiac events 
which may play a role in CAD. 
 Existing prediction models mostly use established risk factors. However, these do not 
explain a substantial proportion of adverse cardiac events. Inflammation has been 
recognized as an important pathophysiological mechanism contributing to CAD. The 
role of C-reactive protein in CAD had been examined extensively. Much less is known 
about the role of cytokines, chemokines and acute phase proteins, which are also 
involved in the inflammatory process. The research questions we examined were:
• Are cytokines, chemokines, and acute phase proteins associated with cardiovascular 
outcome?
• Are cytokines, chemokines, and acute phase proteins associated with the extent and 
composition of  coronary atherosclerosis as assessed by intravascular ultrasound?
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III. To assess diagnostic and predictive value of biomarkers for adverse cardiac events in 
patients with heart failure, and for acute allograft rejection in patients who received a 
donor heart. 
 Due to improved treatment of cardiac disease, patients currently survive longer after 
the initial manifestation of CAD. However, survivors are often left with damaged 
myocardium resulting in left ventricular dysfunction and, potentially, clinical heart 
failure. Blood biomarkers are potentially valuable tools in risk stratification of these 
patients. The following research questions were defined:
• Which biomarkers play a role in patients with heart failure with normal ejection 
fraction?
• Are repeatedly measured NT-proBNP, cardiac troponin T and/or CRP associated with 
acute allograft rejection in heart transplant recipients?
The outline of this thesis is as follows. Part II focuses on prediction models of both fatal 
and non-fatal adverse cardiac events in patients with established, stable CAD. An overview 
of the existing prognostic models for the prediction of fatal endpoints in patients with 
established, stable CAD is presented in Chapter 2. We discuss the strengths and weaknesses 
that underlie the statistical analyses which were applied to assess model performance. 
Furthermore, we develop and validate a series of risk prediction models for both fatal and 
non-fatal endpoints in a large prospective cohort of European patients with established CAD, 
making use of the EUROPA database[3]. In Chapter 3, we present an alternative for clinical 
decision-making in individual patients, so-called micro-simulation [4]. Micro-simulation 
replicates individual patient histories, and may thus inform physicians by estimating the 
most likely outcomes regarding a broad range of clinical events. Subsequently, we develop 
a new micro-simulation software package which is applicable for prognostic modeling in 
patients with established CAD.
Part III focuses on inflammatory agents for the prediction of cardiovascular outcome[5], as 
well as the extent and composition of coronary atherosclerosis in patients with acquired 
heart disease [6, 7]. In Chapter 4 we describe several signaling cascades of biomarkers 
implicated in the pathogenesis of atherosclerosis, and the utility of these biomarkers to 
improve the prediction of clinical events, and the extent and vulnerability of coronary 
atherosclerosis as determined by virtual histology (VH)- intravascular ultrasound (IVUS)
[8]. In this context, we consecutively evaluate cytokines, chemokines, and acute phase 
proteins. In Chapter 5, we study whether there are differences in extent and composition 
of coronary atherosclerosis between smokers and non-smokers.
In Part IV, we provide an overview of blood biomarkers that have been found to be associated 
with the occurrence and prognosis of heart failure with normal ejection fraction (Chapter 
6). Furthermore, we examine diagnostic and predictive value of the biomarkers NT-pro-B-
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1
type natriuretic peptide (NT-proBNP), cardiac troponin T and C-reactive protein (CRP) for 
allograft rejection in patients that have undergone heart transplantation(Chapter 7). In 
examining predictive value, we apply sophisticated methods for repeated measurements 
data analysis known as joint modelling [9].
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ABSTRACT
Background: Installment of appropriate measures to prevent adverse events in 
patients with established, stable coronary artery disease (CAD) may contribute to 
efficient healthcare. This review gives an overview of existing models for prediction 
of cardiovascular adverse events in such patients and discusses model performance.
Methods: We used a computerized literature search in the EMBASE, PubMed publisher, 
MEDLINE, Google Scolar, Web of Science and Cochrane databases. Studies were 
selected if they included patients with stable CAD (stable angina pectoris, myocardial 
infarction more than 3 months ago or coronary intervention more than 6 months ago) 
and if they presented a model that included mortality as the endpoint. 
Results: Sixteen studies met our inclusion criteria. Clinical variables that were 
included in the models differed highly between the studies. Still, age, smoking status, 
hypertension, diabetes, cholesterol and heart failure were present in a large part of 
the models. Several studies examined model discrimination, but the majority paid 
insufficient attention to calibration and validation.
Conclusions: Although multiple prediction models for adverse events have been 
developed in patients with stable CAD, variables included in these models display large 
heterogeneity, and model performance is often insufficiently addressed.    
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2.1
INTRODUCTION
Coronary artery disease (CAD) is the leading cause of death in the Western world, and 
the burden of CAD continues to rise in developing countries(1). It has been estimated 
that by the year 2020, nearly 20.5 million deaths worldwide will be due to cardiovascular 
disease (1). This trend may be altered by installing additional preventive measures. For this 
purpose, appropriate risk stratification tools should be available. As such, a large number 
of risk prediction models and risk charts have been developed in the field of cardiovascular 
disease, both for primary prevention and for secondary prevention (2-4). 
Secondary prevention, or prevention of mortality and recurrent events in patients with 
established CAD, may contribute to efficient healthcare, because these patients are at 
risk of needing medical attention and may benefit most from additional treatment (5). 
Appropriate risk stratification in this population may identify patients that could be 
followed-up more closely, may be treated more aggressively, and whose compliance to 
prescribed drugs may be monitored more carefully, in order to prevent recurrent events. 
Furthermore, patient awareness of the magnitude of their risk for having a recurrent event 
might enhance their compliance to prescribed medication (6) and may also stimulate 
lifestyle changes (6).Therefore, there is a great need for adequate prediction models that 
assess long-term risk of adverse cardiovascular events in patients with stable CAD. Such 
models, designed specifically for stable patients with established CAD are scare.
The purpose of this review is to give an overview of the existing prognostic models for 
the prediction of sudden cardiac death, cardiovascular mortality and all-cause mortality 
in patients with established, stable CAD. An overview of model performance will be given. 
Moreover, the strengths and weaknesses that underlie the statistical analyses which were 
applied to assess model performance will be addressed.
METHODS
On 1 September 2013 we performed a literature search using  EMBASE, PubMed publisher, 
MEDLINE, Google Scolar, Web of Science and Cochrane for studies which included patients 
with stable, established coronary artery disease and developed a prediction model or risk 
stratification model for long-term predictions of sudden cardiac death, cardiovascular 
mortality, and all-cause mortality. We defined patients who had stable coronary artery 
disease at inclusion as those that had stable angina pectoris, those that had experienced a 
myocardial infarction more than 3 months ago, or those that had undergone a percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG) more than 6 months 
ago(7, 8). Only studies which examined one or more of the endpoints sudden cardiac 
death, cardiovascular mortality, all-cause mortality, or mortality in combination with 
one or more non-fatal cardiovascular endpoints, were selected. We limited our search to 
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articles written in English.  The search strategy is described in detail in the appendix. A total 
of 3672 articles were obtained, and their titles and abstracts were screened for relevance. 
Another 3 articles were added by searching the reference lists for relevant articles,
Based on title and abstract, 202 articles were selected that apparently met our inclusion 
criteria. Articles were subsequently excluded: when the study included patients with 
merely suspected CAD, alone or in combination with established CAD; when the main 
outcome was limited to short-term (in-hospital) mortality only; when patients with LVEF 
< 40% or arrhythmias were included;  when only patients with specific cardiovascular risk 
factors such as hypertension or diabetes were selected; or when the research question 
was limited to the prognostic value of a specific variable (e.g., a blood biomarker), without 
presentation of a complete risk stratification model. After reading the full articles, 16 
publications remained, and were included in this review (figure 1).
3672 records identified 
through database 
searching
3 additional records 
identified through 
the reference lists
3675 records screened 3473 records excluded
202 full-text articles 
assessed for eligibility
186 full-text articles 
excluded:
20 included suspected 
CAD
50 conference abstracts
45 MI <3 months or 
intervention <6 months 
after inclusion in study
7 public health studies
11 patients with a 
certain risk factor
6 patients with 
vascular disease other 
than cardiovascular
20 specific interest in 
only one particular 
predictor 
27 other
16 studies included in 
review
Figure 1. Flowchart showing the number of abstracts identified by the search, the number of full texts which 
remained, and the number of studies included in the review.
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2.1
RESULTS
A total of 16 risk prediction models were found. Sample sizes were generally large, ranging 
up to 37,258 (9) patients, with a mere 4 studies consisting of less than 1000 patients 
(10-13). Table 1 shows the inclusion criteria, the mean follow-up time and the primary 
endpoints of the included studies. 
Study design
Of the 16 studies we found, one study collected data retrospectively from medical 
records (14). One study was designed as a survey analysis(15). Fourteen studies had a 
prospective design (9-13, 16-24), eight of which were clinical trials. These clinical trials 
tested the effectiveness of  perindopril versus placebo (16, 17), pravastatin versus placebo 
(20), atenolol, nifedipine or a combination of both(13), trandolapril versus placebo(21), 
nicorandil versus placebo(22), atorvastatin versus placebo(23)  and nifedipine versus 
placebo(24).
Patient population
Four studies included patients with clinically diagnosed stable angina pectoris (13, 19, 22, 
24). Two studies included patients with stable angina pectoris as well as a certain degree of 
stenosis on angiography (9, 18). Two studies included patients with a confirmed diagnoses 
of MI in the last 3 years(11, 20), and one study included patients 5  years after a CABG (10). 
The remaining studies used various combinations of criteria to define established CAD (12, 
14-17, 21, 23). 
Outcomes
Most of the studies aimed to predict the risk of cardiovascular mortality(10, 14-16, 20, 23), 
all-cause mortality (11, 12, 24), or sudden cardiac death(9, 21) with a median follow-up 
duration after inclusion up to 11.3 years(12). Some of these studies additionally examined 
separate, non-fatal outcomes such as MI or stroke (11, 16, 20, 24). One study used the 
combined endpoint of all-cause mortality and MI (19), and five studies uses the combined 
endpoint cardiovascular mortality and MI (10, 13, 17, 18, 22). The incidence rates of the 
endpoints which were examined ranged between 0.3 (21) and 13.8 (11) percent per year 
(table 1)
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2.1
Variable selection and content of ensuing models 
Table 2 displays the variables included in the 16 prediction models. All studies applied Cox 
proportional hazard regression. Variables contributing to the prediction of the endpoint(s) 
were selected using the stepwise backward method (11, 14, 16, 17, 21), or the stepwise 
forward method(9, 10, 13, 22-24), and two studies applied both methods(12, 19). Schnabel 
et al. (18) did not use a variable selection procedure; they constructed their model from the 
ESC SCORE risk factors. Ingle et al. (15) did not use a variable selection procedure either; 
they constructed their model from the Framingham risk factors and included further novel 
predictors. Cui et al. (20) considered a variety of risk models with and without laboratory 
data without using variable selection.
Only gender (12, 14-16, 22) or both age and gender (9, 10, 13, 19) were absent in many of 
the risk prediction models we reviewed. Presence of the clinical variables age (11, 12, 14-
18, 20-24), diabetes (9, 10, 12, 14-20, 23, 24), hypertension (9, 17, 18, 20, 23, 24), smoking 
(9, 14-18, 20, 22, 23), cholesterol (11, 14-18), heart failure (9, 12, 13, 16, 19, 21, 24), and 
heart rate (12, 22) in the models differed among the studies.
Several studies included routinely used laboratory biomarkers for long-term prediction. 
Ingle et al. (15) examined whether addition of CRP to clinical variables improved model 
discrimination. Goliasch et al. (12) hypothesized that biomarkers representing renal and liver 
functions might be useful to add to the prediction model, because these may be influenced 
by the set of drugs that CAD patients receive. Of these biomarkers, only cholinesterase 
was an independent predictor for all-cause mortality. Schnabel et al.(18) examined the 
prognostic ability of 12 biomarkers in the prediction of cardiovascular endpoints. They 
used classical cardiovascular risk factors to derive the primary risk categories, and assessed 
the added value of the selected biomarkers. They showed that adding NT-proBNP, GDF-15, 
MR-proANP, cystatin C, and MR-proADM to the models provided incremental value. Mora 
et al. (23) investigated determinants of risk in the Treating to New Targets (TNT) study, a 
clinical trial that randomized patients to atorvastatin 80 or 10 mg/d. They concluded that 
high-dose statin use and baseline apolipoprotein A-I were determinants of decreased risk 
for cardiovascular events, while baseline apolipoprotein B and blood urea nitrogen were 
determinants of increased risk.
Clayton et al. (24) included modifiable, procedural, and laboratory variables in their 
multivariate analysis. Of the laboratory variables, white blood cell count, glucose and 
creatinine were independent predictors of the combined endpoint all-cause mortality, MI, 
or stroke. 
Eight studies developed risk scores based on the prediction models they described (table 
3). These risk scores were usually based on points systems, and could serve as a means for 
making the above-described risk prediction models useful to clinicians.
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Table 2.Overview of variables included in the prediction models resulting from the studies.
Variable STUDY
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6
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01
2
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8
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gl
e,
 2
01
3
M
cM
ah
on
, 2
00
5
M
or
a,
 2
01
2
Sc
hn
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el
, 2
01
0
Age 0 1 0 1 1 1 0 0 1 1 1 1 1 1 1 1
Gender 0 1 0 0 1 1 0 0 0 1 0 1 0 0 1 1
Race 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Hypertension 0 0 1 0 1 1 0 0 0 1 0 0 0 0 1 1
Heart rate 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0
Smoking status 0 0 1 1 0 1 0 0 1 1 0 0 1 1 1 1
Diabetes Mellitus/ blood glucose 1 0 1 1 1 1 0 1 1 1 1 0 1 0 1 1
Cholesterol 0 1 0 1 0 0 0 0 1 1 0 0 1 0 0 1
BMI+ 0 0 0 1 0 1 0 0 0 1 0 0 0 0 1 1
Peripheral vessel disease 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Angina Pectoris 0 0 0 0 0 1 0 1 0 1 0 0 0 1 0 0
Prior CHD/revascularization 0 0 0 1 1 1 1 0 0 1 0 0 0 1 1 0
Prior stroke/TIA 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0
Congestive heart failure/LVEF++ 0 0 1 1 1 0 1 1 0 0 1 1 0 0 0 0
Renal disease/renal function 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0
Family history CAD 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Comorbidity 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Cardiac medication use 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 0
Laboratory findings 0 0 0 0 1 0 0 0 0 0 1 0 1 0 1 1
Priority PCI% /CABG* 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0
Multivessel disease/ no. of diseased vessels 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1
ECG findings # 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0
Ischemia/ perfusion defects at SPECT 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Physical activity 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
Change number of risk factors 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Exercise test results/ST segment changes 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
Echographic findings 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0
+ BMI =  Body Mass Index; ++ LVEF = Left Ventricular Ejection Fraction; % = PCI = Percutaneous Coronary Intervention; 
* = CABG= Coronary Artery Bypass Grafting; # ECG = electrocardiography
Performance assessment
Performance assessment of risk stratification models and prediction models is essential, 
since they are meant to support decision making in clinical practice or to provide 
prognostic estimates (25). Several methods are available to examine model performance 
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and to evaluate the quality of the predictions (26), including measures of discrimination 
and calibration as well as overall performance measures. Table 3 displays the various 
performance measures which were used in the studies we reviewed.
Calibration
The Hosmer-Lemeshow test is one of the traditional performance measures which 
compares observed to predicted outcome, often by deciles of predicted probability, thus 
testing calibration. Only 6 of the 16 studies described model calibration. Atwater et al.(9), 
Battes et al.(16), Clayton et al. (24), Cui et al. (20), Deckers et al.(17), and Mora et al. (23) 
used the Hosmer-Lemeshow plot. In all six studies the agreement between observed and 
predicted mortality rates was adequate. 
 
Discrimination
Discrimination refers to the ability of a model to discriminate between those with and 
those without the outcome of interest. Calculating the concordance ( c) statistic or the 
area under the receiver operating characteristic (ROC) curve (AUC) is the method which 
is applied most often for this objective(26). Ten of the 16 studies used this method, the 
remaining six studies did not quantify the discriminative abilities of their model. Cui et 
al.(20), Goliasch et al.(12), Mora et al.(23), and Daly et al. (19) used the Harrell’s C-statistic, 
which approximates the AUC. (27) C statistics ranged from 0.66 for the model of Cui et 
al.(20), which predicted cardiovascular mortality, MI or stroke in patients who had an acute 
MI or were hospitalized for unstable AP in the last 3 years (n=5654), to 0.77 for the model 
of Goliasch et al. (12) which predicted all-cause mortality in patients with stable CAD 
(n=547) defined as angiographical evidence of stenosis of an epicardial coronary artery of 
≥ 60% in the derivation cohort and of ≥ 50% in the validation cohort. 
Four models, those of Cui et al.(20), Schnabel et al. (18), Deckers et al.(17), and Mora 
et al.(23), displayed c statistics below 0.70, which was somewhat lower than those of 
the six other studies. The study of Cui et al. (20) considered 6 models with and without 
laboratory-based variables. The models were constructed using selected variables which 
are generally used in risk models meant for primary prevention, without using stepwise 
routines. The model of Schnabel et al.(18) was constructed based on variables from the 
ESC SCORE (2). This score, on its part, was based on data from the general population, 
not data from patients with pre-existing CAD. These results imply that the ESC SCORE, as 
well as variables derived from other primary prevention risk scores, may not discriminate 
well in CAD patients. On the other hand, it should be noted that model performance 
assessment in datasets which are also used for model development, may provide overly 
optimistic performance estimates because of overfitting (28). Deckers et al.(17) and Battes 
et al.(16) both developed their prediction models making use of the EUROPA dataset(29). 
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While Deckers et al.(17) focused on a combined endpoint which comprised fatal as well as 
nonfatal cardiovascular adverse events, Battes et al.(16) examined additional cardiovascular 
endpoints, both fatal and nonfatal as well as combined. The latter analyses demonstrated 
that discrimination with regard to fatal endpoints was good, while discrimination for 
nonfatal endpoints was poor. The latter held up when nonfatal endpoints were combined 
with fatal endpoints into a composite outcome. These results suggest that, when modeling 
prognosis in patients with stable CAD, pooling several outcomes may influence model 
performance to a great extent and caution is needed when examining nonfatal endpoints 
or combined outcomes that include such end points. In parallel, Mora et al. (23) used 
a combined endpoint which included coronary death, non-fatal MI, resuscitation after 
cardiac arrest, and fatal or non-fatal stroke.
Overall performance measures
The distance between the predicted outcome and actual outcome is central to quantify 
overall model performance from a statistical perspective. This distance is related to the 
concept of “goodness-of-fit” of a model, with better models having smaller distances 
between predicted and observed outcome (30), and may be assessed by using measures 
such as the amount of explained variation (R2), Nagelkerke’s R2 , (log) likelihood ratio, Bayes 
information criterion (BIC), Akaike information criterion (AIC), or the Brier score. Battes et 
al.(16) tested the overall performance of their model using Nagelkerke R2, which was good 
for cardiovascular mortality (12%). Several studies used the (log) likelihood ratio during 
model development (9, 14, 18, 23). Cui et al.(20) examined both AIC and BIC to select the 
best fitting model. 
   
Reclassification
To quantify improvement in model performance introduced by adding new variables to 
the existing model, net reclassification improvement (NRI) can be calculated (31). For 
this purpose, patients that have experienced an event are divided into categories of low-, 
intermediate- and high-risk, and the same is done in patients that have not experienced 
an event. This division in categories is done with and without the addition of the new 
marker. The correct movement in categories - upwards for events and downwards for non-
events - can subsequently be quantified. Only Schnabel et al. (18) applied this method. 
They examined the prognostic ability of 12 biomarkers in the prediction of cardiovascular 
endpoints, using classical cardiovascular risk factors to derive the primary risk categories, 
and assessed the added value of the selected biomarkers.
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The strongest reclassification improvement for single biomarkers, with a NRI of over 10%, 
was observed for GDF-15, NT-proBNP, MR-proANP and cystatin C. A related method to 
assess improvement in risk stratification models is integrated discrimination improvement 
(IDI), which uses differences between integrated sensitivities and ‘one minus specificities’ 
for models with and without the new marker (26). Schnabel et al.(18) found an IDI for the 
combination of biomarkers GDF-15, NT-proBNP, MR-proANP, MR-proADM and cystatin C 
of 0.04 (p<0.0001).
Validation
Internal validation assesses validity for the setting from which the data originated (30). 
Original data may be split into a testing and training set; models may be developed in 
the testing set and may subsequently be validated in the training set. Techniques to 
obtain testing and training sets include split-sample, cross-validation, and bootstrapping 
(32) methods. Bootstrapping is advantageous is terms of statistical power. It replicates 
the process of sample generation from an underlying population by drawing samples 
with replacement from the original data set, of the same size as the original data set (32). 
External validity, or generalizability, refers to assessment of model performance in patients 
from a different but “plausibly related” population (28). External validation enables 
investigation of general applicability of the prediction model. 
Testing the validity of a model is essential to assess its reliability. Internal validation 
was done by five studies. Atwater et al. (9), Goliasch et al. (12), and Clayton et al. (24) 
used bootstrapping, Battes et al.(16) used split-sample and Hsia et al.(21) used cross-
validation. In none of the studies, internal validation pointed to overoptimism in the 
final model’s discrimination. In three of the models we reviewed, external validity was 
assessed. Atwater et al.(9) externally validated their risk score in patients with ischemic 
cardiomyopathy, with a moderate c-index of 0.64, compared to 0.75 on internal validation. 
Cui et al.(20) developed their models based on data from individuals recruited in Australia, 
and validated these models using data from individuals recruited according to a similar 
protocol in New Zealand. After recalibration, the models displayed a good fit (Hosmer-
Lemeshow test: p=0.42). Goliasch et al.(12) validated their risk score in the Ludwigshafen 
Risk and Cardiovascular Health study and achieved similar results as those in their original 
dataset (c-index= 0.73, p <0.001).
  
DISCUSSION
In this review, we have summarized 16 risk prediction models for patients with stable 
coronary artery disease by reviewing their content and their performance. In general, the 
sample sizes of the studies we reviewed were large, ranging up to 37.258 (9) patients, and 
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heterogeneous, ranging from patients with stable angina to patients who experienced MI 
in the past. All studies in this review used outcomes that included cardiovascular mortality 
and/or all-cause mortality. Notably, incidence rates of the outcomes that were examined 
varied substantially across the studies. Overall, the variables that were available for 
multivariable model building in the various studies were highly similar. The majority of the 
studies had data available on established cardiovascular risk factors (including laboratory 
variables like cholesterol or renal function), with the exception of  Daly et al. (13), who 
were particularly interested in the value of routine non-invasive tests as predictors. 
Nevertheless, the variables which were eventually included in the prediction models 
differed largely between the studies; there were no predictors which were included in all 
of the models. Many prediction models included established cardiovascular risk factors; 
four studies (17, 18, 20, 23) included at least age, diabetes, hypertension and smoking. 
Furthermore, several models contained the variables cholesterol (11, 14-18), heart failure 
(9, 12, 13, 16, 19, 21, 24), and heart rate (12, 22). Five studies also included laboratory 
findings in addition to clinical variables to their final model. Overall, model performance, 
including calibration and discrimination, was not examined extensively in the studies.  
Currently, use of risk prediction models is widely accepted in the field of primary prevention 
of cardiovascular disease. One of the models that is frequently used is the Framingham risk 
score (33). The variables in this score are age, sex, blood pressure, total cholesterol, high-
density lipoprotein (HDL), cigarette smoking and diabetes. Recently, the clinical significance 
of the age-adjusted Framingham risk score for secondary prevention was evaluated by 
Park et al.(34). They investigated the predictive power of this score for incident coronary 
events in patients with stable angina pectoris, without a history of ACS. The AUC was 
0.863, which indicates adequate discrimination. However, the study population was small 
(n =71), and elaborate exclusion criteria were applied, resulting in inclusion of relatively 
healthy patients. Therefore, the reliability of this optimistic estimate of the AUC may be 
questioned. The Framingham risk score has also been used by Ingle et al.(15) to examine 
the predictive value of CRP or lifestyle related variables (including moderate-to-vigorous 
physical activity, BMI and psychological distress) on top of this score in 1372 patients with 
pre-existing CHD from the Health Survey for England and Scottish Health Survey. The AUCs 
of this risk score with addition of CRP for the endpoint CVD death were 0.73 for males and 
0.74 for females, respectively. In this study, calibration measures were also missing. These 
results illustrate that additional research is warranted to examine the generalizabilty of the 
Framingham risk score to patients with a pre-existing CHD. 
Remarkably, only gender(12, 14-16, 22) or both age and gender (9, 10, 13, 19) were 
absent in many of the risk prediction models we reviewed. Gerber et al. (35) investigated 
Chapter 2.1 | Overview of existing prediction models
36
the influence of gender differences on the role of classic risk factors in the prediction of 
recurrent ischemic events after MI. Hypertension and diabetes were stronger predictors 
in women than in men for having a recurrent event. Hypercholesterolemia was associated 
with recurrent events only in women. Furthermore, a recent study of Lehto et al. (36) 
examined the difference in CVD risk between men and women from a general population 
according to different age groups. In the age group younger than 55, CVD risk was similar in 
both genders, probably due to the high prevalence of diabetes in relatively young women, 
while men had a higher CVD risk than women in the age group greater than 55, due to 
smoking, hypertension and history of a prior CVD event. These findings illustrate that the 
association of classic risk factors with the risk of having recurrent ischemic events differs 
by gender and age, and demonstrate the potential importance of these risk factors for 
prediction models.
In general, large variation was present in classic cardiovascular risk factors, other than 
age and gender, which were included in the different models. Part of this variation may 
probably be explained by differences in the study populations and in the incidence rates. 
Furthermore, the variation might also in part be due to differences in prevalence of 
risk factors and in use of cardioprotective medication between different countries (37). 
EUROASPIRE III (37), for example, showed that a large number of patients with CAD do not 
reach the lifestyle and therapeutic targets for cardiovascular disease prevention according 
to the guidelines. These differences may play a part in the selection of the variables in the 
various prediction models. 
The majority of prediction models we reviewed included diabetes. Fox et al. (38) have 
shown that the proportion of cardiovascular disease due to diabetes has drastically 
increased over the past 50 years. It has been demonstrated that after a cardiovascular event 
has occurred, risk of recurrent events stays high in diabetic patients (39). Furthermore, 
diabetes is often associated with other cardiovascular risk factors like hypertension (39). 
Of the studies we reviewed, twelve included diabetes in their prediction model (9, 10, 12, 
14-20, 23, 24), and of these studies six included hypertension as well (9, 17, 18, 20, 23, 24), 
which is in agreement with previous findings from the literature. The remaining studies did 
not include diabetes in their final model because of a non-significant result after running 
the multivariable analysis (11, 13, 21, 22). 
Some aspects of our review warrant further consideration. The definition of stable CAD 
was somewhat different between the various studies. We included studies that examined 
patients with stable angina pectoris, patients with myocardial infarction more than 
3 months ago, or patients that had undergone coronary revascularization more than 6 
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months ago. The risk of having a recurrent event differs between the first months after a 
coronary event and the time period that follows. We tried to account for this by using the 
criterion of 3 months post-MI and 6 months post-procedure, which has previously been 
applied for such purposes (7, 8). Evidence exists that risk of recurrent events may be higher 
even up to a year after having unstable angina or an MI, while after this period the overall 
risk is reduced to the same level as that of stable CAD patients (6). To further account for 
such differences in risk, we only included studies that had follow-up durations longer than 
one year available. This enabled all patients to eventually reach a risk comparable to stable 
CAD patients. Nevertheless, the definition of stable CAD varied between the articles, as 
did the exclusion criteria, which influences the homogeneity and the comparability of the 
study populations. 
CONCLUSION
Although multiple prediction models have been developed for adverse events in patients 
with established, stable CAD, the variables contained in these models display large 
heterogeneity. Differences in study design, study populations and incidence rates may in 
part account for this heterogeneity. Still, most models include classic risk factors such as 
age, diabetes, hypertension, smoking and cholesterol.  The majority of existing studies 
have paid insufficient attention to model performance and validation. 
Thus, development of a reliable prediction model for incident coronary events in patients 
with stable coronary disease is warranted. Such a model should preferably be based 
on a large, multinational population, use a clear and uniform definition of stable CAD, 
and should examine long-term follow-up that includes (cardiovascular) mortality as well 
as non-fatal cardiovascular adverse events. Performance assessment should be done 
including measures of discrimination, calibration, as well as overall performance measures. 
Moreover, attention should be paid to external validation. 
Such a model is essential in order to serve as a starting-point to better prevent recurrent 
events in patients with stable coronary artery disease, and to herewith optimize secondary 
prevention strategies.
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ABSTRACT
Background: Appropriate risk stratification of patients with established, stable coronary 
artery disease (CAD) may contribute to the prevention of recurrent cardiovascular 
events. The purpose of this study was to develop and validate risk prediction models 
for various cardiovascular endpoints in a large cohort of CAD patients.
Methods: the EUROPA database, consisting of 12 218 patients with established CAD, 
with a median follow-up of 4.1 years, was used. Cox proportional hazards models 
were used for model development. The endpoints examined were cardiovascular 
mortality, non cardiovascular mortality, non-fatal MI, coronary artery bypass 
grafting, percutaneous coronary intervention, resuscitated cardiac arrest, as well as 
combinations of these endpoints. Performance measures included Nagelkerke R2, 
time-dependent ROC curves, and calibration-plots with the Hosmer and Lemeshow 
test. 
Results: Backward selection resulted in a prediction model for cardiovascular 
mortality (646 events)  that included age, current smoking, diabetes mellitus, total 
cholesterol, BMI, prior MI, history of congestive heart failure, peripheral vessel 
disease, prior revascularization, and prior stroke. Model performance was adequate 
for cardiovascular mortality with a Nagelkerke R2 of 12%, and an AUC of 0.73. However, 
performance of models constructed for non-fatal and combined endpoints was 
considerably worse, with AUCs around 0.6. 
Conclusions: In patients with established CAD, the risk of cardiovascular mortality 
during longer-term follow-up can be adequately predicted based on clinical 
characteristics which are available at baseline. However, the prediction of non-fatal 
outcomes, both separately and in combination with fatal outcomes, poses major 
challenges for clinicians and model developers.
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INTRODUCTION
Since the late 1960s, coronary artery disease (CAD) mortality rate has declined (1, 2). 
Several developments have contributed to this decline. First, multiple aspects of patient 
risk profile have improved, which is partly due to preventive interventions (3, 4). Examples 
include a decline in serum total cholesterol concentration and prevalence of smoking. 
Moreover, improved treatment of stable CAD (statins, beta blockers, and ACE-inhibitors) 
and acute coronary syndromes, including myocardial infarction (MI), has been enabled by 
the introduction of reperfusion therapy with thrombolysis or PCI with stent implantation 
and the addition of antiplatelet agents to aspirin (5-7). Also, improved cardiac rehabilitation 
after MI or CABG has resulted in a reduction of the total number of re-hospitalizations, 
although the results were modest (8-11). Nevertheless, CAD is still the leading cause of 
death in the Western world (12). It has been estimated that by the year 2020, nearly 20.5 
million deaths worldwide will be due to cardiovascular disease. (13)
This trend may be altered by installing further preventive measures. In order to do this 
most effectively, first, appropriate risk stratification tools should be developed. Focusing 
on patients with established CAD for prevention of recurrent events and mortality may 
contribute to efficient healthcare, because these patients are at high risk of needing medical 
attention and may benefit most from additional treatment. Appropriate risk stratification 
in this population may identify patients that could be followed-up more closely, may be 
treated more aggressively, and whose compliance to prescribed drugs may be monitored 
more carefully, in order to prevent recurrent events. 
While several risk stratification models have been designed for primary prevention, such 
as the Framingham risk score, the SCORE project, Prospective Cardiovascular  Münster 
Study (PROCAM) and QRISK, (14-17) risk stratification models for patients with established 
CAD are less abundant (18-22) and no consensus currently exists on which is most 
appropriate. Furthermore, existing models (18-21, 23-25) have several limitations. These 
include retrospective study design (19), different endpoints, lack of validation (20), lack 
of uniformity in baseline characteristics because of a long inclusion period during which 
changes in treatment recommendations have occurred (21), and focus on specific ethnic 
groups (25).
In the current study, we set out to develop and validate a series of risk prediction models 
for different endpoints in a prospective cohort of European patients with established CAD. 
Our cohort consists of over 12 000 patients, making this the largest study to date to develop 
such a model. Endpoints examined included cardiovascular mortality, non cardiovascular 
mortality, non-fatal MI, coronary artery bypass grafting (CABG), percutaneous coronary 
intervention (PCI), and resuscitated cardiac arrest, as well as combinations of these 
endpoints.
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METHODS
Study design, patients and data collection
The design of the EUROPA study has been reported elsewhere (26). In brief, this randomized, 
double-blind, placebo-controlled trial investigated the efficacy of perindopril in reduction 
of cardiovascular events in 12 218 patients. Informed consent was obtained from each 
patient and the study protocol conforms to the ethical guidelines of the Declaration of 
Helsinki.
Study participants consisted of men and women 18 years or older, with evidence of coronary 
heart disease documented by previous MI (>3 months before screening), percutaneous or 
surgical coronary revascularization (> 6 months before screening), angiographic evidence 
of at least 70% narrowing of at least one major coronary artery, or (in men) a history of 
typical chest pain with an abnormal stress test. Informed consent was obtained from all 
patients. Exclusion criteria included clinically evident (NYHA ≥ 2) heart failure, planned 
revascularization procedure, hypotension (sitting systolic blood pressure <110 mmHg), 
uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood 
pressure >100 mmHg), use of ACE-inhibitors or angiotensin-2 receptor blockers in the 
last month, renal insufficiency (serum creatinine >150 µmol/L or 1.5 mg/dL), and serum 
potassium >5.5 mmol/L. Patients were randomly assigned to perindopril 8 mg or placebo 
once daily for at least 3 years. The first patient was enrolled in October 1997. 
At baseline, exposure data were collected for age, current smoking (patients who were 
current smokers or smoked in the previous month), diastolic blood pressure (mmHg), 
systolic blood pressure (mmHg), heart rate (beats/min), diabetes (known history of 
diabetes or use of antidiabetic agents), total cholesterol (mmol/L), BMI (kg/m2), family 
history of coronary artery disease, history of congestive heart failure, history of peripheral 
vessel disease, history of prior MI,  history of prior revascularization, and prior stroke. 
Patients were followed up for cardiovascular mortality, non cardiovascular mortality, 
myocardial infarction, CABG, PCI, and resuscitated cardiac arrest until March 2003. 
Intensive monitoring and endpoint validation was done by a Clinical Event Committee 
(CEC) (27). Median follow-up was 4.1 years (interquartile range 4.0–4.5 years). 
STATISTICAL METHODS
Development of the risk prediction models
Several techniques are available for the development of risk prediction models with 
subsequent internal validation, including the split-sample and bootstrap methods. 
According to the split-sample method, the original sample is (randomly) divided into two 
parts: a training set for model development and a testing set for model validation (28). 
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Bootstrap replicates the process of sample generation from an underlying population by 
drawing ‘bootstrap samples’ with replacement from the original sample; the bootstrap 
samples usually have the same size as the original (29). 
Table 1. Patient baseline characteristics stratified by training set and testing set*
Training set (n=8144) Testing set (n=4074) p-value
Age, years (SD) 60 (9.30) 60 (9.38) 0.89
Male 6965 (85.5) 3474 (85.3) 0.71
Current smoking 1250 (15) 612 (15) 0.64
Diastolic blood pressure (mmHg), mean (SD) 82 (8) 82(8) 0.50
Systolic blood pressure (mmHg), mean (SD) 137 (16) 137 (15) 0.81
Total cholesterol (mmol/L), mean (SD) 5.37 (1.05) 5.36 (1.05) 0.66
Diabetes 1021 (12.5) 481 (11.8) 0.25
BMI (kg/m2), mean (SD) 27.4 (3.5) 27.4 (3.5) 0.72
eGFR (mL * min-1 *1.73 m-2), mean (SD) 75 (20) 75 (20) 0.71
Heart rate (bpm), mean (SD) 68 (10) 68 (10) 0.18
Peripheral vessel disease 581 (7.1) 302 (7.4) 0.58
Family history of coronary artery disease 2173 (26.7) 1155 (28.4) 0.05
Congestive heart failure 105 (1.3) 48 (1.2) 0.60
Prior MI 5267 (64.7) 2643 (64.9) 0.81
Prior revascularization 4454 (54.7) 2255 (55.4) 0.49
Prior stroke 154 (1.9) 68 (1.7) 0.39
* Results are presented as (n) % unless otherwise indicated
According to the bootstrap method, risk prediction models are developed on the original 
sample and validated in the set of bootstrap samples. The bootstrap method is preferred 
in small datasets. Our original sample was large, so that we were confident to apply the 
split-sample method: the original sample was randomly divided into a training set of 8144 
patients (two thirds of the original sample) and a testing set of 4074 patients.
To develop the optimal risk prediction model, multivariable Cox proportional hazards 
analysis was applied in the training set. All available predictors, as described under ‘study 
design’, were considered as potential determinants of the outcomes that we studied. 
Backward stepwise selection was used for variable selection, because this has been argued 
to render reliable predictors.(28) Variable exclusion was performed using a 5% significance 
level as a stopping criterion. We elected not to apply the Lasso-shrinkage method for 
variable selection [36], since this method extensively uses computer CPU time, particularly 
so in large datasets, whereas it has no major advantages over stepwise selection in such 
large datasets.
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We examined the endpoints cardiovascular mortality, non cardiovascular mortality, non
 fatal MI, CABG, and PCI. Moreover, we examined the combination of cardiovascular mortality, 
non-fatal MI, and resuscitated cardiac arrest, which was originally the primary endpoint 
of the EUROPA study (combined endpoint 1(22)), and the combination of cardiovascular 
mortality, non cardiovascular mortality, non fatal MI, CABG,  PCI, and resuscitated cardiac 
arrest (combined endpoint 2). In the analysis of the combined endpoints, we applied 
censoring at the first moment that any one of the endpoint components occurred in a 
patient. In the analysis of the separate outcomes, we additionally accounted for competing 
risk, by using time-dependent covariates. For instance, when CABG was the endpoint of 
interest, we used non-fatal MI and PCI as time-dependent variables.
Complete information was available on most variables. Values for total cholesterol, 
heart rate, history of MI and revascularization, and BMI were missing in less than 5% of 
participants. Missing values were handled using expectation maximization(30), which is 
an iterative method for finding maximum likelihood estimates of parameters in statistical 
models, where the model depends on unobserved latent variables. SPSS 17.0 for Windows 
was used for the above-described analyses. 
Validation of the risk prediction models
After deriving the models in the training set, we assessed their performance in the testing 
set. We used Nagelkerke’s R2 to assess global model performance (28). R2 is a likelihood-
based measure that provides information about the goodness of fit of the model, or in 
other words, how well the regression line estimates the real survival. There are several 
different definitions of R2 (28). The definition proposed by Nagelkerke can readily be 
applied to survival outcomes has the advantage of being scaled between 1 and 100%. Of 
note is that the value of R2 partly depends on incidence of the outcome. Lower incidence 
results in lower values of R2, which thus should be interpreted in their appropriate context 
(31) Subsequently, we assessed model discrimination for every endpoint by calculating 
area under the receiver operating characteristic curve (AUC). Model discrimination is the 
ability of the model to rank persons appropriately, from low to high risk. We calculated 
time-dependent AUCs using the statistical program R (32). This approach takes into 
account the follow-up time until event occurrence. Standard errors (SEs) were calculated 
by bootstrapping. 
To assess differences in model discrimination between the testing set and the validation 
set, we compared the AUCs with the method of Hanley and McNeil (33) by using MedCalc 
(34). A two-tailed probability < 0.05 was considered a statistically significant result. 
Moreover, we investigated calibration, or how closely the predicted probabilities reflect 
actual risk. For this purpose, we compared observed survival, derived from Kaplan Meier 
curves, with predicted survival, calculated from the Cox proportional hazards models. We 
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constructed calibration plots based on categories defined by deciles of predicted risk. To 
test the goodness-of-fit we performed the Hosmer-and-Lemeshow test.
RESULTS 
Baseline characteristics are summarized in Table 1. Mean age was 60 years and 85% 
were men. No significant differences were present between the training and testing sets. 
Incidence of the endpoints is displayed in table 2.
Incidence of cardiovascular mortality was 9.6 per 1000 person years in the training set. 
Table 2. Event rates of the endpoint in the training set and the testing set.
Outcome Total number of 
events
Event rate training set (per 
1000 person years)
Event rate testing set 
(per 1000 person years)
Cardiovascular mortality 464 9.6 8.1
Non cardiovascular mortality 323 6.1 6.8
Non-fatal MI* 673 13.6 12.4
PCI ** 671 13.4 12.7
CABG§ 564 11.6 10.0
Combined endpoint 1# 1091 22.9 20.2
Combined endpoint 2§§ 2188 43.6 47.1
*MI = myocardial infarction; ** PCI= Percutaneous Coronary Intervention, §CABG =coronary artery bypass grafting; 
# combined endpoint 1 = cardiovascular mortality + non-fatal MI + resuscitated cardiac arrest,; §§combined 
endpoint 2= cardiovascular mortality + non cardiovascular mortality + MI + CABG + PCI + resuscitated cardiac 
arrest 
Model development 
In the training set, 16 potential variables were evaluated for model inclusion. The variables 
included in the best-fitting prediction model for cardiovascular mortality after backward 
selection were age, current smoking, diabetes mellitus, total cholesterol, BMI, prior MI, 
history of congestive heart failure, peripheral vessel disease, prior revascularization, and 
prior stroke (table 3). Hazard ratios for the variables in this model are displayed in table 4. A 
smaller number of variables were included in the predictive model for non cardiovascular 
mortality after backward selection, namely age, current smoking, and heart rate. Variables 
included in the prediction models for MI, CABG, PCI and the combined endpoints are also 
displayed in table 3. 
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Model performance in the training set
Nagelkerke’s R2 and time-dependent AUC were calculated for each endpoint (table 3). Overall 
performance, assessed with Nagelkerke R2, was 10% for cardiovascular mortality. Overall 
performance was worse for the other outcomes. The model for cardiovascular mortality 
risk prediction displayed the best discrimination with an AUC of 0.70. The prediction 
models for non cardiovascular mortality, MI, CABG, PCI and the combined endpoints 1 
and 2 resulted in lower AUCs of 0.69, 0.60, 0.67, 0.55, 0.64 and 0.62 respectively. Model 
calibration, as assessed by the Hosmer and Lemeshow test, was adequate. The Chi square 
values and corresponding p-values for all endpoints are displayed in table 5.
Table 4. Hazard ratios for cardiovascular mortality for baseline variables included in the prediction 
model. 
Variable
Hazard ratio 
(95% confidence interval)
P-value
Age (years) 1.06 (1.04-1.07) < 0.001
Current smoking 1.96 (1.47-2.62) < 0.001
Diabetes Mellitus 1.01 (0.76-1.35) 0.93
Total cholesterol (mmol/L) 1.25 (1.12-1.39) < 0.001
BMI* 1.01 (0.98-1.05) 0.39
Prior MI** 1.96 (1.48-2.58) < 0.001
History of congestive heart failure 3.10 (1.84-5.23) < 0.001
Peripheral vessel disease 1.43 (1.04-1.98) 0.03
Prior revascularization 0.98 (0.77-1.23) 0.83
Prior stroke 1.77 (1.09-2.88) 0.02
*BMI = Body Mass Index; **MI = Myocardial Infarction
Model performance in the testing set
The models were subsequently validated in the testing set. Values for Nagelkerke R2 
indicated a good overall performance for cardiovascular (12%) and non cardiovascular 
mortality (8%) (table 3). For the other outcomes, overall performance was worse, and 
values were in a similar range as those in the training set. Discrimination was comparable 
to the training set (including an AUC=0.73 for cardiovascular mortality). The mean and 
confidence intervals of the AUCs for both sets are also displayed in table 3. AUCs were not 
significantly different between the training and testing set. 
Figure 1 a., 1 b., 1 c., and 1 d. show the calibration plots for cardiovascular mortality, non-
fatal MI and combined endpoints 1 and 2 in the testing set. Because of the relatively low 
event rate in this study population (9.6/1000 person years for cardiovascular mortality and 
13.6/1000 person years for non-fatal MI), the observed fraction of the population that 
remained event-free ranged between 0.8 and 1.0 for each decile of predicted probability 
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of being free from cardiovascular mortality. These deciles of predicted probability of being 
event-free also ranged from 0.7 upwards. As such, the calibration plot only displayed values 
in the upper range of both the x and y-axis. A similar situation occurred during evaluation of 
the prediction model for non-fatal MI and the models for the combined endpoints. It was 
not possible to construct calibration plots for non cardiovascular mortality, PCI and CABG, 
because survival was even closer to 1.0 for these endpoints. As such, these calibration 
plots were not informative. Nevertheless, calibration as evaluated by the Hosmer and 
Lemeshow tests was sufficient (table 5). 
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Figure 1a. calibration plot cardiovascular mortality, four years follow-up
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Figure 1b. calibration plot non fatal MI, four years follow-up
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Combined	endpoint	1
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Figure 1c. calibration plot combined endpoint 1, four years follow-up
*combined endpoint 1 = cardiovascular mortality + non-fatal MI + resuscitated cardiac arrest;  
Combined	endpoint	2
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Figure 1d. calibration plot combined endpoint 2, four years follow-up
§§combined endpoint 2 = cardiovascular mortality + non cardiovascular mortality + non-fatal MI + CABG + PCI + 
resuscitated cardiac arrest
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Table 5. Model calibration as assessed by the Hosmer and Lemeshow test 
Training set Testing set
Chi square p-value Chi square p-value
Cardiovascular mortality 3.61 0.89 13.77 0.09
Non cardiovascular mortality 6.84 0.55 3.50 0.90
Non-fatal MI* 5.84 0.67 4.26 0.83
PCI ** 14.80 0.06 2.23 0.97
CABG§ 3.97 0.86 9.83 0.28
Combined endpoint 1# 20.43 0.01 16.56 0.04
Combined endpoint 2§§ 1.98 0.98 8.58 0.38
*MI = myocardial infarction; ** PCI= Percutaneous Coronary Intervention, §CABG =coronary artery bypass 
grafting; #combined endpoint 1 = cardiovascular mortality + non-fatal MI + resuscitated cardiac arrest;  §§combined 
endpoint 2 = cardiovascular mortality + non cardiovascular mortality + non-fatal MI + CABG + PCI + resuscitated 
cardiac arrest
DISCUSSION 
Risk prediction models and ensuing risk scores may be used in CAD patients to adjust 
individual treatment to the patient’s risk profile (18). Furthermore, they may provide 
patients with further insight into their individual risk and thus motivate them to reduce 
modifiable risk factors (35). In this paper, we developed and validated a comprehensive 
set of prediction models in patients with established, stable coronary artery disease, 
to estimate the risk of cardiovascular mortality, non cardiovascular mortality, non-fatal 
MI, CABG or PCI. The model for the prediction of cardiovascular mortality, which is the 
‘hardest’ endpoint, displayed good overall performance with Nagelkerke’s R2 being 12%,. 
Furthermore, the model displayed good discrimination, with an AUC of 0.73. The model 
was well-calibrated, as assessed by the Hosmer and Lemeshow test. 
Our main results show that cardiovascular mortality in CAD patients can to a large extent 
be predicted by ‘established’ clinical risk factors such as DM and cholesterol level, and by 
history of vascular disease including CAD and peripheral vessel disease. These traditional 
risk factors are easily obtainable during patient assessment. Of note is that, while blood 
pressure was part of the prediction model for the combined endpoint, it did not predict 
cardiovascular mortality in our data. These seemingly discrepant findings may partly result 
from the fact that a large part of the study population was using ACE inhibitors and beta 
blockers. Established risk factors were also implicated in the INTERHEART study, a case-
control study performed in 52 countries worldwide, which examined primary prevention, 
and demonstrated that traditional risk factors account for 90% of the population 
attributable risk of MI (36). Earlier studies by St. John Sutton et al. (37) and Maas et al. 
(38), that studied long-term survival after MI in more than 500 patients, also implicated 
Development of prediction models for both fatal and non-fatal adverse events | Chapter 2.2
53
2.2
established risk factors. These studies included demographic variables, co-morbid 
conditions as well as procedural variables in their models and showed that age (37, 38), 
history of prior MI (37, 38), congestive heart failure (37), left ventricular function (37, 38), 
and multivessel disease (38) were independent predictors of long-term mortality. Deckers 
et al (22) previously examined risk factors for cardiovascular events within the EUROPA 
study, using a combined endpoint. In the present paper, we examine additional outcomes 
and further explore aspects of model performance.
Although, as mentioned above, several studies have examined the associations of risk 
factors with recurrent events, the number of risk prediction models that have been 
developed for patients with established CAD is limited. Examples of prediction models that 
have previously been developed and validated include those of Clayton et al. (18), Prugger 
et al. (19), Singh et al.(21) and Blankenberg et al.(23). The demographic variables and co-
morbid conditions they used in their models largely concur with our variables, including 
age, smoking, prior MI, and history of congestive heart failure. In addition, Sing et al. (21) 
included several procedural variables obtained from index PCI, while Blankenberg et al. 
(23) added biomarkers to inventorise whether this improves model performance. They 
calculated AUCs of 0.74 and 0.69, respectively, using combined endpoints which included 
all-cause mortality and MI, and MI, stroke, and cardiovascular mortality, respectively. 
While the performance of our models for the prediction of cardiovascular and non 
cardiovascular mortality is comparable to that of these models, we also demonstrate that 
model performance is considerably worse for non-fatal MI, PCI and CABG examined as 
separate outcomes, which has not been examined previously. 
Previous existing models for cardiovascular risk prediction in CAD patients have several 
limitations (18-21, 23-25) Clayton et al. (18) developed a risk score in patients with stable 
symptomatic angina and examined occurrence of all-cause mortality, MI or disabling 
stroke, but did not assess model performance. The same was true for Marschner et al. 
(24). They developed a multivariate risk factor model in 9014 patients with acute MI or 
hospitalization for unstable angina, but performance was not assessed. Prugger et al. 
examined the relationships between cardiovascular risk factors and long-term mortality in 
CAD patients, however, they used a retrospective study design. Singh et al. (21)  designed 
a model in 9165 patients undergoing PCI, but their study lacks of uniformity in baseline 
characteristics because of a long inclusion period (7 years) during which changes in 
treatment recommendations have occurred. Marchioli et al. (25) included over 11000 
Mediterranean patients to develop a risk chart. However, they included patients directly 
after occurrence of MI. Such patients are known to have higher risk of recurrent events in the 
first months after their index event, which complicates model development. Furthermore, 
this was a specific group (Mediterranean patients), and therefore generalizability of the 
chart is limited. A comprehensive review of the strengths and limitations of CAD policy 
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models in CAD patients developed so far  is given by Unal et al. (20)  Likewise, they noted 
that the biggest part of the models were either not calibrated or not validated.
Most studies that have developed prediction models for CAD patients did not include PCIs 
and CABGs as outcomes, nor did they examine these outcomes separately. To provide 
an extensive framework for cardiovascular disease prediction, we chose to also examine 
these outcomes in the current study. When we examined non-fatal MI, CABG and PCI 
separately, model performance and discrimination were notably lower than those for 
cardiovascular mortality. For non-fatal MI, this may in part be explained by the fact that 
this endpoint is not a pathophysiological entity, as part of the patients that experience 
MI die immediately. Moreover, there is a difference between acute risk, which is most 
often related to thrombosis, and long-term risk, which is related to the evolution of the 
atherosclerotic process. Hence, we also investigated a combined endpoint containing non-
fatal MI, as well as cardiovascular mortality and resuscitated cardiac arrest. Nevertheless, 
discrimination remained relatively low for this combined endpoint with a c-statistic of 0.64. 
For PCI and CABG, worse model performance and discrimination may in part be explained 
by the fact that undergoing revascularization is heavily influenced by the opinion of the 
treating physician (39).
The calibration-plots of the prediction models for non-fatal endpoints were not informative, 
because of the relatively low incidence rates of the separate endpoints. We also examined 
two combined endpoints that included fatal as well as non-fatal events. We found that the 
relatively poor model performance for non-fatal outcomes influenced model performance 
for both combined endpoints as well. Addition of non-fatal MI and resuscitated cardiac 
arrest to the endpoint cardiovascular mortality (resulting in combined endpoint 1) resulted 
in a reduction of the c-statistic from 0.7 to 0.64. Concerning combined endpoint 2, since 
non-fatal MI, CABG, PCI and resuscitated cardiac arrest were the first events to occur in 
66.8% of subjects that suffered any event, the AUC of this combined endpoint was closer to 
the AUC of these non-fatal endpoints, namely 0.62. Furthermore, the calibration-plot for 
combined endpoint 2 showed discrepancies in the highest decile of predicted probability 
of being event-free. This was partly due to the fact that follow-up time until the occurrence 
of non-fatal events was generally shorter than that until the occurrence of fatal events. 
Furthermore, the number of non-fatal events was much higher than the number of fatal 
events. These results suggest that when modeling prognosis in patients with stable CAD, 
study endpoints should be chosen with care, as pooling several outcomes may influence 
model performance to a great extent. 
Strengths of our study include the availability of a large, prospective CAD patient cohort for 
model development, and the availability of a wide range of risk factors, whose importance 
we were able to explore for the prediction of non-fatal as well as fatal cardiovascular 
outcomes. Moreover, since our study consists of a multicenter, multinational population, it 
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is likely that the results apply to a broad range of clinical practices. Heterogeneity in center-
specific policies was minimized by a uniform study protocol. Furthermore, we performed 
an extensive assessment of model performance, which is key for model appraisal (20). We 
applied multiple methods to do so, which has been recommended (40). Notably, we used 
time-dependent receiver operating characteristic curves (ROC), thus taking follow-up time 
into account, in contrast with previous studies (21, 23).  
Several aspects of this study warrant further consideration. Although the absolute number 
of events was high (combined endpoint 2, n=2188), incidence rate was relatively low,  which 
posed challenges for constructing informative calibration-plots for the non-fatal endpoints. 
Furthermore, follow-up was limited to four years, which hampers longer-term prediction. 
Also, the EUROPA study is a clinical trial with strict in- and exclusion criteria, which resulted 
in a very specific study population. Moreover, we did not have biomarker information 
available, which may have further improved model performance. However, although 
studies investigating incremental value of biomarkers over ‘established’ cardiovascular risk 
factors have rendered significant results, absolute differences in model performance, as 
assessed by measures such as the AUC, have been modest so far. 
Various performance measures may be applied in prognostic modeling (28) We strived 
to provide a comprehensive assessment of model performance by applying measures of 
overall performance as well as measures of model discrimination and calibration. To assess 
overall model performance, we used Nagelkerke’s R2. The value of R2 partly depends on 
the prevalence of the outcome variable in the dataset (40). Thus, occasionally, if event 
rates are low in survival data, R2 may be relatively low, and should be interpreted within its 
appropriate context (40). This also holds for the current study; event rates were relatively 
low because we examined patients with stable CAD. Furthermore, while the AUC increases 
linearly as the fraction of cases identified as high-risk by the model decreases, R2 increases 
hyperbolically (40). This may also lead to relatively low R2 values for models that may be 
considered to have good overall performance.  
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CONCLUSIONS
The models we have developed in the current study illustrate the potential of established 
cardiovascular risk factors to serve as risk stratification tools for CAD patients. The 
prediction models for cardiovascular and non cardiovascular mortality performed well 
with time-dependent AUCs of 0.73 and 0.72, respectively, and Nagelkerke’s R2 of 13% and 
8%, respectively. Performance of prediction models for non-fatal MI, CABG and PCI in the 
same dataset was considerably worse, and thus prediction of these outcomes poses major 
challenges for clinicians and model developers. Caution should be used when examining 
these types of clinical outcomes or combined endpoints that include these outcomes.
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ABSTRACT 
Background: In cardiovascular disease, numerous evidence-based prognostic models 
have been created, usually based on regression analyses of isolated patient datasets. 
They tend to focus on one outcome event, based on just one baseline evaluation of 
the patient, and fail to take the disease process in its dynamic nature into account. 
We present so-called micro-simulation as an attractive alternative for clinical decision-
making in individual patients. We aim to further familiarize clinicians with the concept 
of micro-simulation and to inform them about the modelling process.
Methods and results: We describe the modelling process, advantages and 
disadvantages of micro-simulation. We illustrate the concept using a hypothetical 60 
year old patient, with several cardiac risk factors, who is hospitalized for myocardial 
infarction. By using micro-simulation, we calculate this patient’s probability of death. 
In our example, this particular patient’s estimated life-expectancy turns out to be 8.9 
years. While calculating this life-expectancy, we were able to account for multiple 
outcome events and changing patient characteristics.   
Conclusions: Micro-simulation takes into account the dynamic nature of coronary 
artery disease by estimating most likely outcomes regarding a broad range of clinical 
events. Moreover, micro-simulation can be used to evaluate treatment effects 
by estimating the event-free life expectancy with and without treatment. Hence, 
micro-simulation has several advantages compared to modelling techniques such as 
regression.  
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INTRODUCTION
Predictive thinking plays a fundamental role in medicine. Before certain therapy is initiated, 
a physician must consider the probability that the patient will improve or deteriorate 
without such therapy, the chances of improvement if the therapy is initiated, the risks 
of adverse events, and the therapy-related costs.[1] The improvement of our predictive 
ability is one of the driving forces behind clinical research.[2, 3] 
Numerous evidence-based prognostic models have been created to help physicians make 
optimal and consistent decisions, usually based on regression analyses of isolated patient 
datasets.[4, 5] These so-called parametric models tend to focus on one outcome event, 
and are based on one baseline evaluation of the patient, thus failing to take the disease 
process in its dynamic nature into account. An alternative for clinical decision-making in 
individual patients is micro-simulation.[6] Micro-simulation replicates individual patient 
histories, and may thus inform physicians by estimating the most likely outcomes regarding 
a broad range of clinical events. 
In this paper, we will present micro-simulation as an attractive alternative for parametric 
models for clinical decision-making in individual patients. While the general technique 
of micro-simulation is applicable to various disease areas, it has not yet been applied in 
coronary artery disease (CAD). During the last decades, our understanding of CAD has 
considerably improved, and major progress has been achieved in patient management and 
outcome.[7] Although CAD is a common disease area,[8] the number of prediction models 
that has been developed for patients with established CAD is limited.[9, 10] 
The aim of this paper is to further familiarize clinicians with the concept of micro-simulation 
and to inform them about the modelling process, which is often perceived as a ‘black box’.
CLASSICAL CONCEPTS
Regression models
Newly developed therapies are usually introduced in clinical practice after proof of 
their efficacy and safety by clinical trials. The results of these trials apply by necessity 
to a patient population that is defined by the trial eligibility criteria. In clinical practice, 
however, physicians don’t treat populations, but individual patients, in whom the 
benefits, risks, effectiveness, and cost-effectiveness of therapy depend on a large number 
of characteristics. To provide physicians with tools for rational clinical decision making, 
cardiovascular risk models have been created for several categories of patients with 
(suspected) atherosclerotic disease, which are based on the results of regression analyses 
that relate patient characteristics to treatment effects and outcome.[4, 11, 12] Logistic 
regression and Cox proportional hazard regression are most frequently used for this 
purpose.
Chapter 3.1 | Principles of micro-simulation modeling
64
Meet Mr. Jones, a 60-year old accountant without cardiac history. He is admitted to the 
coronary care unit with severe chest pain, which originated 4 hours ago, and significant ST-
segment elevations in V3-V5. Mr. Jones has no signs of heart failure, and is hemodynamically 
stable with a pulse of 70 b/m and a blood pressure of 130/80 mmHg. What is his estimated 
probability of death during hospitalisation? 
 Both logistic regression and Cox proportional hazard regression may provide the answer. 
These regression methods provide a mathematical formula that relates a set of explanatory 
variables to the probable occurrence of one binary outcome event, based on one baseline 
evaluation of the patient.[13]  Logistic regression is appropriate if follow-up duration is 
limited and incidence of the outcome event is infrequent. Otherwise, Cox’ proportional 
hazards regression is recommended.[14] Typical examples of logistic regression models 
are the TIMI and GUSTO-1 risk scores for the prediction of 30-day mortality after admission 
with ST-elevation myocardial infarction[4, 5], and the EuroSCORE for the prediction of 
hospital mortality in adult patients undergoing cardiac surgery[15]. According to the TIMI 
and GUSTO-1 risk scores, Mr. Jones’s 30-day mortality probability is approximately 2-3%. 
Cox regression was applied to develop the SCORE chart to estimate the 10-year risk of fatal 
cardiovascular events in individuals in the general European population.[16] 
Especially in situations that require immediate decisions, the simplicity of the methods 
has stimulated the application of regression models and the practice of evidence-based 
medicine.[17] The main disadvantage of regression models is that they typically describe 
only one outcome event, based on one baseline patient evaluation. Herewith, they fail 
to take into account the dynamic nature of the disease process. When the objective is to 
provide predictions over an extensive time-span, by using for example a traditional Cox 
analysis, the probability that baseline characteristics will have changed over time is large, 
which influences the accuracy of the predicted prognosis.
This may be in part accounted for when repeated measurements are available. These 
may be incorporated into the Cox model as risk factors whose value changes over time. 
Basically, in such a “time-dependent” analysis, the complete follow-up time for each 
patient is divided into different time windows and for each time-window, a separate 
Cox analysis is carried out using the specific value of the time-dependent variable.[18] 
However, the maximum number of consecutive Cox analyses that may thus be combined 
is limited for computational reasons.[18] Therefore, if the value of a time-dependent risk 
factor changes several times, this approach poses challenges. Hence, it is only suitable to 
address relatively short-term effects[18].
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Cardiovascular risk as a dynamic phenomenon
The management of patients that have experienced a coronary event is a dynamic process. 
In fact, throughout hospitalisation a continued refinement of the initial treatment strategy 
is necessary to treat the patient as well as possible. For example, Mr. Jones will be treated 
with a percutaneous coronary intervention (PCI) directly when he arrives to the hospital. 
To prevent recurrent events he will receive cardiac medication including anticoagulants. 
As such, his ‘baseline characteristics’ change: he now has a cardiac history, consisting of 
myocardial infarction and primary PCI. Suppose that Mr. Jones initially survives the coronary 
event and the PCI, but experiences a hemorrhagic stroke on day 3: then the treatment 
strategy and risk of death during his hospitalisation will have changed. Therefore, it would 
be logical to update risk assessments continuously, based on actual patient status and 
intervening events. For Mr. Jones this means that ‘previous stroke’ will be added to his 
profile and the use of anticoagulants will be removed. His risk for recurrent events will 
again be different now.
The concept of dynamic prognostication has been introduced for patients presenting with 
non-ST-elevation acute coronary syndromes.[19] Based on the GUSTO-IIb and PURSUIT 
databases, several logistic regression equations were developed to predict 30-day mortality 
using baseline information, and variables obtained during hospitalisation. These separate 
regression models were then integrated into a composite, dynamic model to describe the 
effects of changing conditions over time. The performance of this model was considerably 
better than the ‘static’ regression model that used only baseline characteristics.[19]
The approach of dynamic risk modelling may also be applied in other settings such as 
established, stable CAD.[20] In general, this approach may provide a valuable guidance 
for the short-term management of patients with established CAD; however, as far as long-
term patient management is concerned, it becomes rather impractical. More importantly, 
such dynamic risk decision-models remain focused on one outcome event, do not provide 
detailed insight into the life history of a patient, and cannot take into account the versatile 
nature of atherosclerotic disease because of the limited follow-up time. In order to 
overcome these limitations the clinical course of a patient with CAD can be described by a 
simulation model.
SIMULATION MODELLING
Simulation modelling refers to the process of imitating a real-life phenomenon with a 
set of mathematical equations, which are based on observational data, using computer 
software[21]. In medicine, simulation models can be used to study the natural course of 
a disease, as well as the effects of chronic treatment,[22] and can apply for populations 
or individual patients. We will describe the Markov state transition model and micro-
simulation.
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Markov state transition model 
The application of Markov models for determining prognosis has been first described in 
1983.[23]-[24] According to this modelling technique, individuals from a virtual patient 
population are distributed across distinct health states (so-called Markov states) and 
subsequently make transitions between these states.[23] In order to simulate their 
remaining course of life, the virtual time-axis is divided into a finite number of time intervals 
whose length can vary according to the probability of making a transition between states 
(i.e. having an event).[25] At the end of each interval, patients who are still alive can move 
to a different state according to predefined transition probabilities. Consequently, the time 
spent in a certain state depends on the incidence of the predefined events. Rare events 
result in a longer time spent in a certain state than common events. 
The transitions between states continue until the entire cohort is absorbed into the ‘dead’ 
state or until the cycle sum becomes too low, and subsequently the simulation ends.[23] 
The output usually includes the estimated population average life expectancy. Treatment 
effects can be studied by repeating the simulation with adjusted probabilities.
No prior MI  
Starting point 
Prior MI 
Preserved LVF 
(n= 1000) 
 
Prior MI 
Impaired LVF 
Endpoint 
Dead 
P=1 
P 
P 
P 
P P 
P 
P P P 
Figure 1. Simple Markov model to study the lifetime clinical course of CAD patients
Mr. Jones has experienced his first MI, and thus has established CAD now. He falls into the 
category of “prior MI, preserved left ventricular function (LVF)”. The simple Markov model 
that is presented in Figure 1 and panel A and B in table 1, might be used to study the 
virtual lifetime of a cohort of 1000 patients who are copies of Mr. Jones. In this example, 
the probabilities of changing health state are independent of patient characteristics and 
are based on probabilities obtained from prior research. At the beginning of the first model 
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cycle, all patients are in the health state ‘Prior MI, preserved LVF’ (Panel B, row: 1, column: 
‘prior MI, preserved LVF’; this cell contains 1000 patients). Panel A shows fictive transition 
probabilities between the different health states. As can be seen in panel A, row 2, the 
probabilities of staying in the health state ‘Prior MI, preserved LVF’, or moving from this 
state to the states ‘prior MI, impaired LVF’ or ‘Dead’, are 0.85, 0.05 and 0.10, respectively. 
Hence, at the end of the first cycle (i.e. at the end of the first year), 850 patients will have 
remained in this state (1000 patients multiplied by the transition probability of 0.85 from 
panel B), and 50 patients will have moved to the health state ‘Prior MI, impaired LVF’ (1000 
patients multiplied by the transition probability of 0.05). These patients are still alive, but 
their prognosis has changed. Another 100 patients will have moved to the health state 
‘dead’ (1000 patients multiplied by 0.10). This process is repeated for the second year of 
follow-up, again using the appropriate transition probabilities from panel A. 
Table 1. Panel A Input and output of a simple Markov model to study the lifetime course of 1000 
patients of age 60 without prior myocardial infarction 
Health state before transition Health state after transition
Prior MI Prior MI Prior MI Dead
Preserved LVF Impaired LVF
No prior MI 0.94 0.04 0.005 0.015
Prior MI – preserved LVF 0 0.85 0.05 0.10
Prior MI – impaired LVF 0 0 0.85 0.15
Dead 0 0 0 1
Input: transition probabilities (related to a cycle-interval length of 1 year)
Table 1. Panel B
Cycle * Health states
No prior MI Prior MI Prior MI Dead
Preserved LVF Impaired LVF
1 0 1000 0 0
2 0 850 50 100
3 0 723 85 193
11 0 197 116 687
21 0 39 46 916
31 0 8 13 979
40 † 0 2 4 994
0 6657 2195 31 148
Output: number of patients in each health state at the start of selected simulation cycles
LV = left ventricle; LVF = left ventricular function; MI = myocardial infarction
* The cycle-interval length is 1 year
† The patients who were still alive at the end of cycle 40 were supposed to have died just at the start of cycle 41 
(i.e. at the virtual age of 100)
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At the end of the second year, 723 patients are still alive and have preserved LVF, 85 another 
have impaired LVF and a total of 193 patients have died. The process continues until a 
virtual maximum age is reached; in this case for example age 100. After 40 simulation 
cycles, the total number of life years in the state ‘Prior MI, preserved LVF’ amounted 6657. 
Hence, the estimated life expectancy in a condition with preserved left ventricular function 
is estimated at 6.7 years, while the estimated life expectancy with impaired left ventricular 
function is estimated at 2.2 years. Total life expectancy is estimated at 6.7 years plus 2.2 
years equals 8.9 years. Since simulation started with a population of patients who are 
copies of Mr. Jones, these results might be used for the management of Mr. Jones as an 
individual.
 The ‘classical’ Markov model has no ‘memory’: the past history such as clinical events 
has no influence on the risk of death or clinical events such as myocardial infarction.
[24]  Hence, the Markov model assumes that all individuals starting a cycle in a given 
state are a homogenous group.[25] This fundamental property represents an obvious 
oversimplification of reality, since the incidence of events as well as treatment choices 
usually depend on patient characteristics. If one would like to account for these relations, 
additional health states should be added to the model. However, with each added relation 
the number of health states roughly doubles, and soon the model becomes quite complex 
and disorderly, whereas the running time increases rapidly. 
Alternatively, memory can be added to the model by making use of tracking variables.
[25] When a certain event has occurred in a patient, a virtual marker is attached to 
this patient, so that in future simulations the risk and time to a consecutive event will 
be adapted accordingly. Likewise, a large amount of tracking variables adds to excessive 
model complexity. In conclusion, although it is generally recognized that the Markov 
model provides a useful tool for modelling processes at population level, its properties 
limit studying the remaining lifetime of an individual patient. Micro-simulation, also 
termed discrete-event simulation, Monte Carlo simulation or dynamic risk modelling offers 
a better solution for this situation.
Micro-simulation
In contrast to Markov models, which simulate the remaining lifetime of a virtual patient 
population, micro-simulation simulates the remaining lifetime of one single virtual patient 
at a time and builds a virtual patient population by repeating the simulation numerous 
times.[26] In the late 1950s, the first practical use of micro-simulation was introduced at 
the decision-making units for social policy.[6] Gradually, the concept of micro-simulation 
was used in broader policy questions at different departments.[6] The development of 
prediction models for health policy questions using micro-simulation has subsequently 
been increasing.   
Principles of micro-simulation modeling | Chapter 3.1
69
3.1
A virtual CAD patient like Mr. Jones, with his unique risk profile is at risk of several disease 
related events (myocardial infarction, stroke, etc.) for the remainder of life. For each of 
the possible events that can happen to a patient, micro-simulation can simulate the age at 
which these will happen. Patient characteristics influence the occurrence of these events. 
This is also called stochastic uncertainty.[27] This simulation can be done repeatedly for 
individual subjects by randomly drawing from the probability distribution of the time to 
that particular event.[26] The shape and parameters of the distribution are related to the 
patient’s unique profile. 
The event with the earliest age of occurrence is then the one that ‘really’ happens. The 
patient may or may not survive the event. If he survives, he may or may not receive specific 
treatment. If he survives treatment, his unique profile is adjusted, since at least his virtual 
age has increased and his simulated medical history has been altered, and new random 
times until events are drawn. In practical terms: Mr. Jones started as a healthy 60 years 
old male who experienced an MI, and was treated with a PCI. The event and treatment 
altered his unique profile so the probability for having a recurrent event also will change. 
Further simulations will take these changes into account, and consequently provide the 
‘memory’ in this model. The process continues until the patient dies. If the simulation of 
the lifetime of this patient is repeated numerous times, a virtual population is created, 
consisting of patients with identical baseline characteristics and with a broad range of 
possible outcomes. This dataset can then be used to determine the most likely prognosis 
of an individual patient with those characteristics. Currently available desktop computers 
will be able to run this entire process within seconds for simple simulations. Software has 
been developed to perform micro-simulation in several studies, for instance the global 
diabetes model[28], the colorectal cancer screening[29] and for aortic valve replacement.
[30] A general software package for wider application of micro-simulation still needs 
development.[31]
The above examples illustrate that both Markov and micro-simulation models are capable 
of taking serial outcomes into account, contrary to regression. Another similarity between 
Markov and micro-simulation is that both modelling techniques use input parameters from 
prior research, such as meta-analyses, or analyses on existing datasets available to the 
researcher. Micro-simulation has several advantages over a Markov state transition model. 
Since micro-simulation does not work with predefined cycle lengths, it allows events to 
occur at any point in time.[25] Furthermore, since patient characteristics need not be 
defined by certain states in micro-simulation, the model is capable of considering a wide 
range of individual variations in state of health. Also, micro-simulation allows changing 
hazards over time.[32] Hazards may change over time because of changes in risk profile, 
such as increasing age, or because of competing events that occur during follow-up. The 
main advantage of micro-simulation is that it can be used as a tool for tailored clinical 
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decision making, since it provides detailed insight into the life history of individuals. The 
output of the simulation will be sharpened to the individual patient with his unique patient 
profile at the beginning of the simulation, and take into account all the events occurring 
over time during simulation. For a particular patient, the expected benefits of treatment 
can be quantified in terms of numbers of each of the events that will occur during the 
remaining life, the duration of event-free periods, and the remaining life expectancy. 
Dead  
Event  P E_D  
1-P E_D  
LVF  Patient  
profile 
MI history  
time to event  
Figure 2. Simple micro-simulation to study the lifetime clinical corse of CAD patients
Figure 2 and Table 2 describe a simple micro-simulation model that is equivalent to the 
Markov model in Figure 1, and might be used to study the long-term clinical course of Mr. 
Jones. Specifically, panel A and B in table 2 summarize the input of the micro-simulation 
model, and panel C summarizes the output. The probabilities chosen in this example 
are all fictive. Besides the medical history, the patient profile may comprise all kinds of 
variables which might influence the time to event, without disorganizing the model. We 
ran this model 1000 times in order to construct a virtual population with identical baseline 
characteristics, but with varying life courses. In the first run, Mr. Jones died at age 61.3 
after having had another MI at age 61.3. His LV function became severely impaired at age 
55.0. In the second run, Mr. Jones died at age 83.8 after having had 2 MI’s at age 67.0 
and 74.4. He had preserved LV function until the end of his life. The average age of death 
of the 1000 clones of Mr. Jones was 68.8 years. Hence, for this 60 years old male, his 
estimated life-expectancy was 8.8 years. His life expectancy in a condition with preserved 
left ventricular function was estimated at 6.4 years.
Table 2, panel A. Occurrence estimates of a simple micro-simulation model to study the lifetime 
course of 1000 patients of age 60 with prior myocardial infarction and preserved LV function
Event Patient profile Probability function Parameter
MI All profiles Exponential 0.05
Impaired LVF No prior MI Exponential 0.005
Prior MI – preserved LVF Exponential 0.05
Other profiles Fixed probability 0
All-cause death No prior MI Exponential 0.01
Prior MI – preserved LVF Exponential 0.09
Prior MI – impaired LVF Exponential 0.135
Input: time to event distributions; the unit of time is year
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Table 2, panel B. Mortality risks of the events
Event Patient profile Outcome Probability
MI No prior MI Alive, preserved LVF 0.80
Alive, impaired LVF 0.10
Dead 0.10
Prior MI –preserved LVF Alive, preserved LVF 0.60
Alive, impaired LVF 0.20
Dead 0.20
Prior MI – impaired LVF Alive, impaired LVF 0.70
Dead 0.30
Impaired LVF All profiles Alive 1
All-cause death All profiles Dead 1
Input: immediate outcome after the event
Table 2, panel C. Model output
Median (Q1,Q3) time to death, year 6.2 (2.7, 12.2)
Median (Q1,Q3) time to impaired LV function, year 4.8 (1.8, 8.9)
Life expectancy, year 8.8
Life expectancy with preserved LV function, year 6.4
Output: number of patients in each health state at the start of selected simulation cycles
LV = left ventricle, LVF = left ventricular function; MI = myocardial infarction
One of the variables that might influence the time to event is the choice of treatment by 
physicians. Table 3 shows in more detail how micro-simulation can be helpful to estimate 
life-long treatment effects in an individual patient. In this particular example, we simulated 
treatment with a drug that reduces death and myocardial infarction by 20%. Apparently, 
according to the simulation, the effects on life-expectancy are highly dependent on the 
patient profile. This kind of data can be used by physicians to decide on treatment, as well 
as to increase patient awareness of the magnitude of the effects of prescribed medication.
Although micro-simulation has several advantages, it also entails practical challenges.[32] 
First, after the determinants and events of interest have been specified, the parameters of 
their associations should be assessed. The value and uncertainty of the parameters (beta 
coefficients) can be estimated using various approaches. Databases at the researcher’s 
disposal may be used. A drawback of this approach is that the results may not be 
generalizable to patient populations other than the ones used for parameter estimation. 
Alternatively, literature research and a subsequent meta-analysis or meta-regression could 
be performed. 
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This leads to availability of larger groups of subjects, and, since various studies are 
combined, improved generalizability. Furthermore, a combination of both available 
databases and literature research may be used. For all of the alternatives the main 
challenge is how to obtain reliable parameters. Nevertheless, the advantage of micro-
simulation is the diversity of patient profiles that can be taken into account, while in RCT’s 
patients characteristics are dependent on inclusion criteria of the trial and may not apply 
to the specific patient a physician is treating.
Second, the shapes of the associations should be assessed.[33] The most straightforward 
approach is to assume that the hazards of experiencing the endpoints of interest are 
constant over time. However, this may be an oversimplification of reality. Alternatively, 
risk may be assumed to take two phases of constant hazard, with the hazard being greater 
during the first phase than during the subsequent period. For example, the first months 
after an MI the risk of having a recurrent event will be higher than later on in time, when 
risk will stabilize. The concomitant distribution has two periods with two different hazards 
which can be calculated with the so-called two-period function. Other functions may also 
be applied to accommodate a changing risk over time. A risk that increases with time may 
be present with ageing; the risk of having an event will become larger and the hazard ratios 
should be adjusted. To calculate this, a so-called Weibull function can be applied. This is a 
generalization of the exponential distribution to accommodate a changing risk over time. 
In summary, the choice of a particular shape of an association depends on the situation 
that is being modelled and should be well-considered.
Furthermore, validation forms an essential part of the development of a micro-simulation 
model as it demonstrates the model’s credibility and reliability.[34] In our context, validation 
refers to the process of determining the extent to which the relationships that have been 
modelled are able to describe patient prognosis as specified by empirical data. One way to 
go about this is to utilize a training set and a testing set by randomly dividing the available 
database into two data sets. The training set is used for developing the model, and the 
testing set is used to assess model discrimination and calibration. Alternatively, another 
study population could be used for validation. Finding a study population that has similar 
characteristics and is consequently suitable for this purpose may be challenging. 
Finally, if the objective is to model long-term survival, validating and calibrating the right 
hand tails of the model may be problematic. We face the intrinsic difficulty that there 
are often no sufficiently large datasets containing observational data followed-up until 
death. A solution for this problem is currently not at hand. Thus, we often resort to making 
assumptions about the risk of clinical events beyond the end of the follow-up of a study. 
From the above it is evident that the quality, reliability and usefulness of a simulation 
model are mainly determined by the quality of the input, which requires empirical data of 
sufficient quality. 
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Micro-simulation models have been developed for patients requiring aortic valve 
replacement, in order to assist with the choice of an appropriate type of valve.[35] Van 
Geldorp et al. used a predefined group of baseline characteristics which could change 
after the occurrence of an event.[30] Model parameters were extracted from published 
literature. Different hazard functions were used depending on the clinical situation; 
for example, a constant hazard was used to model the probability of an event which is 
constant over time, while a Weibull function was used to model a risk that increases with 
time. The micro-simulation model dealt with competing risk by allowing occurrence of 
events to change the patient’s profile, resulting in changes in probability of having a next 
event. The model that was developed was meant to predict long-term outcome. Since 
follow-up time after aortic valve replacement was limited in the literature, the model was 
extrapolated and validated on the investigator’s own database that contained a longer 
follow-up time. Similar models have been developed for prediction of prognosis after 
aortic valve replacement.[6, 36, 37] 
Since the above-described research has been used for the development of new guidelines 
in the field of aortic valve replacement,[38] it has had direct consequences for clinical 
practice. The choice of treatment by physicians and the quality of life of patients have been 
improved. Micro-simulation has had a great share in this improvement, for example by 
lowering the age threshold for using biological valves.[36] This demonstrates that micro-
simulation may also be a promising technique in other medical fields.
CONCLUSION AND PERSPECTIVE
In conclusion, by applying micro-simulation, the most likely prognosis of an individual 
patient can be calculated by means of a virtual dataset. The remaining lifetime of one 
single virtual patient is simulated based on the unique individual profile. For each of the 
possible events that can happen to a patient, micro-simulation can simulate the age at 
which it will occur. The event with the earliest age of occurrence is then the one that 
‘really’ happens. By repeating this simulation numerous times, and by subsequently 
building a virtual patient population from the total of these virtual patient lifetimes, the 
virtual dataset is obtained. 
Consequently, the results of a micro-simulation can inform physicians by estimating 
most likely outcomes regarding a broad range of clinical events in large numbers of 
virtual patients with equal baseline conditions. Micro-simulation can be used to evaluate 
treatment effects by estimating the event-free life expectancy without and with treatment. 
An important advantage of micro-simulation models compared to regression models, is 
that multiple events, occurring consecutively in time, may be examined. While Markov 
models may also examine consecutive events, these models have limited possibilities to 
accommodate changing baseline characteristics.  Furthermore, micro-simulation is able to 
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take into account changing hazards over time, making the model more reliable. The main 
challenges that should be addressed while constructing a micro-simulation model include 
the input data requirements, assessment of the shapes and parameters of the associations 
between the determinants and events of interest, the validation of the model and the 
often limited follow-up time of the input data.  
For readers who wish to read more about micro-simulation, or who wish to bring it into 
practice, we recommend the following resources. For more information about decision 
analyses, Markov models and micro-simulation, Hunink et al.[25] is an excellent reference. 
Rutter et al.[6] give additional insight into the development and application of micro-
simulation models for health policy questions. Weinstein et al.[39] have described 
methodological aspects which can help in evaluating a health-care model. For a practical 
example of a micro-simulation model that is currently being used, readers may refer to the 
website of CardioThoracicResearch.[40] 
The European Society of Cardiology, the American College of Cardiology and the American 
Heart Association have established guidelines for the diagnosis and management of 
cardiovascular diseases. These guidelines aim to support the treating physician by 
summarising the evidence for the usefulness of treatment that has emerged from 
clinical research. However, the guidelines for ischemic heart disease, which encompass 
chronic stable angina and (non)-ST-elevation acute coronary syndromes, contain almost 
500 recommendations[41] and it is unrealistic to assume that physicians will be able to 
adhere to all of these without computer assistance. We anticipate that micro-simulation 
for decision-making in established CAD may act as an electronic assistant, which helps to 
ensure that guideline recommendations will be effectively implemented. Furthermore, it 
may serve as a practical tool that facilitates tailored clinical decision making in individual 
patients with established CAD in whom optimal management is unclear (for example, 
when individual patient characteristics differ from those of specific populations on which 
trial results and recommendations are based).
Such a micro-simulation model would take into account patient characteristics, medical 
history and medication use (Figure 3).
Dead  
Treatment  
Event  
time to event  
1-P E_D  
anginal symptoms  
Patient  
profile 
age, gender  
risk factors, medical history  
medical treatment, revascularisation  
cardiac imaging  
cardiovascular events  
P T_D  
P E_D  
1-P T_D  
Figure 3. Extended micro-simulation model for tailored decision making in individual CAD patients
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Based on these determinants it would provide detailed insight into the life history of an 
individual patient, and thereby guide treatment decisions for that particular patient. A 
treatment decision could be added to the patient profile, and subsequently prognosis with 
or without this treatment could be compared. Thus, a well-grounded treatment decision 
could be made by the physician. 
Such a micro-simulation model could be expandable to the broader range of atherosclerotic 
diseases. We expect that such a development would ultimately result in improved care and 
a better life for patients with cardiovascular disease.
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ABSTRACT
Microsimulation can be used to predict the prognosis of an individual patient based on 
a virtual patient population of copies of that patient. 
In this study we compare the outcomes of an existing validated microsimulation 
program that is designed to study valvular heart disease and a newly developed 
microsimulation program that is designed to study heart diseases in general.
We studied in depth the results of both systems to model the prognosis of a 40 year 
old male patient undergoing allograft surgery. Furthermore we studied the model 
results in relation to age and sex to provide a general overview of the most important 
outcome variables including operative mortality, average survival time, average event 
free time and average time to reoperation.
Our results show a good agreement between the two systems regarding all simulations 
of allograft surgery. We intend to use the newly developed software to explore other 
disease/event related prognostic models.
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INTRODUCTION
One of the simplest forms of microsimulation is the simulation of a coin flip. By using 
computer software we may throw a coin a large number of times. For an honest coin (i.e. 
probability of “head” is 0.5; note that parameters can be freely chosen) we should expect 
to observe approximately the same number of either heads or tails. A more advanced 
version of this technique can be used in medicine to predict disease prognosis as described 
below.[1]
Microsimulation in AVR
The use of microsimulation is a widely accepted and useful strategy to support clinicians 
in choosing an appropriate treatment for patients with an indication for aortic valve 
replacement (AVR).[2, 3] Microsimulation simulates the probability of operative mortality 
and AVR related adverse events for an individual patient based on his clinical characteristics 
and the type of AVR that is being considered. Specifically, it creates a virtual population of 
patients with identical baseline characteristics, and calculates the event-free period after 
surgery, reoperations and life expectancy, for each type of AVR. 
For each virtual patient, a lifetime of events and reoperations is simulated, using functions 
and random distributions, based on parameters derived from epidemiological studies. 
Consecutive events during the patients’ lifecourse are simulated as follows. After the initial 
operation, the time to each individual valve-related incident is calculated. The event that 
occurs after the shortest time period is chosen as the one that actually took place in the 
virtual patient. After this event, a reoperation may be needed or another event may occur. 
This second event is simulated by repeating the procedure. The simulation for a virtual 
patient ends when the patient dies, either due to background mortality, event-related 
mortality or operative mortality.
AVRSim
In the past, our centre has developed software (AVRSim) for simulating the lifecourse of 
AVR patients to support physicians in choosing the most appropriate type of AVR. This 
software was validated internally and externally.[4-6] 
AVRSim is specifically tailored to handle AVR patients. The software compares the following 
types of AVR: allograft, bioprothesis, mechanical, and autograft. Unfortunately, the current 
version of AVRSim could not be easily transformed to other disease/event/treatment 
related models. AVRSim is available, after registration, for download.[7] 
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General microsimulation toolkit
We hypothesize that the microsimulation technique can also be applied to other clinical 
patient populations. For this purpose, we have developed a new software package, General 
Microsimulation Toolkit (GMT). With this package we aim to provide a microsimulation 
toolkit that is applicable to any given type of disease (or disease related event) and 
treatment strategy. 
The key features of a disease in the system are the time function to develop the disease (or 
disease related event), the mortality function for the disease, the adjustment for baseline 
parameters and the function to determine the most likely treatment. Each treatment has 
a mortality function (for example the risk of dying during an operative procedure), a time 
function to determine the most likely time to treatment-related event and the adjustment 
for baseline parameters. 
The GMT is a web based system developed in C# and uses the JEP.NET library[8] for the 
mathematical functions. The system can handle a variety of statistical methods such as: 
(logistic) regression models, (log) normal, 2-period, Weibull, Pareto, and Gompertz.
The system has a user-friendly interface to incorporate these statistical methods into a 
patient-event-treatment microsimulation model. It calculates the time-to-event, event-
free period, life expectancy, treatment efficiency and treatment related events. Moreover, 
it facilitates the comparison of the outcomes of each simulation (statistically and graphically 
in a survival curve) for different treatment choices.
METHODS
The aim of this study is to compare the results of AVRSim and GMT. In this paper, we 
consider one case in depth; the case of a 40 year old male undergoing allograft surgery. We 
also consider different populations with different ages and genders.  
Case of a 40 year old male
In this study, we compare the results of a hypothetical case study of a 40 year old male 
undergoing allograft surgery. We have generated a virtual patient population of 10000 
identical individuals in both systems.
In Table 1 we show the parameters of the allograft model. The risk function, together with 
the age dependency, calculates the time to an AVR related event, of the event occurrence 
after an allograft procedure. 
The mortality risk describes the mortality risk when the event occurs. The reoperation risk 
is the risk of undergoing a reoperation after the event. The reoperation type describes the 
reoperation which is performed after the event.
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Table 1. Parameters of the allograft microsimulation model used in both systems
Event Risk function Age dep. Mortality Risk Reoperation risk Reoperation 
Valve thrombosis Zero-risk 0 0 1 Allograft
Thromboembolism Exponential(0,006) 0 0.1 0
Hemorrhage Exponential(0,001) 0 0.07 0
Non-structural 
dysfunction
Exponential(0,005 ) 0 0 1 Mechanical
Endocarditis Exponential(0,005 ) 0 0.25 1 Allograft
Structural dysfunction Weibull(2,234,;3,669) 0,0112 0 1 Mechanical
The operative mortality odds for an allograft at age 40 is 0.0260; the odds ratio (OR) for age (per year) is 0.0218; 
the OR per reoperation is 0.5306. We used a background mortality based on the Dutch life tables and a hazard 
ratio of 3.65. 
Different patient populations
In a second analysis we constructed different virtual patient populations consisting of men 
and women with ages defined by 10-year age-intervals (n=10000, age-range 10 to 70). We 
simulated an allograft replacement operation in each population. We analyzed operative 
mortality, the average survival, the average freedom of event time and the average 
freedom of reoperation time. 
We used similar parameters for an allograft as described in table 1 and subheading 2.1. 
However the operative mortality is different because it is age dependent. The hazard ratio 
used to calculate the background mortality is age and gender dependent. Again, we use 
the Dutch life tables for the background mortality.
RESULTS
Results case of a 40 year old male 
Negligible differences were present in the average survival in years after the allograft 
procedure, average event free period, average number of persons free of reoperation, 
number of event free persons, number of individuals that didn’t receive a reoperation, the 
mortality of the initial allograft procedure and the number of individuals that died due to 
non-valve related events/operations (‘mortality non related’). 
Table 2 also shows also the number of events for each event. In AVRsim, 1600 individuals 
developed a thromboembolism, 177 individuals developed 2 thromboembolisms and 13 
individuals developed 3 thromboembolisms. 
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Table 2. Results of a case study of 40 year old male after allograft surgery in AVRSim and GMT.
AVRSim GMT
Survival (years) 21.17 21.30
Event free (years) 10.70 10.76
Reoperation free (years) 11.11 11.41
Number of event free 1670 1683
Number of reoperation free 1937 2073
Mortality first operation 242 234
Mortality non-related 8218 8235
Valve thrombosis
1 46 44
Thromboembolism
1 1600 1556
2 177 144
3 13 13
4 0 1
Hemorrhage
1 1337 1378
2 203 144
3 23 12
4 3 1
Non structural dysfunction
1 878 878
2 63 54
3 1 2
Endocarditis
1 575 631
2 29 23
3 2 0
Structural dysfunction
1 7326 7144
Results different patient populations
Table 3 shows the results for the populations of patients undergoing allograft operation 
that we generated. For each population, we simulated age from 10 to 70 for both genders. 
The table shows the most relevant outcome parameters; percentage of operative mortality 
of the allograft operation (‘Op. mortality’), average survival time in years, average time to 
first event (‘Event free’) and average time to first reoperation (‘Reoperation free’). The last 
row displays the range of the maximum difference between each of the columns.
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Due to the fact that AVRSim uses a non-seeded random function, the results are always the 
same. This is clearly shown by the identical operative mortality for both genders. 
Table 3. The results of AVRSim vs. GMT for different virtual populations with different initial age in 
years and gender (M for male and F for female). Op. mortality is the percentage of the population 
that died during the initial allograft procedure.
Gender Op. mortality (%) Survival (years) Event free (years) Reoperation free (years)
AVRSim GMT AVRSim GMT AVRSim GMT AVRSim GMT
10 M 1.38 1.15 41.34 41.60 8.49 8.48 8.74 8.94
F 1.38 1.45 44.35 44.30 8.51 8.47 8.76 8.96
20 M 1.55 1.50 33.58 33.60 9.27 9.25 9.57 9.81
F 1.55 1.42 36.51 36.55 9.35 9.37 9.66 9.97
30 M 1.94 2.09 26.77 26.98 10.12 10.01 10.48 10.72
F 1.94 2.06 28.62 28.62 10.14 10.09 10.50 10.76
40 M 2.42 2.34 21.17 21.30 10.70 10.76 11,11 11.41
F 2.42 2.30 22.67 22.84 10.73 10.75 11,14 11.42
50 M 2.97 3.07 16.77 16.82 10.76 10.77 11.20 11.37
F 2.97 3.12 18.78 18.90 11.15 11.04 11.61 11.76
60 M 3.58 3.88 13.08 12.92 10.05 9.93 10.45 10.43
F 3.58 3.77 14.41 14.41 10.76 10.72 11.2 11.36
70 M 4.46 4.72 9.87 9.77 8.52 8.41 8.82 8.75
F 4.46 4.60 10.29 10.37 8.93 8.91 9.25 9.32
Range diff -0.3 ; 0.23 -0.26 ; 0.16 -0.06 ; 0.12 -0.31 ; 0.07
DISCUSSION AND CONCLUSIONS
We have demonstrated good agreement between AVRSim and GMT. We conclude that the 
underlying mathematical functions are correctly implemented. The AVRSim models have 
been internally and externally validated. With the current study, the GMT model for AVR 
has been validated against the AVRSim AVR model.
The next step is the application of this software to other prognostic models, including 
cardiovascular diseases and treatments. Obviously, these new models need to be evaluated 
internally and externally before they can be used in daily practice.
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ABSTRACT
Introduction: We investigated whether concentrations of TNF-α, TNF-β, TNF-receptor 
2, interferon-γ, IL-6, IL-8, IL-10 and IL-18 are associated with extent and composition 
of coronary atherosclerosis determined by grayscale and virtual histology (VH)- 
intravascular ultrasound (IVUS).
Methods: Between 2008-2011, IVUS(-VH) imaging of a non-culprit coronary artery 
was performed in 581 patients (stable angina pectoris (SAP), n=261; acute coronary 
syndrome (ACS), n=309) undergoing coronary angiography from the ATHEROREMO-
IVUS study. Plaque burden, presence of VH-IVUS-derived thin-cap fibroatheroma 
(TCFA) lesions, and presence of VH-TCFA lesions with plaque burden ≥70% were 
assessed. Blood samples for cytokine measurement were drawn from the arterial 
sheath prior to the angiography procedure. We applied linear and logistic regression. 
Results: TNF-α levels were positively associated with plaque burden (beta (β) [95%CI]: 
4.45 [0.99-7.91], for highest vs lowest TNF-α tertile) and presence of VH-TCFA lesions 
(odds ratio (OR) [95%CI] 2.30 (1.17-4.52), highest vs lowest TNF-α tertile) in SAP 
patients. Overall, an inverse association was found between IL-10 concentration and 
plaque burden (β [95%CI]: -1.52 [-2.49- -0.55], per Ln(pg/mL) IL-10) as well as IL-10 
and VH-TCFA lesions with plaque burden ≥70% (OR: 0.31 [0.12-0.80],highest vs lowest 
IL-10 tertile). These effects did not reach statistical significance in the separate SAP 
and ACS groups. 
Conclusions: Higher circulating TNF-α was associated with higher plaque burden and 
VH-TCFA lesions in SAP patients. Lower circulating IL-10 was associated with higher 
plaque burden and large VH-TCFA lesions. These in-vivo findings suggest a role for 
these cytokines in extent and vulnerability of atherosclerosis.
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INTRODUCTION
Inflammation is known to play a major role in atherosclerosis(1-3).The development of 
atherosclerosis includes, among others, expression of adhesion molecules by inflamed 
endothelium, migration of leukocytes into the intima, uptake of modified lipoprotein 
particles, and formation of lipid-laden macrophages(4). During the evolution of 
atherosclerotic lesions, T-lymphocytes join the macrophages in the intima(4). This T-cell 
infiltrate produces proinflammatory cytokines (including tumor necrosis factors (TNFs), 
interferons (IFNs), and interleukins (ILs)), but may also stimulate a T helper cell type 2 
(Th2) response which can promote anti-inflammatory actions (and cytokines such as IL-10 
and transforming growth factor β) (2, 5). This dual role of cytokines  is believed to control 
the subsequent development and destabilization of arherosclerotic plaques in coronary 
(among other) arteries(6), potentially leading to plaque rupture or erosion and ultimately 
resulting in adverse  clinical events such as myocardial infarction or sudden cardiac death 
(7). 
While previous research has provided ample insights into the signalling cascades of 
cytokines and their roles in the pathogenesis of atherosclerosis, studies on the associations 
of cytokines with in-vivo determined extent and particularly composition of coronary 
atherosclerosis are currently scarce. Cytokines are located both inside the affected vessel 
walls and in the circulation (8). We hypothesize that circulating cytokines are associated with 
in-vivo measures of plaque burden and features of plaque vulnerability, and consequently 
may be useful for clinical risk stratification with regard to cardiovascular outcome. 
The aim of this study is to examine the associations of the cytokines TNF-α, TNF-β, interferon 
γ (IFNγ), IL-6, IL-8, IL-10 and IL-18 and of circulating TNF receptor 2 (TNF R2) with the 
extent and composition of coronary atherosclerosis as determined in-vivo by intravascular 
ultrasound (IVUS) and IVUS-virtual histology (IVUS-VH), in a non-culprit vessel in patients 
undergoing coronary angiography.
METHODS
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described elsewhere(9). In brief, 581 patients who underwent diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for acute coronary syndrome 
(ACS; n=309) or stable angina pectoris (SAP; n=261) have been included from November 
2008 to January 2011 in the Erasmus MC, Rotterdam, the Netherlands. Intravascular 
ultrasound (IVUS) of a non-culprit coronary artery was performed subsequent to 
angiography. The ATHEROREMO-IVUS study has been approved by the human research 
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ethics committee of Erasmus MC, Rotterdam, the Netherlands. Written informed consent 
was obtained from all included patients and the study protocol conforms to the ethical 
guidelines of the Declaration of Helsinki.
Biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure, and were available in 570 patients for the current study. 
The blood samples were transported to the clinical laboratory of Erasmus MC for further 
processing and storage at a temperature of -80 0C within two hours after blood collection. 
C-reactive protein (CRP) was measured in serum samples using a immunoturbidimetric 
high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Cobas 8000 
modular analyzer platform (Roche Diagnostics Ltd., Rotkreuz, Switzerland). These analyses 
were performed in the clinical laboratory of  Erasmus MC.
Frozen EDTA-plasma samples were transported under controlled conditions (at a 
temperature of -80oC) to Myriad RBM, Austin, Texas, USA, where the concentrations of 
TNF-α, TNF-β, TNF R2, INFγ, IL-6, IL-8, IL-10 and IL-18 were determined using a validated 
multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). While TNF-α, TNF 
R2, IL-6, and IL-8 were determined in the full cohort of 570 patients, TNF-β, INFγ, IL-10 and 
IL-18, were determined in a random subset of 473 patients. This difference in numbers 
resulted from batch-wise handling of the samples in combination with an update of the 
composition of the multiplex assay by the manufacturer in-between two batches. None of 
the biomarker laboratories had knowledge of clinical or intracoronary imaging data.
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit, non-treated, coronary vessel, without significant luminal narrowing. The 
order of preference for selection of the non-culprit vessel was: 1. Left anterior descending 
(LAD) artery; 2. Right coronary artery (RCA); 3. Left circumflex (LCX) artery. All IVUS data 
were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, 
USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback 
system was used with a standard pull back speed of 0.5 mm per second. The IVUS images 
were analyzed offline by an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) that had no knowledge of clinical or biomarker data. The IVUS gray-scale 
and IVUS radiofrequency analyses, also known as IVUS virtual histology (IVUS-VH), were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The 
external elastic membrane and luminal borders were contoured for each frame (median 
interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were 
assessed. 
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Plaque burden was defined as the plaque and media cross-sectional area divided by 
the external elastic membrane cross-sectional area and is presented as a percentage. A 
coronary lesion was defined as a segment with a plaque burden of 40% in at least three 
consecutive frames(9). Using IVUS-VH, the composition of the atherosclerotic plaque was 
characterized into 4 different types: fibrous, fibro-fatty, dense calcium and necrotic core 
(10). A VH-IVUS-derived thin-cap fibroatheroma (TCFA) lesion was defined as a lesion with 
presence of > 10% confluent necrotic core in direct contact with the lumen(11).
Statistical analysis
Categorical variables are presented in percentages. The distributions of continuous 
variables, including biomarker levels and IVUS parameters, were examined for normality 
by visual inspection of the histogram and calculation of the skewness coefficient. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD), while 
non-normally distributed continuous variables are presented as median and interquartile 
range (IQR). For reasons of uniformity, all biomarkers are presented as median (IQR).
In further analyses, biomarker concentrations were examined both as continuous and as 
categorical variables (the latter by dividing the variables into tertiles). Biomarkers with 
a non-normal distribution were ln-transformed. Biomarkers in which the concentrations 
were too low to detect in more than 20% of the patients, were not examined as continuous 
variables. They were examined as tertiles, or else as dichotomous variables (measurable 
vs not measurable).
To take into account possible effect modification by indication for coronary angiography, 
we performed all analyses separately in patients with SAP and patients with ACS. We also 
present the results for the full cohort, in order to evaluate the effect of higher statistical 
power in those cases where associations were present in both groups of patients.
First, we examined associations of biomarker concentrations with the extent of 
atherosclerosis according to IVUS. We applied linear regression analyses with biomarker 
concentrations as the independent variable (ln-transformed or categorized when 
appropriate) and segmental plaque burden in the imaged coronary segment as the 
dependent variable. The results are presented as βs (per unit increase in ln-transformed 
biomarker concentration or per category of biomarker concentration) with 95% confidence 
intervals (95% CI). Subsequently, we examined the associations between biomarker 
concentrations and composition of atherosclerosis, specifically  the presence of VH-TCFA 
lesions as well as VH-TCFA lesions with plaque burden ≥ 70%. We used logistic regression 
analyses with biomarker concentrations as the independent variable (ln-transformed 
or categorized when appropriate). The results are presented as odds ratios (ORs) per 
unit increase in ln-transformed biomarker concentration or per category of biomarker 
concentration, with 95% CIs. 
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First, all above-described analyses were performed univariably. Subsequently, we adjusted 
for age, gender, indication for coronary angiography, diabetes, hypertension and CRP. 
All data were analyzed with SPSS software (IBM SPSS Statistics for Windows, Version 21.0. 
Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were considered 
statistically significant. 
RESULTS
Baseline characteristics
Baseline characteristics are summarized in Table 1. Mean age was 61.5 ± 11.4 years and 
75.4% were men. Coronary angiography or PCI was performed for several indications: 159 
(27.9%) patients had an acute myocardial infarction, 150 (26.3%) patients had unstable 
angina pectoris and 261 (45.8%) had SAP. The median length of the imaged coronary 
segment was 44.1 [33.7-55.4] mm. Based on IVUS-VH, a total of 239 (41.9%) patients 
had at least 1 TCFA lesion, including 69 (12.1%) patients with at least 1 TCFA lesion with 
a plaque burden ≥ 70%. Concentrations of INFγ, TNF R2, IL-8, IL-10 and IL-18 were not 
normally distributed; these biomarkers were therefore ln-tranformed for further analyses. 
TNF-α, TNF-β and IL-6 were too low to detect in a large part of the patients, and thus 
were not examined as continuous variables in the statistical models. TNF-α was too low to 
detect in 24%, and hence was categorized into tertiles for further analyses. TNF-β and IL-6 
were too low to detect in 92% and 62% of the patients, respectively, and these markers 
were dichotomized into measurable versus not measurable for further analyses. IL-10 
concentrations could be measured in 99%. TNF R2, IL-8, IL-18 and IFNγ were measurable 
in all patients. 
Biomarkers and extent of atherosclerosis
The results of the analyses for plaque burden of the entire measured segment are shown 
in Figure 1 and supplemental tables 1a,b and c. Higher TNF-α was associated with higher 
coronary plaque burden in patients with SAP (β [95%CI]: 4.45 [0.99-7.91], for the highest vs 
the lowest tertile of TNF-α). Such an effect could not be demonstrated in patients with ACS. 
Furthermore, lower IL-10 concentrations were associated with higher coronary plaque 
burden in the full cohort (β [95%CI]: -3.88 [-6.00- -1.76], for the highest vs the lowest 
tertile of IL-10). This effect was driven by both the SAP patients and the ACS patients. 
Although effect estimates for the highest tertile of IL-10 were similar in both groups (SAP: 
-2.95 [-6.23-0.33], ACS: -3.42 [-6.57- -0.27], in the SAP patients the estimates, as well as 
the linear trend, did not reach statistical significance. 
After multivariable adjustment, associations remained essentially the same for both TNF-α 
and IL-10. 
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Table 1. Baseline characteristics.
Total (n=570) ACS patients (n=309) SAP patients (n=261)
Patient characteristics
Age, years (mean±SD) 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n(%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes Mellitus, n(%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n(%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.5) 140 (45.5) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n(%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
IVUS characteristics
Segment length (mm), median (IQR) 44.1 (33.7-55.4) 43.9 (32.9-54.1) 44.8 (34.2-57.2)
Plaque burden (%), median (IQR) 39.2 (30.0-46.4) 37.2 (28.0-45.5) 40.2 (31.8-47.8)
Presence of VH-TCFA, n(%) 239 (41.9) 140 (45.3) 99 (37.9)
Presence of VH-TCFA with PB ≥ 70%, n(%) 69 (12.1) 32 (10.4) 37 (14.2)
Serum biomarker concentrations
C-reactive protein (mg/L), median (IQR) 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5 [0.6-3.1]
Tumor Necrosis Factor α (pg/mL) median 
(IQR)+ 
2.0 [1.4-2.9] 1.8 [1.4-2.6] 2.0 [1.4-3.3]
Tumor Necrosis Factor β (pg/mL) median 
(IQR)†§
35.0 [18.0-116.0] 20.5 [16.5-44.3] 36.5 [27.0-152.8]
Tumor necrosis factor receptor 2 (ng/mL) 
median (IQR)#
4.5 [3.6-5.7] 4.4 [3.5-5.8] 4.5 [3.7-5.6]
Interferon γ (pg/mL) median (IQR)* § 5.1 [3.9-7.3] 4.8 [3.8-6.6] 5.7  [4.2-8.2]
Interleukin-6 (pg/mL) median (IQR)- 3.5 [2.2-5.8] 3.7 [2.5-6.8] 2.5 [2.1-4.1]
Interleukin-8 (pg/mL) median (IQR)# § 8.9 [6.8-12.0] 9.9 [7.1-12.6] 8.3 [6.5-10.3]
Interleukin-10 (pg/mL) median (IQR)# § 5.2 [3.6-9.4] 6.9 [4.1-15.0] 4.4 [3.0-6.0]
Interleukin-18 (pg/mL) median (IQR)* 171.0 [132.3-215.0] 173.0 [133.0-216.3] 169.5 [130.5-211.3]
*Measurable in all patients
#Measurable in >99% of patients, too low to detect in <1%
+Measurable in 76% of patients, too low to detect in 24%
- Measurable in 38% of patients, too low to detect in 62%
†Measurable in 8% of patients, too low to detect  in 92%
§ TNFβ, IFNγ, IL-10 and IL-18: total n= 473, ACS n=309, SAP n= 261
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Figure 1. Association of TNF-α, TNF-β, TNF R2, INFγ, IL-6, IL-8, IL-10 and IL-18 with segment plaque 
burden in all patients, patients with stable AP and patients with ACS.
 
▪ Tertile 2 vs tertile 1, p < 0.05 □ Tertile 2 vs tertile 1, p ≥ 0.05 
● Tertile 3 vs tertile 1, p < 0.05 
○  Tertile 3 vs tertile 1, p ≥ 0.05 
*   p for linear association < 0.05 
Data showed in the figures are
 unadjusted estimates
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Figure 2. Association of TNF-α, TNF-β, TNF R2, INFγ, IL-6, IL-8, IL-10 and IL-18 with presence of VH-
TCFA in all patients, patients with stable AP and patients with ACS.
 
▪ Tertile 2 vs tertile 1, p < 0.05 □ Tertile 2 vs tertile 1, p ≥ 0.05 
● Tertile 3 vs tertile 1, p < 0.05 
○  Tertile 3 vs tertile 1, p ≥ 0.05 
*   p for linear association < 0.05 
Data showed in the figures are
 unadjusted estimates
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Figure 3. Association of TNF-α, TNF-β, TNF R2, INFγ, IL-6, IL-8, IL-10 and IL-18 with presence of VH-
TCFA with plaque burden ≥ 70% in all patients, patients with stable AP and patients with ACS.
 
▪ Tertile 2 vs tertile 1, p < 0.05 □ Tertile 2 vs tertile 1, p ≥ 0.05 
● Tertile 3 vs tertile 1, p < 0.05 
○  Tertile 3 vs tertile 1, p ≥ 0.05 
*   p for linear association < 0.05 
Data showed in the figures are
 unadjusted estimates
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Biomarkers and composition of atherosclerosis 
The results of the analyses for VH-TCFA lesions are displayed in Figure 2 and supplemental 
tables 2a, b and c. High TNF-α was positively associated with presence of VH-TCFA lesions 
in patients with SAP (OR[95%CI]: 2.30 [1.17-4.52] for the highest vs the lowest tertile of 
TNF-α). Such an effect was absent in patients with ACS. Furthermore, higher IL-8 seemed 
to confer lower risk of VH-TCFA in ACS patients; however, this effect was mainly driven by 
tertile 2. No associations were present between any of the other biomarkers and VH-TCFA.
Higher TNF-α was positively associated with presence of VH-TCFA lesions with a plaque 
burden ≥ 70% in the full cohort (OR[95%CI]: 2.85 [1.28-6.31] for the highest vs the lowest 
tertile of TNF-α) (table 4). This effect was driven by both patients with SAP and patients 
with ACS. Although the effect estimate reached statistical significance in the full cohort, 
this was not the case in the SAP and ACS groups. Nevertheless, the effect estimates for the 
highest tertile of TNF-α were similar in magnitude in both groups (SAP: 3.44 [0.89-13.29], 
ACS: 2.39 [0.89-6.45]. Higher IL-10 displayed an inverse association with presence of VH-
TCFA lesions with a plaque burden ≥ 70% in the full cohort (OR[95%CI]: 0.31 [0.12-0.80] 
for the highest vs the lowest tertile of IL-10, p for trend=0.037). Again, effect estimates did 
not reach statistical significance in these separate groups. After multivariable adjustment, 
associations remained essentially the same. 
DISCUSSION
This study examined whether circulating cytokine concentrations are associated with 
extent and composition of coronary atherosclerosis, as determined by IVUS and IVUS-VH 
in a non-culprit vessel, in patients with SAP or ACS undergoing coronary angiography. In 
patients with SAP, higher concentrations of TNF-α were associated with higher coronary 
plaque burden and with presence of VH-TCFA lesions, and displayed a tendency towards a 
positive association with presence of VH-TCFA lesion with a plaque burden ≥ 70%. Overall, 
higher concentrations of IL-10 were inversely associated with coronary plaque burden and 
with presence of VH-TCFA with a plaque burden ≥ 70%. These effects of IL-10 did not reach 
statistical significance in the separate groups. 
Inflammation is known to play a major role in atherosclerosis. In a previous study in the 
current patient population, we have demonstrated an association between CRP and IVUS 
characteristics (12). TNF-α is a proinflammatory cytokine that is secreted from activated 
innate immunity cells and is capable of inducing a cascade with a broad range of effects, 
including immunological activation, apoptosis, and procoagulative and antifibrinolytic 
actions, all of which can have an effect on the course of atherosclerosis (5, 13). Experimental 
studies on the role of TNF-α in plaque development and stability in mice have rendered 
inconsistent results, some finding anti-atherogenic effects and others finding pro-
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atherogenic effects (5). This discrepancy in results may be due to differences in underlying 
mechanisms of atherogenesis in different types of mouse models. A recent study (14) 
in human saphenous vein organ culture, to which a combination of TNF-α and LDL was 
applied, demonstrated phenotypic changes characteristic of the initial development of 
atherosclerotic plaques. Clinical studies on the role of TNF-α in cardiovascular disease 
have also rendered inconsistent results. A prior study found an increase of serum TNF-α in 
patients with MI and unstable angina pectoris compared to healthy subjects(15). Ridker et 
al. (16) found that plasma concentrations of TNF-α are persistently elevated among post-
MI patients at increased risk for recurrent coronary events. (17). Furthermore, Naranjo et 
al. (18) found that TNF-α therapy was associated with a lower incidence of cardiovascular 
events in patients with rheumatoid arthritis, who are known to be at high cardiovascular 
risk. On the other hand, Cherneva et al. (19) and Sukhija et al. (20) examined the prognostic 
abilities of TNF-α in patients with known coronary artery disease, but did not find any 
associations between TNF-α and patient outcome. In the current study, we found that 
higher TNF-α level are associated with both extent of atherosclerosis and with plaque 
vulnerability in patients with SAP, which is in line with the presumed proinflammatory 
nature of this cytokine. 
IL-10 is an anti-inflammatory cytokine that is produced by macrophages and lymphocytes 
(6). This cytokine is capable of inhibiting many cellular processes that may play an important 
role in atherosclerotic lesion development and in the modulation of plaque composition 
(6, 21). Mallat et al. (21) investigated atherosclerotic lesions in IL-10 deficient mice and 
showed increased infiltration of inflammatory cells, increased production of INF-γ, and 
decreased collagen content, which resulted in development of atheromatous lesions with 
signs of increased vulnerability. Several clinical studies have been performed on IL-10 
and cardiovascular disease. Heeschen et al. (22) demonstrated that a reduced serum IL-
10 level in patients with ACS is indicative of a poor prognosis. Most subsequent studies 
on the association of elevated circulating IL-10 levels with cardiovascular outcome have 
demonstrated positive associations with better prognosis (23-27). In line with this, we 
found an inverse association between IL-10 and coronary plaque burden as well as between 
IL-10 and presence of large, vulnerable plaques (i.e., VH-TCFA lesions with a plaque burden 
≥ 70%) in the overall study population. However, we did not find an association of IL-10 
with presence of TCFA lesions in general. These results suggest that IL-10 may in particular 
be associated with lower extent of coronary atherosclerosis and slower growth of VH-
TCFAs. In any case, these findings further support the hypothesis of a protective role of 
IL-10 in atherosclerosis. 
The associations of TNF-α and IL-10 with extent and composition of atherosclerosis 
demonstrated in the current study, suggest that these cytokines may potentially be useful 
for clinical risk stratification with regard  to cardiovascular outcome. However, we did not 
Cytokines, coronary atherosclerosis and clinical outcome | Chapter 4.1
103
4.1
find any associations between the cytokines we investigated and major adverse cardiac 
events during 1-year follow-up, adjusting for clinical covariates (supplemental table 4a-
c).  Possible explanations may include the fact that the magnitude of the effects of TNF-α 
and IL-10 may be relatively small in the context of this multifactorial disease, or that the 
current study lacks statistical power to expose these effects. 
We did not find any associations between several cytokines we examined and the  extent 
or composition of atherosclerosis. Analysis of some of the biomarkers (TNF-β and IL-6) 
was complicated by the fact that over 50% of the measurements were too low to detect. 
Cytokine assays are generally known to display limitations in terms of % detectability (28, 
29). This makes clinical investigations into the pathophysiological role and the prognostic 
value of these biomarkers challenging. In line with this, few clinical studies have been 
performed on circulating TNF-β. Furthermore, IL-6 is known to have large circadian 
variations, and a relatively short half-life of less than 6 hours (30) which also makes this 
marker difficult to investigate. Clinical studies on circulating TNFR2, INFγ, and IL-8 in 
patients with coronary artery disease are also limited in number. IL-18 has been examined 
more often, and has been suggested to be associated with the presence and severity of 
coronary atherosclerosis (31, 32). In the present study, we could not demonstrate such an 
association. 
Some aspects of this study warrant consideration. Our study population consisted of 
patients with SAP as well as patients with ACS. The group of patients with ACS is likely to be 
more heterogeneous, which may have influenced the findings. To account for this, we have 
performed the analyses separately in both groups. Furthermore, VH-IVUS imaging took 
place of a prespecified single target segment of a single non-culprit coronary artery, based 
on the assumption that such a non-stenotic segment adequately reflects coronary wall 
pathophysiology of the larger coronary tree. Although this assumption may be debated, 
previous studies evaluating IVUS have demonstrated that the coronary wall of comparable 
non-culprit, non-stenotic segments of a single vessel does reflect coronary disease burden 
at large and is associated with subsequent cardiovascular outcome (33-35). Moreover, 
it is important to note that IVUS is formally not capable of detecting the most rupture 
prone of all plaque phenotypes, the TCFA (36, 37), because the spatial resolution of IVUS is 
insufficient for thin cap detection (23, 24). Nonetheless, a concept of VH-IVUS derived TCFA 
has been postulated for plaques with a plaque burden ≥ 40% and a confluent necrotic core 
≥ 10% in direct contact with the lumen in at least three VH-IVUS frames (13, 23). Notably, 
we have recently demonstrated that such VH-IVUS derived TCFA lesions are strongly and 
independently predictive of the occurrence of major adverse cardiac events within the 
current study population (33). 
In conclusion, in patients undergoing coronary angiography, higher circulating TNF-α was 
associated with higher plaque burden and with presence of VH-TCFA lesions in patients 
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with SAP. Overall, lower circulating IL-10 was associated with higher plaque burden and 
with presence of VH-TCFA lesions with a plaque burden ≥ 70%. The latter effects did not 
reach statistical significance in the separate SAP and ACS groups. These in-vivo findings 
illustrate that TNF-α and IL-10 appear to play a role in both extent and vulnerability of 
coronary atherosclerosis, which is in line with experimental studies. 
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ABSTRACT
Introduction: This study aims to investigate the relations of several circulating 
chemokines with the extent and phenotype of coronary atherosclerosis as determined 
in-vivo by intravascular ultrasound (IVUS) and with 1-year clinical outcome.  
Background: Chemokines are involved vascular inflammation and progression of 
atherosclerosis. 
Methods: Between November 2008 and January 2011, IVUS imaging of a non-culprit 
coronary artery was performed in 570 patients who underwent coronary angiography 
for acute coronary syndrome (ACS) (n=309) or stable angina pectoris (SAP) (n=261). 
Subsequent events during 1-year follow-up were adjudicated to be either culprit 
lesion-related (n=11), non-culprit lesion related (n=27) or indeterminate (n=18). 
Results: Higher plasma monocyte chemoattractant protein-1 (MCP-1) (p=0.002 in 
SAP patients), macrophage inflammatory protein-1α (MIP-1α) (p=0.001) and lower 
Regulated upon Activation Normal T cell Expressed and Secreted (RANTES) (p=0.025 
in ACS patients) were associated with higher coronary plaque burden. Higher MCP-1 
(p=0.045 in SAP patients) and MIP-1α (p=0.021) were associated with higher necrotic 
core fraction. Higher MCP-1 (p=0.052 in SAP patients), higher MIP-1α (p=0.021) and 
lower RANTES (p=0.067) were associated with the presence of thin-cap fibroatheroma 
(TCFA) lesions. RANTES was independently associated with the composite endpoints 
of non-culprit related or indeterminate all-cause mortality, ACS or coronary 
revascularization (HR per SD increase in ln-RANTES 0.71, 95%CI 0.53-0.96) and non-
culprit related or indeterminate all-cause mortality or ACS only (HR per SD increase in 
ln-RANTES 0.64, 95%CI 0.44-0.94).
Conclusions: Higher plasma MCP-1, MIP-1α, and lower RANTES concentrations are 
associated with a higher extent, a more advanced phenotype and a higher vulnerability 
of coronary atherosclerosis. RANTES is a promising biomarker that is independently, 
inversely associated with occurrence of cardiac events, particularly of death and ACS. 
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INTRODUCTION
Inflammation has been recognized as an important contributing factor in all phases of 
atherosclerosis.(1-3) In particular, inflammation is believed to play a crucial role in the 
development and rupture of vulnerable plaques, resulting in major cardiovascular problems 
such as myocardial infarction and stroke.(1-3) Circulating inflammatory biomarkers may 
potentially improve prognostication of patients with atherosclerotic cardiovascular 
disease.(4) 
Chemokines are involved in the recruitment of various leukocytes, such as monocytes, 
macrophages and T lymphocytes, into the atherosclerotic plaque.(5, 6) Monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), 
MIP-1β and regulated upon activation normal T cell expressed and secreted (RANTES) are 
typical C-C motif chemokines that have been studied extensively.(5, 6) Several studies have 
shown that these chemokines have an important role throughout the entire atherosclerotic 
process from atherogenesis to plaque destabilization.(5, 6) However, their clinical utility as 
biomarker remains unclear.(5, 6) Furthermore, prospective data on associations of these 
biomarkers with in-vivo measurements of extensiveness, phenotype and vulnerability of 
coronary atherosclerosis is currently lacking. This study aims to evaluate the usefulness 
of MCP-1, MIP-1α, MIP-1β and RANTES by investigating their relations with intravascular 
ultrasound (IVUS)-derived measures of coronary plaque burden, quantity of necrotic core, 
and presence of thin-cap fibroatheroma lesions, and by investigating their prognostic value 
for major adverse cardiac events.  
METHODS
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described elsewhere.(7) In brief, 1098 patients who underwent diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS) or stable angina pectoris have been enrolled in ATHEROREMO-IVUS. The 
ATHEROREMO-IVUS study population consists of 330 patients who were previously enrolled 
in the randomised double-blinded Integrated Biomarker and Imaging Study-2 (IBIS-2) trial 
from November 2005 to August 2006 and of 768 patients who were additionally included 
at Erasmus MC, Rotterdam, the Netherlands from November 2008 to January 2011. Blood 
samples were drawn prior to the coronary catheterization procedure and IVUS imaging 
of a non-culprit coronary artery was performed subsequent to angiography. Baseline 
characteristics of the included patients were prospectively entered into a dedicated 
database. This study has been approved by the human research ethics committee of 
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Erasmus MC, Rotterdam, the Netherlands. Written informed consent was obtained from 
all participants. 
Patients were included in the current study analyses when the following criteria were 
met: 1. not participating in the IBIS-2 trial; 2. IVUS of a non-culprit coronary artery was 
performed; and 3. plasma samples were available for biomarker measurements. Patients 
participating in the IBIS-2 trial were excluded from the present analysis in order to prevent 
possible treatment interaction from the study drug darapladib, which was found to 
prevent necrotic core expansion as measured by IVUS.(8) In patients who were additionally 
included at Erasmus MC (n=768), IVUS of a non-culprit coronary artery was performed in 
581 patients. In these patients, blood samples were available in 570 patients.  
Biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure. The blood samples were transported to the clinical 
laboratory of Erasmus MC for further processing and storage at temperature of -80oC 
within 2 hours after blood collection. MCP-1, MIP-1α, MIP-1β and RANTES were measured 
in the stored EDTA-plasma samples using a validated multiplex assay (Custom Human Map, 
Myriad RBM, Austin, Texas, USA). 
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit coronary vessel. Selection of the non-culprit vessel was predefined in the 
study protocol. The order of preference for selection of the non-culprit vessel was: 1. left 
anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left circumflex (LCX) 
artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., 
San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic 
pullback system was used with a standard pull back speed of 0.5 mm per second. The 
IVUS images were analyzed offline by an independent core laboratory (Cardialysis BV, 
Rotterdam, the Netherlands) that had no knowledge of clinical data. The IVUS gray-
scale and IVUS radiofrequency analyses, also known as IVUS virtual histology, were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The 
external elastic membrane and luminal borders were contoured for each frame (median 
interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were 
assessed. Plaque burden was defined as plaque and media cross-sectional area divided 
by external elastic membrane cross-sectional area and is presented as a percentage. The 
composition of the atherosclerotic plaque was characterized into 4 different tissue types: 
fibrous, fibro-fatty, dense calcium and necrotic core.(9) A coronary lesion was defined as a 
segment with a plaque burden of more than 40% in at least 3 consecutive frames. A thin-
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cap fibroatheroma (TCFA) lesion was defined as a lesion with presence of >10% confluent 
necrotic core in direct contact with the lumen.(10, 11) TCFA lesions with a plaque burden 
of at least 70% were classified as large TCFA lesions.
Study endpoints
In this study, follow-up started at inclusion and lasted up to 1 year. Post-discharge survival 
status was obtained from municipal civil registries. Post-discharge rehospitalizations were 
prospectively assessed during follow-up. Questionnaires focusing on the occurrence of 
major adverse cardiac events (MACE) were sent to all living patients. Treating physicians 
and institutions were contacted for additional information whenever necessary. ACS 
was defined as the clinical diagnosis of ST segment elevation myocardial infarction 
(STEMI), non-STEMI or unstable angina pectoris in accordance with the guidelines of 
the European Society of Cardiology.(12-14) Unplanned coronary revascularization was 
defined as unplanned repeat PCI or coronary artery bypass grafting (CABG). All events 
were adjudicated as related to a coronary site that was treated during the index procedure 
(culprit lesion related event) or as related to the coronary site that was not treated during 
the index procedure (non-culprit lesion related event). Events that were related to both the 
culprit lesion and a non-culprit site (e.g. revascularization of multiple vessels with CABG) 
were classified into both categories. When information was not sufficient to classify an 
event as either culprit lesion related or non-culprit lesion related, the event was classified 
as indeterminate.     
The primary endpoint was MACE, defined as non-culprit lesion related or indeterminate 
all-cause mortality, ACS or unplanned coronary revascularization. The secondary endpoint 
was defined as the composite of non-culprit lesion related or indeterminate all-cause 
mortality or ACS. Definite culprit lesion related events were excluded from the primary 
and secondary endpoints, because the pathophysiology of culprit lesions related events 
(e.g. in-stent restenosis or in-stent thrombosis) differs from our primary research focus on 
spontaneous plaque rupture leading to unanticipated, spontaneous MACE. The endpoints 
were adjudicated by a clinical event committee that had no knowledge of biomarkers and 
IVUS data.  
STATISTICAL ANALYSIS
The distributions of the continuous variables, including biomarker levels and the IVUS 
parameters, were tested for normality by visual examination of the histogram. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD), while 
non-normally distributed continuous variables are presented as median and interquartile 
range (IQR). MCP-1, MIP-1α, MIP-1β and RANTES concentrations were not normally 
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distributed and were therefore ln-tranformed for further analysis. Categorical variables 
are presented in percentages. We examined associations of biomarker concentrations with 
plaque burden and necrotic core fraction in the imaged coronary segment. Specifically, 
we calculated means of plaque burden and necrotic core fraction according to tertiles 
of biomarker concentration. To test for trends, we used linear regression analyses with 
continuous ln-transformed biomarker concentrations as the independent variable. 
The final results are presented as β (per SD increase in ln-transformed biomarker 
concentration) with 95% confidence interval (95% CI). Furthermore, we have examined 
the relation between biomarker concentrations and the presence of TCFA lesions using 
logistic regression analyses with continuous ln-tranformed biomarker concentration as the 
independent variable. The final results are presented as odds ratio (OR) per SD increase in 
ln-transformed biomarker concentration with 95% CI.  
Patients lost to follow-up were considered at risk until the date of last contact, at which 
time-point they were censored. Cumulative event rates were estimated according to 
the Kaplan-Meier method. Cumulative Kaplan-Meier event curves were compared by 
log-rank test. Cox proportional hazards regression analyses were performed to evaluate 
the relationship between biomarker concentration and clinical endpoints. Biomarkers 
that were significantly associated with occurrence of MACE in univariable analysis were 
further evaluated in multivariable analyses. The variables age, gender, diabetes mellitus, 
hypertension, history of MI and indication for coronary angiography were considered as 
potential confounders and were entered into the full model. These covariates were a priori 
chosen, taking into account the number of events available. The final results are presented 
as hazard ratio (HR) per SD increase in ln-transformed biomarker concentration with 
95% CI. All statistical analyses were primarily performed in the overall study population. 
Heterogeneity in effect estimates between patients with ACS and patients with stable 
angina were examined using the Z-test for heterogeneity. If there was no heterogeneity, 
conclusions were based on the effect estimates belonging to the total study population. 
If there was significant heterogeneity between patients admitted with and without ACS, 
conclusions were based on effect estimates of the separate groups. 
All data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). All 
statistical tests were two-tailed and p-values <0.05 were considered statistically significant.
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Table 1. Baseline characteristics
Total
(n=570)
ACS 
patients
(n=309)
SAP
patients
(n=261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension. n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
Indication for catheterization
   Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
      Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
      Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5 0 (0)
   Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
   No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
   1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
   2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
   3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0%)
Serum biomarker concentrations
   MCP-1, pg/ml * 91 [70-122] 92 [70-133] 88 [71-111]
   MIP-1α, pg/ml † 16.0 [12.0-21.9] 15.0 [12.0-21.9] 17.0 [12.0-21.9]
   MIP-1β, pg/ml * 123 [92-165] 130 [95-179] 114 [89-146]
   RANTES, ng/ml ‡ 11.0 [6.4-19.0] 14.0 [7.6-23.0] 9.1 [5.0-14.3]
IVUS segment characteristics
Imaged coronary artery
   Left anterior descending, n (%) 204 (35.8) 117 (37.9) 87 (33.3)
   Left circumflex, n (%) 190 (33.3) 107 (34.6) 83 (31.8)
   Right coronary artery, n (%) 176 (30.9) 85 (27.5) 91 (34.9)
Segment length, mm 44.1 [33.7-55.4] 43.9 [32.9- 54.1] 44.8 [34.2-57.2]
At least 1 TCFA 239 (41.9) 140 (45.3) 99 (37.9)
At least 1 TCFA with PB≥70% 69 (12.1) 32 (10.4) 37 (14.2)
* Measurable in >99% of patients; below limit of detection in <1% of patients.
† Measurable in 84% of patients; below limit of detection in 16% of patients.
‡ Measurable in all patients. 
ACS indicates acute coronary syndrome; CABG, coronary artery bypass grafting; MCP-1, monocyte chemoattractant 
protein-1; MI, myocardial infarction; MIP-1α, macrophage inflammatory protein-1α; MIP-1β, macrophage 
inflammatory protein-1β; PB, plaque burden; PCI, percutaneous coronary intervention; RANTES, Regulated upon 
Activation Normal T cell Expressed and Secreted; SAP, stable angina pectoris; TCFA, thin-cap fibroatheroma. 
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RESULTS
Baseline characteristics
Mean age of the patients was 61.5 ± 11.4 years, 75.4% were men and 17.4% had diabetes 
mellitus (Table 1). Coronary angiography or PCI was performed for various indications: 159 
(27.9%) patients had an acute myocardial infarction, 150 (26.3%) patients had unstable 
angina pectoris and 261 (45.8%) patients had stable angina pectoris. Some patients had 
biomarker concentrations beneath the lowest detection limit of the assay, which especially 
pertains to MIP-1α (measurable in 84% of patients). The median length of the imaged 
coronary segment was 44.1 [33.7-55.4] mm. On basis of radiofrequency IVUS, a total of 
239 (41.9%) patients had at least 1 TCFA, including 69 (12.1%) patients with at least 1 TCFA 
with a plaque burden ≥70%. 
Associations with coronary atherosclerosis
In patients who were admitted with stable angina pectoris, higher plasma MCP-1 
concentrations were associated with higher coronary plaque burden (per SD increase of 
ln-transformed MCP-1: β=2.56, 95% CI 0.91-4.21, p=0.002) and a higher fraction of plaque 
consisting of necrotic core (per SD increase of ln-transformed MCP-1: β=1.14, 95% CI 0.02-
2.25, p=0.045) (Table 2). Higher MCP-1 concentrations also seemed to be associated with 
the presence of TCFA lesions (OR per SD increase in ln-transformed MCP-1 1.90, 95% CI 
1.00-3.61, p=0.052) in patients who were admitted with stable angina pectoris (Table 3). 
Higher MIP-1α concentrations were associated with higher plaque burden (per SD increase 
of ln-transformed MIP-1α: β=1.66, 95% CI 0.72-2.61, p=0.001), higher necrotic core 
fraction (per SD increase of ln-transformed MIP-1α: β=0.89, 95% CI 0.23-1.55, p=0.008) 
and with the presence of TCFA lesions with plaque burden ≥70% (OR per SD increase in ln-
transformed MIP-1α 1.75, 95% CI 1.09-2.81, p=0.021) in the total study population.
In patients who were admitted with ACS, lower RANTES concentrations were associated 
with higher plaque burden (per SD increase of ln-transformed RANTES: β=-1.57, 95% CI 
-2.94;-0.20, p=0.025) (Figure 1). Furthermore, lower RANTES concentrations also seemed 
to be associated with the presence of TCFA lesions with plaque burden ≥70% in the overall 
patient population (OR per SD increase in ln-transformed RANTES 0.76, 95% CI 0.57-1.02, 
p=0.067).
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Table 3. Associations with presence of intravascular ultrasound-derived thin-cap fibroatheroma 
lesions
Total study population 
(n=570)
ACS patients
(n=309)
SAP patients 
(n=261)
Hetero-
geneity
OR (95% CI) P OR (95% CI) P OR (95% CI) P P
Presence of at least 1 thin-cap fibroatheroma 
MCP-1 1.03 (0.74-1.45) 0.85 0.77 (0.51-1.17) 0.22 1.90 (1.00-3.61) 0.052 0.022
MIP-1α 0.87 (0.63-1.21) 0.42 0.94 (0.61-1.42) 0.75 0.83 (0.49-1.39) 0.47 0.72
MIP-1β 1.16 (0.85-1.60) 0.36 1.18 (0.79-1.76) 0.42 0.97 (0.55-1.70) 0.91 0.69
RANTES 0.97 (0.80-1.18) 0.75 0.87 (0.66-1.15) 0.33 0.98 (0.72-1.33) 0.90 0.57
Presence of at least 1 thin-cap fibroatheroma with plaque burden ≥70%
MCP-1 1.23 (0.75-2.04) 0.41 0.94 (0.48-1.83) 0.86 2.16 (0.95-4.93) 0.067 0.12
MIP-1α 1.75 (1.09-2.81) 0.021 2.15 (1.13-4.09) 0.020 1.29 (0.63-2.66) 0.49 0.30
MIP-1β 0.89 (0.54-1.47) 0.66 0.91 (0.47-1.78) 0.79 1.01 (0.46-2.20) 0.98 0.85
RANTES 0.76 (0.57-1.02) 0.067 0.73 (0.47-1.15) 0.17 0.84 (0.55-1.28) 0.41 0.67
Odds ratios are per standard deviation increase in ln-transformed biomarker concentration. 
ACS indicates acute coronary syndrome; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage 
inflammatory protein-1α; MIP-1β, macrophage inflammatory protein-1β; RANTES, Regulated upon Activation 
Normal T cell Expressed and Secreted; SAP, stable angina pectoris. 
Figure 1.
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Major adverse cardiac events
Vital status was acquired for 569 (99.8%) patients. Response rate of the questionnaires 
that were sent to all living patients was 92.3%. After 1 year of follow-up, 56 patients had 
at least 1 event. A total of 11 patients had a definite culprit lesion related event, while 27 
patients had a definite non-culprit lesion related event. Another 18 patients had an event 
that could not be judged to be either culprit lesion related or non-culprit lesion related and 
were therefore classified as having an indeterminate event. The cumulative Kaplan-Meier 
incidences of the 30-day, 6-month and 1-year composite of non-culprit lesion related or 
indeterminate death, ACS or unplanned coronary revascularization were 0.7%, 4.7%, and 
7.9%, respectively. The cumulative Kaplan-Meier incidences of the 30-day, 6-month and 
1-year composite of non-culprit lesion related or indeterminate death or ACS were 0.7%, 
3.2%, and 4.9%, respectively.
Table 4. Associations with non-culprit lesion related and indeterminate major adverse cardiac events
Total study population 
(n=570)
ACS patients 
(n=309)
SAP patients 
(n=261)
Hetero-
geneity
HR (95% CI) P HR (95% CI) P HR (95% CI) P P
Major adverse cardiac events (primary endpoint)
MCP-1 0.87 (0.64-1.18) 0.37 0.81 (0.55-1.20) 0.29 1.00 (0.61-1.65) 1.00 0.51
MIP-1α 1.13 (0.85-1.49) 0.40 1.16 (0.82-1.66) 0.40 1.06 (0.69-1.64) 0.80 0.74
MIP-1β 1.00 (0.74-1.34) 0.99 1.15 (0.82-1.62) 0.42 0.82 (0.50-1.34) 0.42 0.26
RANTES 0.67 (0.50-0.89) 0.005 0.77 (0.50-1.18) 0.23 0.59 (0.40-0.88) 0.009 0.39
Composite of death or acute coronary syndrome (secondary endpoint)
MCP-1 0.73 (0.48-1.09) 0.12 0.74 (0.47-1.16) 0.19 0.69 (0.31-1.53) 0.36 0.88
MIP-1α 1.11 (0.77-1.58) 0.58 1.12 (0.73-1.70) 0.61 1.11 (0.59-2.09) 0.74 0.99
MIP-1β 1.11 (0.78-1.57) 0.57 1.34 (0.98-1.84) 0.071 0.48 (0.24-0.98) 0.043 0.010
RANTES 0.64 (0.45-0.91) 0.013 0.58 (0.36-0.94) 0.028 0.62 (0.35-1.10) 0.10 0.86
Hazard ratios are per standard deviation increase in ln-transformed biomarker concentration. 
MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; MIP-1β, 
macrophage inflammatory protein-1β; 
RANTES, Regulated upon Activation Normal T cell Expressed and Secreted; SAP, stable angina pectoris. 
Associations with non-culprit lesion related and indeterminate events
In univariable analysis, RANTES (HR per SD increase of ln-transformed RANTES 0.67, 95% 
CI 0.50-0.89, p=0.005) was associated with occurrence of the primary endpoint of non-
culprit lesion related and indeterminate MACE during follow-up (Table 4). There was no 
heterogeneity in the hazard ratio estimate between ACS patients and patients with stable 
angina (heterogeneity p=0.39). RANTES (HR per SD increase of ln-transformed RANTES 
0.64, 95% CI 0.45-0.91, p=0.013) was also significantly associated with the composite 
of non-culprit lesion related and indeterminate death or ACS only. After adjustment 
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for clinical characteristics in multivariable analysis, RANTES remained independently 
predictive for non-culprit lesion related and indeterminate MACE (HR per SD increase of 
ln-transformed RANTES 0.71, 95% CI 0.53-0.96, p=0.026) and for non-culprit lesion related 
and indeterminate death or ACS only (HR per SD increase of ln-transformed RANTES 0.64, 
95% CI 0.44-0.94, p=0.022) (Table 5). 
Table 5. Multivariable analysis on non-culprit lesion related and indeterminate major adverse cardiac 
events
Unadjusted model Age and gender adjusted model
Age, gender and 
indication for 
catheterization 
adjusted model
Full model*
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Major adverse cardiac events (primary endpoint)
RANTES 0.67 
(0.50-0.89)
0.005 0.72 
(0.54-0.96)
0.024 0.71
(0.53-0.95)
0.023 0.71 
(0.53-0.96)
0.026
Composite of death or acute coronary syndrome (secondary endpoint)
RANTES 0.64 
(0.45-0.91)
0.013 0.69 
(0.48-0.99)
0.046 0.64
(0.44-0.93)
0.021 0.64 
(0.44-0.94)
0.022
Hazard ratios are per standard deviation increase in ln-transformed biomarker concentration. 
* Variables entered into the full model were age, gender, diabetes mellitus, hypertension, history of myocardial 
infarction and indication for coronary catheterization. RANTES indicates Regulated upon Activation Normal T cell 
Expressed and Secreted. 
DISCUSSION
This study investigated the relations of circulating chemokine concentrations with 
extensiveness of coronary atherosclerosis, amount of necrotic core, the presence of TCFA 
lesions and occurrence of future major adverse cardiac events in patients who underwent 
coronary angiography for ACS or stable angina pectoris. To our best knowledge, this is the 
first study that correlates circulating chemokines with in-vivo measurements of coronary 
atherosclerosis using IVUS virtual histology. Higher plasma MCP-1, MIP-1α, and lower 
RANTES concentrations were all associated with higher coronary plaque burden and more 
advanced plaque phenotypes as determined by IVUS (figure 2). However, only RANTES was 
found to be independently predictive for the occurrence of MACE, particularly of death 
and ACS. 
Circulating chemokines
Chemokines are small cytokines that have the ability to induce directed chemotaxis of 
nearby leukocytes. MCP-1, MIP-1α, MIP-1β and RANTES belong to the C-C motif chemokine 
ligand (CCL) family and are also known as CCL2, CCL3, CCL4 and CCL5, respectively.
(5-6) Pathologic studies have shown that these chemokines are highly expressed in 
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atherosclerotic plaques.(15-17) Animal studies have shown that these chemokines are 
actively involved in atherogenesis and plaque destabilization.(5-6) Furthermore, several 
epidemiological studies have indicated that serum or plasma levels of MCP-1, MIP-1α, 
MIP-1β and RANTES may predict future cardiac events.(5) However, their clinical utility 
as biomarker for cardiovascular risk stratification remains unclear.(5-6) We sought to 
further elucidate the correlations of circulating chemokine concentrations with in-vivo 
measurements of extensiveness, phenotype and vulnerability of coronary atherosclerosis 
by using IVUS.    
Figure 2.
Intravascular ultrasound
Grey-scale IVUS allows for in-vivo measurements of coronary plaque burden. Additionally, 
radiofrequency IVUS allows for differentiation of the composition of the atherosclerotic 
plaque and is therefore also known as IVUS virtual histology.(10) Necrotic core is often 
found in the more advanced and rupture-prone plaques.(18) The Providing Regional 
Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study has 
demonstrated that TCFA lesions as determined by IVUS are associated with MACE.(19) The 
strong and independent associations (adjusted hazard ratios ranging from 1.79 to 3.35) of 
IVUS-derived TCFA with MACE emphasize its biological importance.(18-20) However, there 
are several reasons why IVUS is currently not suitable for use as diagnostic and prognostic 
tool in the overall population of patients with coronary artery disease.(19) Its invasiveness 
is probably the most important limitation in this respect. Therefore, circulating biomarkers 
may have an important role in cardiovascular risk assessment. 
RANTES
In our study, lower plasma RANTES concentrations were independently associated with 
adverse outcomes during 1 year of follow-up. Its association with acute cardiac events 
(death or ACS; HR 0.64) seemed to be even stronger than with all major adverse cardiac 
events (death, ACS or unplanned coronary revascularization; HR 0.71). This may indicate that 
RANTES is especially predictive for plaque rupture rather than plaque growth. Our finding 
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that low serum RANTES concentrations, rather than high, are associated with adverse 
coronary events may seem counterintuitive, since animal studies have shown that RANTES 
and its receptor are actively involved in atherogenesis and that RANTES was found to be 
highly expressed within atheromous lesions.(6,21) However, the inverse associations of 
RANTES may be explained by increased deposition of RANTES on the vascular endothelium, 
resulting in lower free circulating serum concentrations.(22-23) The inverse associations of 
RANTES are also consistent with observations from previous studies. A large case-control 
study reported that serum RANTES levels were lower in coronary heart disease patients 
compared with age- and gender-matched controls.(22) Another study reported that low 
plasma RANTES levels were independently associated with cardiac mortality in 389 male 
patients who underwent coronary angiography.(23) Such an association was not found in 
a population-based case-cohort study that included 363 individuals with incident coronary 
events and 1908 non-cases.(24) 
MCP-1 
We found that higher plasma MCP-1 concentrations were associated with higher coronary 
plaque burden in patients who were admitted with stable angina pectoris. These findings 
are in line with a previous study that measured MCP-1 concentrations in blood from the 
coronary sinus and found that these levels were associated with the extent of coronary 
atherosclerosis as assessed on the coronary angiogram.(25) Although we observed that 
high MCP-1 concentrations were associated with a more advanced plaque phenotype 
(i.e. higher necrotic core fraction) and with the presence of TCFA lesions, MCP-1 was not 
predictive for future events. Previous epidemiological studies have shown that the ability 
of MCP-1 to predict subclinical coronary artery disease is somewhat disappointing, but 
that MCP-1 may have some value in predicting cardiovascular events in patients with 
overt coronary artery disease.(5) For example, a previous study found that MCP-1 was 
independently associated with the composite of death or myocardial infarction in a large 
cohort of 4244 patients with ACS.(26) This study also demonstrated that high MCP-1 values 
at 4 months after the initial ACS were still predictive for long-term mortality afterwards. 
A major difference with our study is that both culprit lesion related and non-culprit lesion 
related events were included in their study endpoints, while definite culprit lesion related 
events were excluded from our study endpoints. Furthermore, we may have lacked 
statistical power to detect the previously reported association. 
MIP-1α
MIP-1α has been studied less extensively. We found that MIP-1α was associated with 
coronary plaque burden, necrotic core fraction and with the presence of large TCFA lesions. 
However, we did not observe a correlation between MIP-1α concentration and occurrence 
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of MACE. Another study, however, found that MIP-1α was predictive for recurrent ACS in a 
relatively small cohort of 54 patients with unstable angina pectoris.(27) Further research is 
required to elucidate the role of MIP-1α in patients with coronary artery disease.        
CONCLUSIONS
Higher circulating MCP-1, MIP-1α, and lower RANTES concentrations were associated 
with a higher extent, a more advanced phenotype and a higher vulnerability of coronary 
atherosclerosis. Such associations were not present for MIP-1β. In addition, RANTES was 
independently associated with occurrence of MACE, particularly of death and ACS. Its 
prognostic value was similar in patients with and without ACS. Its inverse associations are 
consistent with observations from previous studies and may be explained by increased 
deposition of RANTES on the endothelium, resulting in lower free circulating concentrations. 
The findings in this study demonstrate that RANTES may be a useful biomarker for 
assessment of cardiovascular risk. Further research on the incremental prognostic value 
of RANTES over established clinical covariates in large, prospective studies is warranted.  
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ABSTRACT
Introduction: We examined whether the acute phase proteins (APPs) Alpha-1-
Antitrypsin, Alpha-2-Macroglobulin Complement C3, ferritin, haptoglobin, and 
Plasminogen Activator Inhibitor 1 (PAI-1) are associated with cardiovascular outcome, 
as well as with the extent and composition of coronary atherosclerosis as determined 
by intravascular ultrasound (IVUS) virtual histology (VH).
Methods: In 2008-2011, IVUS(-VH) imaging of a non-culprit coronary artery was 
performed in 581 patients from the ATHEROREMO-IVUS study undergoing coronary 
angiography for acute coronary syndrome (ACS) (n=318) or stable angina pectoris 
(SAP) (n=263). Coronary atherosclerotic plaque volume, composition (fibrous, 
fibro-fatty, dense calcium and necrotic core) and vulnerability (VH-derived thin-cap 
fibroatheroma (TCFA) lesions) were assessed. Major adverse cardiac events (MACE; 
all-cause mortality, ACS or unplanned coronary revascularization) were assessed 
during 1-year follow-up. We applied linear, logistic and Cox regression. 
Results: Mean age was 61.5 ± 11.4 years and 75.4% were men. Higher ferritin was 
associated with higher coronary plaque volume (beta [95%CI]: 0.19 [0.07-0.31] 
percent atheroma volume, for the highest vs the lowest tertile of ferritin; p for 
linear association =0.013. Higher PAI-1 was associated with higher rates of all-cause 
mortality or ACS (hazard ratio  [95%CI]: 2.98 [1.10-8.06], for the highest vs the lowest 
tertile of PAI-1. No clear-cut associations could be demonstrated between APPs and 
composition of atherosclerosis or plaque vulnerability. 
Conclusions: Higher circulating ferritin was associated with higher coronary plaque 
volume, and higher PAI-1 was associated with higher incidence of all-cause mortality 
or ACS. None of the APPs displayed consistent associations with composition of 
atherosclerosis or plaque vulnerability. 
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INTRODUCTION
Chronic inflammation of the arterial wall plays an important role in the development of 
atherosclerosis, and it regulates aspects of plaque biology that trigger the thrombotic 
complications of atherosclerosis (1). Inflammation is commonly characterized by increased 
plasma concentrations of acute phase proteins (APPs). Several studies have demonstrated 
the ability of the APP C-reactive protein (CRP) to predict adverse coronary events in patients 
with stable and unstable coronary artery disease (CAD)(2). In order to further explore 
the nature of the association of CRP with coronary atherosclerosis, we have previously 
examined its relation with intravascular ultrasound (IVUS) virtual histology (VH) derived 
measures of coronary atherosclerosis(3). The results showed that higher CRP levels were 
associated with a higher coronary plaque burden, but that they were not associated with 
plaque vulnerability, which was defined as the presence of IVUS-VH- derived thin-cap 
fibroatheroma (VH-TCFA) lesions.The relation between other APPs and cardiovascular 
disease has generally been examined to a much smaller extent, and in particular studies 
on APPs in relation to an in-vivo assessment of the extent and composition of coronary 
atherosclerosis are lacking (4, 5).
APP’s including Alpha-1-Antitrypsin (AAT), Alpha-2-Macroglobulin (α2M), Complement 
C3 (C3), ferritin, haptoglobin, and Plasminogen Activator Inhibitor 1 (PAI-1), are produced 
by the liver in response to circulating cytokines(6) . APPs contribute to the restoration 
of homeostasis by neutralizing inflammatory agents, help to minimize the extent of local 
tissue damage and participate in tissue repair and regeneration(6). Circulating levels of 
APPs may potentially be useful for risk stratification of patients with known CAD, and 
studies on their relation with the extent and composition of coronary atherosclerosis may 
provide further pathophysiological insights with regard to the mechanisms of progression 
and destabilization of atherosclerotic plaques. 
Therefore, the purpose of this study is to examine the associations of AAT, α2M, C3, ferritin, 
haptoglobin, and PAI-1 with the extent and composition of coronary atherosclerosis as 
determined in-vivo by IVUS-VH, in patients undergoing coronary angiography. Furthermore, 
the prognostic value of the APPs for major adverse cardiac outcome during 1 year follow-
up in these patients is investigated. 
MATERIAL AND METHODS
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described elsewhere (7). In brief, 581 patients who underwent diagnostic coronary 
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angiography or percutaneous coronary intervention (PCI) for acute coronary syndrome 
(ACS) or stable angina pectoris (SAP) have been included from November 2008 to January 
2011 in the Erasmus MC, Rotterdam, the Netherlands. Intravascular ultrasound (IVUS) of a 
non-culprit coronary artery was performed subsequent to angiography. The ATHEROREMO-
IVUS study has been approved by the human research ethics committee of Erasmus MC, 
Rotterdam, the Netherlands. Written informed consent was obtained from all included 
patients and the study protocol conforms to the ethical guidelines of the Declaration of 
Helsinki.
Biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure, and were available in 570 patients for the current study. The 
blood samples were transported to the clinical laboratory of the Erasmus MC for further 
processing and storage at a temperature of -80 0C within two hours after blood collection. 
CRP was measured in the clinical laboratory of the Erasmus MC in serum samples using a 
immunoturbidimetric high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) 
on the Cobas 8000 modular analyzer platform (Roche Diagnostics Ltd., Rotkreuz, 
Switzerland). Frozen EDTA-plasma samples were transported under controlled conditions 
(at a temperature of -80oC) to Myriad RBM, Austin, Texas, USA, where the concentrations of 
AAT, α2M, C3, ferritin, haptoglobin, and PAI-1, were measured using a validated multiplex 
assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). While ferritin, haptoglobin, 
and PAI-1 were determined in the full cohort of 570 patients, AAT, α2M, and C3, were 
determined in a random subset of 473 patients. This difference in numbers resulted from 
batch-wise handling of the samples in combination with an update of the composition of 
the multiplex assay by the manufacturer in-between two batches. 
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit coronary artery without significant coronary disease requiring balloon 
angioplasty or stent treatment. The order of preference for selection of the non-culprit 
vessel was: 1. left anterior descending (LAD) artery; 2. Right coronary artery (RCA); 3. 
Left circumflex (LCX) artery. All IVUS data were acquired with the Volcano s5/s5i Imaging 
System (Volcano Corp., San Diego, CA, USA) using a Vulcano Eagle Eye Gold IVUS catheter 
(20 MHz). An automatic pullback system was used with a standard pull back speed of 0.5 
mm per second. The IVUS images were analyzed offline by an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands) that had no knowledge of clinical data. 
The IVUS radiofrequency analyses, also known as IVUS virtual histology (IVUS-VH), were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The 
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external elastic membrane and luminal borders were contoured for each frame (median 
interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were 
assessed. 
Plaque volume was defined as the percent of the volume of the external elastic membrane 
occupied by atheroma, i.e. percent atheroma volume(8). Plaque volume was normalized 
for the length of the imaged segment. Plaque burden was defined as the plaque and media 
cross-sectional area divided by the external elastic membrane cross-sectional area and 
is presented as a percentage. A coronary lesion was defined as a segment with a plaque 
burden of more than 40% in at least 3 consecutive frames. Using IVUS-VH, the composition 
of the atherosclerotic plaque was characterized into 4 different types: fibrous, fibro-fatty, 
dense calcium and necrotic core (9). A IVUS-VH-derived thin-cap fibroatheroma (VH-TCFA) 
lesion was defined as a lesion with presence of > 10% confluent necrotic core in direct 
contact with the lumen.
Clinical study endpoints 
In this study, follow-up lasted up to 1 year after angiography. Post-discharge survival 
status was obtained from municipal civil registries. Post-discharge rehospitalizations 
were prospectively assessed. Questionnaires focusing on the occurrence of major 
adverse cardiac events (MACE) were sent to all living patients. Subsequently, hospital 
discharge letters were obtained and treating physicians and institutions were contacted 
for additional information whenever necessary. The primary endpoint was the occurrence 
of MACE, defined as the composite of all-cause mortality, ACS or unplanned coronary 
revascularization. The secondary endpoint was the composite of all-cause mortality or ACS. 
ACS was defined as the clinical diagnosis of ST segment elevation myocardial infarction 
(STEMI), non-STEMI or unstable angina pectoris in accordance with the guidelines of the 
European Society of Cardiology.(10, 11) Unplanned coronary revascularization was defined 
as unplanned repeat PCI or coronary artery bypass grafting (CABG). The endpoints were 
adjudicated by a clinical event committee that had no knowledge of biomarkers and IVUS 
data. 
 
Statistical analysis
Categorical variables are presented in percentages. The distributions of continuous 
variables, including biomarker levels and IVUS parameters, were examined for normality 
by visual inspection of the histogram and calculation of the skewness coefficient. Normally-
distributed continuous variables are presented as mean ± standard deviation (SD), while 
non-normally distributed continuous variables are presented as median and interquartile 
range (IQR). For reasons of uniformity, all biomarker levels are presented as medians (with 
IQR). 
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In further analyses, biomarker concentrations were examined both as continuous and as 
categorical variables (the latter by dividing the variables into tertiles). Biomarkers with a 
non-normal distribution were ln-transformed or were transformed by using the square 
root. 
First, we examined associations of biomarker concentrations with the extent of 
atherosclerosis according to IVUS. We applied linear regression analyses with biomarker 
concentrations as the independent variable (transformed or categorized when appropriate) 
and, consecutively, plaque volume and plaque burden in the imaged coronary segment as 
the dependent variable. The results are presented as βs (per unit increase in transformed 
biomarker concentration or per category of biomarker concentration) with 95% confidence 
intervals (95% CIs).
Subsequently, we examined the associations between biomarker concentrations and 4 
types of atherosclerosis composition (fibrous, fibrofatty, necrotic core, and dense calcium), 
each expressed in percentages. The results are again presented as βs. We also examined 
the associations between biomarker concentrations and the presence of VH-TCFA lesions 
by using logistic regression analyses with biomarker concentrations as the independent 
variable. The results are presented as odds ratios (ORs) per unit increase in transformed 
biomarker concentration or per category of biomarker concentration, with 95% CIs.
Moreover, we examined associations of biomarker concentrations with MACE and with 
the composite of all-cause mortality or ACS, during 1 year follow-up. Patients lost to 
follow-up were considered at risk until the date of last contact, at which time-point they 
were censored. We used Cox proportional hazard regression analyses with  biomarker 
concentration as the independent variable. The results are presented as hazard ratios (HRs) 
per unit increase in ln-transformed biomarker concentration or per category of biomarker 
concentration, with 95% CIs. 
All above-described analyses were performed univariably. Subsequently, we adjusted 
for age, gender, indication for coronary angiography, diabetes, hypertension and CRP. 
Additionally, to further examine possible effect modification by indication for baseline 
coronary angiography, we repeated the analyses separately in patients with acute coronary 
syndrome and in patients with stable angina pectoris.
All data were analyzed with SPSS software (IBM SPSS Statistics for Windows, Version 21.0. 
Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were considered 
statistically significant. 
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Table 1. Baseline characteristics
Total 
(n=570)
ACS patients 
(n=309)
SAP patients 
(n=261)
Patient characteristics
Age, years, mean±standard deviation 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n(%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes Mellitus, n(%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n(%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.5) 140 (45.5) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n(%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
Serum biomarker concentrations
C-reactive protein (mg/L), median (IQR) 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5 [0.6-3.1]
Alpha-1-Antitrypsin (mg/mL)*, 
median (IQR)
1.40 [1.20-1.70] 1.40 [1.20-1.70] 1.40 [1.20-1.60]
Alpha-2-Macroglobulin (mg/mL)*, 
median (IQR)
1.50 [1.40-1.80] 1.50 [1.30-1.80] 1.60 [1.40-1.80]
Complement C3 (mg/mL)*, median (IQR) 0.90 [0.78-1.10] 0.90 [0.78-1.10] 0.92 [0.79-1.00]
Ferritin (mg/mL)#, median (IQR) 173.00 [94.50-282.50] 191.00 [102.25-319.00] 144.00 [82.00-242.50]
Haptoglobin (mg/mL)#, median (IQR) 1.40 [0.91-2.01] 1.50 [0.98-2.20] 1.26 [0.85-1.90]
Plasminogen Activator Inhibitor 1 
(ng/mL)+, median (IQR)
 35.00 [23.00-53.00] 38.00 [27.00-61.50] 31.00 [21.00-46.00]
AAT, α2M, and C3:  total n= 473, ACS n=309, SAP n= 261
*Measurable in all 473 patients
+Measurable in all 570 patients
#Measurable in >99% of 570 patients, too low to detect in <1%
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RESULTS
Baseline characteristics
Baseline characteristics are summarized in Table 1. Mean age was 61.5 ± 11.4 years and 
75% were men. Coronary angiography or PCI was performed for several indications: 159 
(28%) patients had an acute myocardial infarction, 150 (26%) patients had unstable angina 
pectoris and 261 (46%) patients had stable angina pectoris. The median length of the 
imaged coronary segment was 44.1 [33.7-55.4] mm. C3 was the only biomarker with a 
normal distribution. AAT, α2M, ferritin, haptoglobin and PAI-1 concentrations were not 
normally distributed; haptoglobin was square root-transformed for further analyses, and 
the remaining biomarkers were ln-tranformed.
Biomarkers and extent of atherosclerosis
The results of the analyses for (ln-transformed) normalized plaque volume normalized for 
the length of the segment are shown in table 2. Higher ferritin levels were associated with 
higher coronary plaque volume (β [95%CI]: 0.19 [0.07-0.31], for the highest vs the lowest 
tertile of ferritin, and β [95%CI]: 0.14 [0.02-0.27], for the middle vs the lowest tertile of 
ferritin; p for linear association =0.01). After multivariable adjustment, only the association 
for the highest vs the lowest tertile of ferritin persisted (Table 2). In a post-hoc analysis, 
we performed the multivariable adjustment without adding CRP to the model (thus, only 
adjusting for age, gender, indication, diabetes and hypertension). The association was 
independent of these clinical covariates (β [95%CI]: 0.17 [0.05-0.30], for the highest vs 
the lowest tertile of ferritin, and β [95%CI]: 0.13 [0.006-0.25], for the middle vs the lowest 
tertile of ferritin; p for linear association =0.045) No associations were present between 
any of the other biomarkers and coronary plaque volume.
Higher ferritin was associated with higher plaque burden (β [95%CI]: 1.22 [0.07-2.38], 
for the highest vs the lowest tertile of ferritin). However, p for linear association was not 
statistically significant (p=0.24).
Biomarkers and composition of atherosclerosis
The results of the analyses for composition of atherosclerosis are shown in Figure 1. Higher 
α2M levels were associated with a lower percentage of fibrous tissue (β [95%CI]: -4.60 [-7.10 
- -2.10], for the highest vs the lowest tertile of α2M, and β [95%CI]: -2.65 [-5.02- -0.28], 
for the middle vs the lowest tertile of α2M; p for linear association =0.005). Furthermore, 
a higher α2M level was associated with a higher percentage of dense calcium tissue (β 
[95%CI]: 0.49 [0.23-0.375], for the highest vs the lowest tertile of α2M, and β [95%CI]: 0.30 
[0.05-0.55], for the middle vs the lowest tertile of α2M; p for linear association =0.003). 
After multivariable adjustment, the associations for the highest tertiles of α2M remained 
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significant, but the trends lost significance. No associations were present between α2M 
and the remaining atherosclerosis components. 
Table 2. Association of AAT, α2M, C3, ferritin, haptoglobin, and PAI-1 with segment plaque volume
Segmental plaque volume Unadjusted model Multivariable model*
beta (95%CI) P beta (95%CI) P
AAT 
Tertile 1 (reference) (reference)
Tertile 2 0.11 (-0.01-0.23) 0.08 0.08 (-0.04-0.21) 0.19
Tertile 3 0.09 (-0.04-0.22) 0.19 0.10 (-0.04-0.24) 0.15
Ln (AAT) 0.07 (-0.13-0.27) 0.50 0.03 (-0.19-0.24) 0.82
α2M     
Tertile 1 (reference)  (reference)  
Tertile 2 0.01 (-0.11-0.14) 0.83 -0.003 (-0.13-0.12) 0.97
Tertile 3 0.06 (-0.07-0.18) 0.40 0.08 (-0.05-0.22) 0.23
Ln (α2M) -0.10 (-0.35-0.14) 0.40 -0.09 (-0.35-0.16) 0.47
C3     
Tertile 1 (reference) (reference)
Tertile 2 0.02 (-0.11-0.15) 0.76 0.00 (-0.13-0.13) 1.00
Tertile 3 -0.05 (-0.18-0.07) 0.39 -0.03 (-0.16-0.10) 0.66
C3 -0.16 (-0.41-0.10) 0.22 -0.15 (-0.41-0.12) 0.27
Ferritin     
Tertile 1 (reference)  (reference)  
Tertile 2 0.14 (0.02-0.27) 0.023 0.12 (-0.01-0.24) 0.061
Tertile 3 0.19 (0.07-0.31) 0.003 0.16 (0.03-0.29) 0.014
Ln (Ferritin) 0.07 (0.02-0.13) 0.013 0.05 (-0.01-0.11) 0.077
Haptoglobin 
Tertile 1 (reference) (reference)
Tertile 2 -0.04 (-0.16-0.09) 0.58 -0.02 (-0.15-0.11) 0.76
Tertile 3 -0.004 (-0.13-0.12) 0.95 0.003 (-0.12-0.13) 0.95
square root  (haptoglobin) -0.003 (-0.13-0.13) 0.97 -0.01 (-0.15-0.13) 0.89
PAI-1     
Tertile 1 (reference)  (reference)  
Tertile 2 0.09 (-0.04-0.21) 0.17 0.09 (-0.03-0.21) 0.15
Tertile 3 -0.03 (-0.15-0.10) 0.65 0.03 (-0.10-0.15) 0.67
Ln (PAI-1) -0.02 (-0.10-0.06) 0.70 0.03 (-0.06-0.11) 0.55
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
Chapter 4.3 | Acute phase proteins, coronary atherosclerosis and clinical outcome
132
Higher ferritin levels were associated with a higher percentage of fibrofatty tissue (β 
[95%CI]: 0.25 [0.05-0.46], for the highest vs the lowest tertile of ferritin; p for linear 
association=0.015) (Figure 1). The trend disappeared after multivariable adjustment. 
Ferritin was not associated with other VH-IVUS-defined components. 
Remaining biomarkers did not display any associations with the 4 components of 
atherosclerosis. Furthermore, associations with individual components of atherosclerosis 
were not reflected by associations with IVUS-VH-derived TCFA: none of the biomarkers 
were associated with IVUS-VH derived TCFA (Table 3). 
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Figure 1. Alpha-2-macroglobulin and ferritin and composition of atherosclerosis
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Table 3. Association of AAT, α2M, C3, ferritin, haptoglobin, and PAI-1 with presence of IVUS-VH 
derived TCFA lesions
VH-TCFA Unadjusted model Multivariable model*
OR (95%CI) P OR (95%CI) P
AAT 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.35 (0.85-2.15) 0.20 1.24 (0.78-1.99) 0.37
Tertile 3 1.19 (0.75-1.91) 0.46 1.09 (0.66-1.77) 0.74
LN (AAT) 1.13 (0.55-2.33) 0.74 0.94 (0.42-2.12) 0.89
α2M 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.09 (0.71-1.70) 0.69 1.16 (0.74-1.81) 0.53
Tertile 3 1.07 (0.67-1.69) 0.79 1.16 (0.71-1.89) 0.55
LN (α2M) 1.00 (0.41-2.41) 0.99 1.22 (0.47-3.13) 0.68
C3 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.05 (0.67-1.66) 0.83 1.02 (0.64-1.63) 0.92
Tertile 3 0.99 (0.63-1.56) 0.97 0.95 (0.60-1.52) 0.84
C3 0.72 (0.29-1.79) 0.48 0.58 (0.22-1.56) 0.28
Ferritin 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.09 (0.72-1.63) 0.69 1.07 (0.70-1.62) 0.77
Tertile 3 1.04 (0.69-1.57) 0.85 0.96 (0.63-1.48) 0.87
LN (Ferritin) 1.03 (0.86-1.25) 0.73 1.01 (0.83-1.23) 0.92
Haptoglobin 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.07 (0.71-1.60) 0.76 1.05 (0.69-1.58) 0.84
Tertile 3 0.81 (0.53-1.22) 0.31 0.75 (0.48-1.16) 0.19
Square root (haptoglobin) 0.81 (0.52-1.25) 0.34 0.72 (0.45-1.18) 0.19
PAI-1 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 1.05 (0.70-1.58) 0.81 0.98 (0.65-1.49) 0.93
Tertile 3 1.00 (0.66-1.49) 0.98 0.94 (0.62-1.43) 0.77
LN (PAI-1) 1.05 (0.80-1.37) 0.73 1.01 (0.76-1.33) 0.96
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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Biomarkers and outcome
Vital status was acquired for 569 (99.8%) patients. Response rate of the questionnaires 
that were sent to all living patients was 92.3%. After 1 year of follow-up, 56 patients 
experienced at least 1 MACE (%). No significant associations were found between the 
APPs and MACE. A total of 30 cases of all-cause mortality or ACS occurred. Hazard ratios 
for the occurrence of the composite of all-cause mortality or ACS are shown in Table 4. 
Higher PAI-1 was associated with higher event rates (HR[95%CI]: 2.98 [1.10-8.06], for the 
highest vs the lowest tertile of PAI-1, and HR[95%CI]: 3.46 [1.30-9.22], for the middle vs the 
lowest tertile of PAI-1). After multivariable adjustment, associations remained significant. 
No associations were present between any of the other biomarkers and all-cause mortality 
or ACS.
Patients with ACS versus stable angina pectoris
To further investigate the possibility of effect modification by baseline indication for 
coronary angiography, we repeated all analyses separately in patients with ACS and 
patients with SAP. The association between ferritin and higher percentage of fibrofatty 
tissue was present in patients with ACS (β [95%CI]: 0.56 (0.27-0.86) for the highest vs the 
lowest tertile of ferritin, p for linear association < 0.001), but was not present in patients 
with SAP. Remaining estimates remained materially the same in both subgroups, although 
statistical significance disappeared on some occasions because of lower statistical power 
in the subgroups.  
DISCUSSION
In this paper, we examined whether circulating APP concentrations are associated with 
the extent and composition of coronary atherosclerosis, as determined by (VH)-IVUS, in 
patients undergoing coronary angiography. We also investigated whether these APPs have 
prognostic value for clinical cardiovascular outcome. Higher concentrations of ferritin 
were associated with higher coronary plaque volume as well as a higher percentage of 
fibrofatty tissue in the coronary atherosclerotic plaque, the latter only in patients with 
acute coronary syndrome at baseline. Furthermore, higher concentrations of α2M were 
associated with lower percentage of fibrous tissue and higher percentage of dense calcium 
tissue in the coronary atherosclerotic plaque. In spite of these associations with individual 
components of atherosclerosis, none of the biomarkers were associated with presence of 
IVUS-VH derived TCFA lesions. Higher concentrations of PAI-1 were associated with the 
composite endpoint of all-cause mortality or ACS. No significant associations were found 
between the other APPs and the clinical endpoints. 
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Table 4. Association of AAT, α2M, C3, ferritin, haptoglobin, and PAI-1 with combination mortality 
and ACS
All-cause mortality 
or ACS Unadjusted model Multivariable model* Multivariable model#
HR (95%CI) P HR (95%CI) P HR (95%CI) P
AAT 
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.37 (0.10-1.38) 0.14 0.18 (0.03-1.07) 0.059 0.30 (0.07-1.20) 0.089
Tertile 3 0.33 (0.08-1.267) 0.11 0.18 (0.03-0.97) 0.046 0.556 (0.13-2.36) 0.43
Ln (AAT) 0.31 (0.06-1.72) 0.18 0.30 (0.06-1.59) 0.16 0.64 (0.07-5.66) 0.69
α2M       
Tertile 1 1 (reference)  1 (reference)  1 (reference)  
Tertile 2 1.35 (0.52-3.51) 0.54 1.45 (0.54-3.91) 0.47 1.18 (0.32-4.41) 0.81
Tertile 3 1.34 (0.46-3.87) 0.59 1.35 (0.43-4.28) 0.61 1.44 (0.33-6.24) 0.63
Ln (α2M) 2.99 (0.38-23.62) 0.30 3.26 (0.35-30.86) 0.30 3.02 (0.14-66.71) 0.48
C3 
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.99 (0.35-2.81) 0.99 1.12 (0.35-3.54) 0.85 0.73 (0.23-2.32) 0.59
Tertile 3 1.77 (0.60-5.23) 0.30 2.41 (0.51-11.32) 0.27 2.11 (0.68-6.57) 0.20
C3 1.60(0.11-23.40) 0.73 1.08 (0.02-61.46) 0.97 2.94 (0.18-48.21) 0.45
Ferritin       
Tertile 1 1 (reference)  1 (reference)  1 (reference)  
Tertile 2 0.80 (0.30-2.10) 0.65 1.03 (0.35-2.98) 0.96 0.56 (0.20-1.57) 0.27
Tertile 3 1.54 (0.62-3.84) 0.36 2.21 (0.71-6.93) 0.17 1.34 (0.53-3.43) 0.54
Ln (Ferritin) 1.04 (0.71-1.53) 0.83 1.12 (0.74-1.70) 0.59 0.98 (0.64-1.49) 0.91
Haptoglobin 
Tertile 1 1 (reference) 1 (reference) 1 (reference)
Tertile 2 0.37 (0.14-1.00) 0.049 0.33 (0.12-0.94) 0.037 0.434 (0.16-1.20) 0.12
Tertile 3 0.49 (0.20-1.18) 0.11 0.40 (0.14-1.10) 0.074 0.89 (0.30-2.66) 0.84
square root 
(haptoglobin)
0.77 (0.31-1.87) 0.56 0.64 (0.23-1.76) 0.39 1.04 (0.40-2.76) 0.93
PAI-1       
Tertile 1 1 (reference)  1 (reference)  1 (reference)  
Tertile 2 3.46 (1.30-9.22) 0.013 3.57 (1.32-9.66) 0.012 3.64 (1.27-10.43) 0.016
Tertile 3 2.98 (1.10-8.06) 0.032 4.12 (1.04-16.41) 0.045 3.51 (1.26-9.74) 0.016
Ln (PAI-1) 1.52 (0.94-2.46) 0.091 2.02 (0.99-4.09) 0.052 1.74 (1.01-2.99) 0.047
*adjusted for age, gender and indication for coronary angiography 
# additionally adjusted for diabetes mellitus, hypertension and CRP
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Ferritin plays a fundamental role in the storage of intracellular iron. Consequently, this 
marker is widely used in diagnosing and monitoring of diseases associated with iron overload 
or iron deficiency(12). Tran et al. (13) showed, in vivo, that serum ferritin concentration 
increases in response to the inflammatory cytokines interleukin-1 and TNF-α, suggesting 
that these cytokines upregulate ferritin and its secretion. Elevated serum concentrations 
of ferritin are seen in several inflammatory conditions like chronic kidney disease, acute 
infection, and malignancy(13). Recently, Sung et al. (14) found a significant association 
between elevated levels of ferritin and the presence of coronary artery calcium, a marker 
of preclinical atherosclerosis. This association was independent of cardiovascular risk 
factors, iron-binding capacity (transferrin), and low-grade inflammation. However, in 
general, clinical studies have given contradictory results regarding the ability of ferritin 
to predict cardiovascular events  (15-18). In our study, higher ferritin levels were clearly 
associated with higher coronary atherosclerotic plaque volume, but their association with 
higher plaque burden was less apparent. This seeming discrepancy may be due to the fact 
that plaque burden is not a direct measure of three dimensional plaque volume, but rather 
a two dimensional measure that also accounts for arterial wall remodelling. 
Furthermore, higher ferritin levels were associated with higher percentage of fibrofatty 
tissue in coronary atherosclerotic plaque, the latter only in patients with acute coronary 
syndrome at baseline. However, no association was found with VH-TCFA lesions, nor 
with clinical cardiovascular events. Since serum concentrations of ferritin may vary in a 
wide range of conditions (19), the interpretation of ferritin level may be complicated and 
additional research is needed to confirm its potential association with extent of coronary 
atherosclerosis. 
α2M is particularly known as an APP that can bind a large array of ligands and remove them 
from blood circulation to protect the body from wide disturbances (20). Its primary function 
is the inhibition of fibrinolysis which, under normal physiological conditions, contributes 
to stabilization of vascular thrombus(21). Furthermore, this protein is fundamental for 
enabling smooth muscle cells to attach, migrate and survive in fibrin (22), which suggests 
that this marker is involved in the mechanism of vascular stenosis. Clinical studies have 
shown that levels of α2M are significantly influenced by nephrotic syndrome, diabetes 
mellitus, and chronic liver disease (23). Moreover, the cardiac isoform of A2macro seems to 
be useful in diagnosing cardiac events in patients with diabetes (24, 25) and in HIV patients 
(26, 27). In the current study, we found a significant association of elevated α2M levels 
with presence of lower percentage of fibrous tissue and higher percentage dense calcium 
tissue in the atherosclerotic plaque. However, these associations with plaque composition 
could not be further translated into associations with number of VH-TCFA lesions. 
PAI-1 was initially described as a protein that controls the plasminogen activation system, 
leading to inhibition of endogenous fibrinolysis and shifting the dynamic balance towards 
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fibrin generation(28). Circulating concentrations of PAI-1 are elevated in both the elderly (29) 
and in the presence of several clinical characteristics, including hypertriglyceridemia (29), 
obesity, insulin resistance, decreased immune responses, and increased inflammation(30). 
Although PAI-1 may contribute to the development of the atherosclerotic plaque by 
stabilizing the fibrin matrix, this protein is also involved in, for example, vascular smooth 
muscle migration, and activation of specific matrix metalloproteases (MMPs) that diminish 
plaque rupture(28, 31). This phenomenon is also known as the ‘PAI-1 paradox’(28). 
Nevertheless, most epidemiological studies have showed that PAI-1 is a risk factor for the 
development (32, 33) and recurrence of cardiovascular disease(34, 35). Furthermore, a 
recent meta-analysis (36) has suggested that the presence of the 4G/5G gene polymorphism 
of PAI-1, resulting in increased PAI-1 levels, is associated with increased risk of MI. Our 
findings, demonstrating that higher concentrations of PAI-1 are associated with higher 
acute cardiac event rates, are in line with these prior studies.
Previous studies on AAT deficiency (37, 38) and complement factor C3 (39) and 
cardiovascular disease have rendered contradictory results. A recent study on common 
haptoglobin variants showed that these variants modify the inflammatory response 
to intraplaque hemorrhage and increase the risk of major cardiovascular events(40). In 
particular, the hp2 allele of haptoglobin was associated with such events. In the current 
study, we could not demonstrate any associations of AAT, C3 and haptoglobin with coronary 
plaque characteristics or clinical events.
Some aspects of this study warrant consideration(7). IVUS-VH imaging was performed 
in a prespecified single target segment of a single non-culprit coronary artery, based on 
the assumption that such a non-stenotic segment would adequately reflect coronary wall 
pathophysiology of the larger coronary tree(8). Although this assumption may be debated, 
previous studies evaluating IVUS have demonstrated that the coronary wall of comparable 
non-culprit, non-stenotic segments of a single vessel does, in fact,  reflect larger coronary 
disease burden and is associated with subsequent cardiac events (41, 42). Furthermore, it 
is important to note that IVUS is formally not capable of detecting TCFA lesions (7, 8, 43), 
because the spatial resolution of IVUS is insufficient for thin cap detection (8). Nonetheless, 
a concept of IVUS-VH derived TCFAs has been postulated for plaques with a plaque burden 
≥ 40% and a confluent necrotic core ≥ 10% in direct contact with the lumen in at least three 
IVUS-VH frames (8). Notably, we have recently demonstrated that such IVUS-VH derived 
TCFA lesions are strongly and independently predictive of the occurrence of MACE within 
the current study population(42). 
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CONCLUSIONS
In this population of patients undergoing coronary angiography for ACS or SAP, higher 
circulating ferritin was associated with higher coronary plaque volume, and higher PAI-1 
was associated with higher incidence of all-cause mortality or ACS during 1-year follow-
up. Of the APPs we investigated, no clear-cut associations could be demonstrated with 
composition of coronary atherosclerosis or with plaque vulnerability, as assessed by 
IVUS-VH. Further research, using various intravascular imaging modalities, is warranted 
to provide additional insights into potential mechanisms through which APPs may affect 
composition of atherosclerosis. 
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ABSTRACT
Background: This study aimed to evaluate the relationship between cigarette smoking 
and coronary atherosclerotic burden, volume and composition as determined in vivo 
by grayscale and virtual histology (VH) intravascular ultrasound (IVUS). 
Methods and results: Between 2008-2011, (VH-)IVUS of a non-culprit coronary artery 
was performed in 581 patients undergoing coronary angiography. To account for 
differences in baseline characteristics, current smokers were matched to never smokers 
by age, gender and indication for catheterization, resulting in 280 patients available for 
further analysis. Coronary atherosclerotic plaque volume,  burden and composition 
(fibrous, fibro-fatty, dense calcium and necrotic core) were assessed and high-risk 
lesions (VH-IVUS derived thin-cap fibroatheroma (TCFA), plaque burden ≥70%, minimal 
luminal area ≤4.0 mm2) were identified. Cigarette smoking showed a tendency towards 
higher coronary plaque burden (mean±SD, 38.6±12.5% in current versus 36.4±11.0% 
in never smokers, p=0.080; and odds ratio (OR) of current smoking for plaque burden 
above versus below the median 1.69 (1.04-2.75), p=0.033). Fibrous tissue tended to 
be lower in current smokers (mean± SD, 57.7±10.5% versus 60.4±12.6%, p=0.050) and 
fibro-fatty tissue was higher in current smokers (median [IQR], 9.6[6.0-13.7]% versus 
8.6[5.8-12.2]%, p=0.039). However, differences in percentage necrotic core and dense 
calcium could not be demonstrated. Also, no differences were found with regard to 
high-risk lesions.           
Conclusions: A substantial association between smoking and degree of coronary 
atherosclerosis could not be demonstrated in patients undergoing coronary 
angiography. Although smoking was associated with higher fibro-fatty percentage, no 
associations could be demonstrated with percentage necrotic core, nor with VH-IVUS 
derived TCFA lesions. 
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INTRODUCTION
Cigarette smoking is a well-known risk factor for developing coronary artery disease (CAD). 
Previous epidemiologic studies have demonstrated that cigarette smoking is associated 
with severity of atherosclerosis on both coronary angiography and coronary CT angiography 
(1, 2), increased risk of myocardial infarction (3) and cardiovascular death (4, 5).
In line with the above, several pathophysiologic effects of cigarette smoke exposure on 
cardiovascular function have been described. Both active and passive cigarette smoke 
exposure have been shown to promote endothelial dysfunction, stimulate inflammatory 
processes at the vessel wall  and enhance vascular prothrombotic effects (6, 7). Thus, ample 
fundamental research evidence is available demonstrating that cigarette smoking directly 
impacts multiple aspects of atherosclerosis. However, less is currently known about the 
associations of cigarette smoking with in vivo, macroscopic plaque composition and plaque 
vulnerability. Although coronary angiography enables evaluation of the unobstructed part 
of the lumen, it does not provide information on the structure of the arterial wall itself. 
Grayscale intravascular ultrasound (IVUS) also provides limited information on plaque 
characteristics. Histopathological studies examining coronary arteries suggest that smoking 
predisposes patients to coronary thrombosis rather than promoting the progression of 
atherosclerosis (8-11). However, given the post-mortem nature of these studies, inherent 
selection bias is present.
Virtual histology (VH)-IVUS of the coronary arteries allows spectral analysis of 
backscattered radiofrequency ultrasound signal and herewith enables in vivo analysis of 
the composition of coronary plaque as well as in vivo identification of VH-IVUS derived 
thin-cap fibroatheroma (TCFA) lesions (12). Until now, the association between smoking 
and in vivo coronary plaque composition has only been examined in two studies. The first 
(13, 14) applied VH-IVUS and examined several plaque components, but did not assess 
VH-IVUS derived TCFA. The second (15) used integrated backscatter IVUS, which is based 
on the same principle as VH-IVUS, but examined 30 patients only. 
The main objective of the current study is to evaluate in detail the relationship between 
cigarette smoking and coronary atherosclerotic plaque burden, volume and composition 
as assessed by (VH-)IVUS, including VH-IVUS derived TCFA lesions, in patients undergoing 
coronary catheterization for stable coronary artery disease (CAD) or acute coronary 
syndrome (ACS). With this investigation we aim to improve our understanding of the 
complex pathophysiologic relation between cigarette smoke exposure and cardiovascular 
disease.
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METHODS
Study population and baseline characteristics 
This study was performed within the framework of the European collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound 
(ATHEROREMO-IVUS) study . The rationale and design of the ATHEROREMO-IVUS study 
have been described in detail elsewhere (16). In brief, 581 patients who underwent 
diagnostic coronary angiography or percutaneous coronary intervention (PCI) for ACS 
or stable CAD have been included in this study between 2008 and 2011 at the Erasmus 
MC, Rotterdam, the Netherlands. The ATHEROREMO-IVUS study has been approved by 
the human research ethics committee of the Erasmus MC. Written informed consent 
was obtained from all participants. The study is registered in ClinicalTrials.gov, number 
NCT01789411. 
Baseline characteristics of the patients, including smoking status, were prospectively 
entered into a dedicated database. Smoking status was determined by self-report. Patients 
were categorized into those who currently smoke cigarettes (including those that had quit 
less than 1 year ago), those who had never smoked, and those who had smoked in the 
past (and had quit more than 1 year ago). For the current substudy, patients from the full 
ATHEROREMO-IVUS study cohort were eligible when they were current or never smokers. 
Patients who had quit smoking more than 1 year ago (n=104), or for whom information on 
smoking was lacking  (n=1), were excluded, leaving 476 patients eligible for analysis.     
Intravascular ultrasound 
Following the standard coronary angiography or PCI procedure, IVUS imaging of a non-
culprit coronary artery was performed. The selection of this non-culprit vessel was 
predefined in the study protocol. The order of preference for selection of the non-culprit 
vessel was: 1. left anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left 
circumflex (LCX) artery. All IVUS data were acquired with the Volcano™ s5/s5i Imaging 
System (Volcano Corp., San Diego, CA, USA), using a Volcano™ Eagle Eye™ Gold IVUS 
catheter (20 MHz). An automatic pullback system was used with a standard pull back 
speed of 0.5 mm per second. The IVUS images were analyzed offline by an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands) that had no knowledge of 
clinical data. The IVUS grayscale and virtual histology analyses were performed using pcVH 
2.1 and qVH (Volcano Corp., San Diego, CA, USA) software.  
The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Degree and phenotype of the atherosclerotic 
plaque were assessed. Plaque volume was defined as the percent of the volume of the 
external elastic membrane occupied by atheroma, i.e. percent atheroma volume. Plaque 
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burden was defined as plaque and media cross-sectional area divided by external elastic 
membrane cross-sectional area. 
A coronary lesion was defined as a segment with a plaque burden of more than 40% in 
at least 3 consecutive frames. Using VH-IVUS, the composition of the atherosclerotic 
plaques was characterized into 4 different tissue types: fibrous (FI), fibro-fatty (FF), dense 
calcium (DC) and necrotic core (NC) (17). These tissue type components were expressed as 
percentages of total plaque volume. Three types of high-risk lesions were identified: 1.VH-
IVUS derived thin-cap fibroatheroma (TCFA) lesion, defined as a lesion with presence of 
>10% confluent necrotic core in direct contact with the lumen; 2. Lesion with large plaque 
burden, defined as a lesion with a plaque burden of ≥70%; 3. Stenotic lesion, defined as 
a lesion with a minimal luminal area of ≤4.0 mm2 (17, 18). In addition, calcified VH-TCFA 
lesions were examined; these were defined as VH-TCFA lesions containing >10% of confluent 
dense calcium. Remodeling index was expressed as the external elastic membrane cross-
sectional area at the site of minimal luminal area divided by the reference external elastic 
membrane cross-sectional area. The reference site was selected <10 mm proximal to the 
lesion. Positive remodeling (arterial expansion) was defined as a remodeling index of >1.05, 
and  negative remodeling (arterial shrinkage) was defined as a remodeling index of <0.95.
STATISTICAL ANALYSIS 
Categorical data are presented as numbers and percentages. Normality of the distributions 
of continuous variables was examined by visual inspection of the histogram and by normal 
Q-Q plots. Continuous data are presented as mean ± standard deviation (SD) or as median 
and interquartile range (IQR), depending on their distribution. Plaque volume, percentage 
fibro-fatty  volume (% FF) and percentage dense calcium volume (% DC) appeared to be 
non-normally distributed and were therefore ln transformed for further analyses.
Baseline clinical and procedural characteristics of current smokers and those who had never 
smoked were compared using the independent Student’s t-test for continuous variables 
and using the χ² test for categorical variables. Subsequently, to account for differences in 
baseline characteristics between current smokers and those who had never smoked, we 
performed a matching procedure. Every current smoker was matched to a never smoker 
by age (± 5 years), gender and indication for catheterization (acute coronary syndrome or 
stable angina pectoris). 
In the matched set, baseline clinical, procedural and (VH-)IVUS characteristics of current 
smokers and those who had never smoked were compared using the paired samples 
t-test for continuous variables and the McNemar test or marginal homogeneity test for 
categorical variables, whichever was appropriate. 
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Subsequently, we performed conditional logistic regression to examine the associations 
between smoking status and high plaque burden (above versus below the median), as well 
as smoking status and the three types of high-risk lesions (VH-IVUS derived TCFA, lesion 
with plaque burden ≥70%, lesion with minimal luminal area ≤4.0 mm2). 
All data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). 
All statistical tests were two-tailed and p-values <0.050 were considered statistically 
significant.
Table 1. Baseline clinical and procedural characteristics, before matching
Current smokers
(n = 169)
Never smokers
(n = 307)
P-value
Patient characteristics
Age, years 55.7 ± 10.8 64.4 ± 10.8 <0.001
Male gender, n (%) 134 (79.3) 217 (70.7) 0.041
Hypertension, n (%) 63 (37.5) 171 (55.7) <0.001
Dyslipidemia, n (%) 80 (47.6) 178 (58.0) 0.030
Diabetes mellitus, n (%) 20 (11.8) 59 (19.2) 0.038
Positive family history, n (%) 86 (51.2) 158 (51.5) 0.95
Peripheral artery disease, n (%) 12 (7.1) 15 (4.9) 0.32
Previous MI, n (%) 38 (22.5) 103 (33.6) 0.011
Previous PCI, n (%) 37 (21.9) 103 (33.6) 0.008
Previous CABG, n (%) 1 (0.6) 12 (3.9) 0.034
Previous stroke, n (%) 4 (2.4) 16 (5.2) 0.14
History of renal insufficiency, n (%) 8 (4.7) 17 (5.5) 0.71
Procedural characteristics
Indication for catheterization <0.001
Acute coronary syndrome, n (%) 119 (72.1) 151 (49.5)
Stable angina pectoris, n (%) 46 (27.9) 154 (50.5)
Coronary artery disease 0.24
     No significant stenosis, n (%) 9 (5.3) 27 (8.8)
     1-vessel disease, n (%) 90 (53.3) 151 (49.2)
     2-vessel disease, n (%) 56 (33.1) 91 (29.6)
     3-vessel disease, n (%) 14 (8.3) 38 (12.4) 
Values are mean ± SD or n (%).
P-values were obtained by independent samples t-test or Chi-squared test, whichever was appropriate.
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RESULTS
Baseline characteristics
Baseline clinical and procedural characteristics of the total patient population are 
presented in Table 1. Current (n=169) and never smokers (n=307) significantly differed at 
baseline. Current smokers, on average, were significantly younger than the never smokers 
(55.7±10.8 years vs. 64.4±10.8, p<0.001). Significantly more men were present among 
the current smokers (79.3% vs. 70.7%, p=0.041), and current smokers were less likely to 
have predisposing risk factors such as hypertension (p<0.001), dyslipidemia (p=0.030) and 
diabetes mellitus (p=0.038). Furthermore, the indication for coronary angiography or PCI 
significantly differed between the two groups. Current smokers more often underwent 
catheterization for ACS and less often for stable CAD compared to the never smokers 
(p<0.001). 
After the matching procedure, baseline clinical and procedural characteristics were 
similarly distributed between the two groups (Table 2).  
Degree of coronary atherosclerosis 
To assess differences in  degree of atherosclerosis between current smokers and never 
smokers, plaque volume and plaque burden were examined in the coronary segments. 
Plaque volume (median (IQR)) was similar for current and never smokers (221.8[134.6-
312.5]mm3 versus 207.5[134.5-293.2]mm3) (Table 3). On the other hand, with regard to 
plaque burden, there was a tendency towards slightly higher values in current smokers 
(Table 3). Plaque burden (mean±SD) was 38.6±12.5% in current smokers versus 36.4±11.0% 
in never smokers, p=0.080 (Figure 1). The odds ratio (OR) (95% confidence interval (CI)) of 
current smoking for plaque burden above the median versus below the median was 1.69 
(1.04-2.75), p=0.033 (Table 4). 
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Figure 1. Difference in plaque burden between current and never smokers
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Table 2. Baseline clinical and procedural characteristics, after matching
Current smokers
(n = 140)
Never smokers
(n = 140)
P-value
Patient characteristics
Age, years 57.9 ± 9.7 58.1 ± 9.5 MV
Male gender, n (%) 108 (77.1) 108 (77.1) MV
Hypertension, n (%) 58 (41.4) 73 (52.1) 0.10
Dyslipidemia, n (%) 74 (52.9) 74 (52.9) 1.00
Diabetes mellitus, n (%) 19 (13.6) 28 (20.0) 0.21
Positive family history, n (%) 68 (48.9) 75 (53.6) 0.53
Peripheral artery disease, n (%) 12 (8.6) 7 (5.0) 0.36
Previous MI, n (%) 33 (23.6) 35 (25.0) 0.89
Previous PCI, n (%) 33 (23.6) 45 (32.1) 0.11
Previous CABG, n (%) 0 (0.0) 3 (2.1) 0.25
Previous stroke, n (%) 4 (2.9) 7 (5.0) 0.51
History of renal insufficiency, n (%) 6 (4.3) 11 (7.9) 0.33
Procedural characteristics
Indication for catheterization MV
Acute coronary syndrome, n (%) 96 (68.6) 96 (68.6)
Stable angina pectoris, n (%) 44 (31.4) 44 (31.4)
Coronary artery disease 0.33
           No significant stenosis, n (%) 6 (4.3) 14 (10.0)
1-vessel disease, n (%) 74 (52.9) 76 (54.3)
2-vessel disease, n (%) 47 (33.6) 36 (25.7)
3-vessel disease, n (%) 13 (9.3) 14 (10.0)
Values are mean ± SD or n (%). 
P-values were obtained by paired samples t-test, McNemar test or Marginal Homogeneity, whichever was 
appropriate. MV=matching variable
The number of patients with ≥1 lesions did not significantly differ between current and 
never smokers (85.7% vs. 87.9%, p=0.72) (Table 3). Also, the odds ratio of having one or 
more lesions with plaque burden ≥70% was not significantly raised (OR (95% CI): 1.47 
(0.76-2.83)), and neither was the odds ratio of having one or more lesions with a minimal 
luminal area of ≤4.0 mm2 (Table 4).
As described above, we found a borderline association with plaque burden, but no 
association with plaque volume. This seeming discrepancy may be due to the fact that 
plaque burden is not a direct measure of three dimensional plaque volume, but rather 
a two dimensional measure that also accounts for arterial wall remodeling. Specifically, 
the discrepancy may be explained by an association with negative remodeling. Therefore, 
we examined associations of smoking with remodeling in a post-hoc analysis. Smoking 
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displayed a tendency toward a positive association with negative remodeling (OR (95% CI): 
1.58 (0.89-2.81), p=0.12), as well as a tendency toward a negative association with positive 
remodeling (OR (95% CI): 0.47 (0.21-1.05), p=0.065).
Composition of coronary atherosclerosis
VH-IVUS segment and lesion characteristics of the matched smokers and never smokers 
are listed in Table 3. Percentage of fibrous tissue (% FI) volume in the examined coronary 
segment tended to be lower in current smokers (57.7±10.5% vs. 60.4±12.6%, p=0.050) and 
percentage of fibro-fatty tissue volume was higher in current smokers (9.6[6.0-13.7]% vs. 
8.6[5.8-12.2]%, p=0.039) (Table 3, Figure 2). However, differences in percentage necrotic 
core (% NC) volume and dense calcium volume could not be demonstrated, and prevalence 
of ≥1 TCFA lesions was exactly the same in current and never smokers (both 40.7%, Table 3 
and Table 4). Similarly, no differences could be demonstrated in prevalence of ≥1 calcified 
TCFA lesions (Table 3 and Table 4).   
Table 3. (VH-)IVUS segment and lesion characteristics, after matching 
Current smokers
(n = 140)
Never smokers
(n = 140)
P-value
(VH-)IVUS segment parameters
Segment length, mm 45.4 ± 15.4 44.7 ± 13.2 0.67
Degree of atherosclerosis
Plaque volume, mm3 221.8 [134.6 - 312.5] 207.5 [134.5 - 293.2] 0.68
Plaque burden, % 38.6 ± 12.5 36.4 ± 11.0 0.080
Composition of atherosclerosis
% FI volume 57.7 ± 10.5 60.4 ± 12.6    0.050
% FF volume 9.6 [6.0-13.7] 8.6 [5.8-12.2] 0.039
% NC volume 21.6 ± 8.0 20.8 ± 8.8 0.40
% DC volume 7.6 [4.7-13.9] 8.0 [4.3-13.3] 0.62
(VH-)IVUS lesion parameters
≥1 Lesions, n (%) 120 (85.7) 123 (87.9) 0.72
Presence of high risk lesions, n (%) 91 (65.0) 83 (59.3) 0.39
High risk lesion type:
Degree of atherosclerosis
    ≥1 Lesion with plaque burden ≥70%, n (%) 32 (22.9) 27 (19.3) 0.32
    ≥1 Lesion with MLA ≤4.0mm2, n (%)                           43 (30.7) 42 (30.0) 0.67
Composition of atherosclerosis
   ≥1 TCFA, n (%) 57 (40.7) 57 (40.7) 1.00
   ≥1 Calcified TCFA, n (%) 29 (20.7) 35 (25.0) 0.48
Values are mean ± SD, median [interquartile range], or n (%). 
P-values were obtained by paired samples t-test or McNemar test, whichever was appropriate. 
FI=fibrous; FF=fibro-fatty; NC=necrotic core; DC=dense calcium; MLA=minimal lumen area; 
TCFA=thin-cap fibroatheroma 
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Table 4. Odds ratios of current smoking for high plaque burden and for presence of high risk lesion 
types
OR (95% CI) P-value
(VH-)IVUS segment parameters
Plaque burden
Below the median 1.00 (reference) 
Above the median 1.69 (1.04 – 2.75) 0.033
(VH-)IVUS lesion parameters
                         ≥1 Lesion with plaque burden  ≥70% 1.47 (0.76 – 2.83) 0.25
                         ≥1 Lesion with MLA ≤4.0mm2                             1.17 (0.67 – 2.05) 0.57
                         ≥1 TCFA 1.00 (0.63 – 1.60) 1.00
                         ≥1 Calcified TCFA 1.09 (0.62 – 1.92) 0.77
P-values were obtained by conditional logistic regression. 
OR=odds ratio; CI=confidence interval; MLA=minimal lumen area; TCFA=thin-cap fibroatheroma
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Figure 2. Difference in composition of coronary atherosclerosis between current and never smokers 
DISCUSSION
This study investigated the associations of cigarette smoking with coronary atherosclerotic 
plaque burden, volume and composition as determined by (VH-)IVUS of a non-culprit 
section of a coronary artery in patients undergoing coronary angiography. Alhough 
cigarette smoking showed a tendency towards slightly higher coronary plaque burden, a 
substantial association between smoking and degree of coronary atherosclerosis could 
not be demonstrated. Furthermore, while cigarette smoking was associated with higher 
percentage of fibro-fatty plaque volume, no associations could be demonstrated with 
percentage necrotic core volume, nor with VH-IVUS derived TCFA lesions, suggesting that 
smoking has no major influence on plaque vulnerability. 
Although several studies have examined the association between cigarette smoking and 
degree  of coronary atherosclerosis as measured by IVUS (13-15, 19-21), so far only one 
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large study has applied virtual histology (VH-IVUS) to assess its association with composition 
of coronary atherosclerosis and plaque vulnerability. Philipp et al (14) examined 990 
patients enrolled in a prospective, multicentre, global VH-IVUS registry, and found that 
smoking was not associated with a specific plaque composition in this study population 
of consecutive, nonselected patients, which is in line with our findings. However, they did 
not perform a lesion-based analysis, or a categorization into high-risk lesions such as TCFA, 
as we did. Missel et al (13) examined a subset of 473 male patients with de novo culprit 
coronary lesions from the same registry, and found that the NC/DC ratio was higher for 
smokers versus non-smokers in this subgroup. Other VH parameters were not significantly 
influenced by smoking. High NC/DC ratio was used as a measure of plaque vulnerability 
in the study by Missel et al. The association they demonstrated, was not present in the 
current study, in which we used TCFA as a measure of plaque vulnerability. When taking 
DC into further account by examining only calcified TCFA in the current study, results 
remained negative. The same applied to a post-hoc analysis examining NC/DC ratio (results 
not shown). An earlier, small study by Sano et al (15) examined plaque characteristics in 30 
patients with stable angina pectoris, and did not find an association with smoking either. 
However, since only 6 patients smoked in this study, statistical power was very limited.  
 With regard to degree  of coronary atherosclerosis as assessed by IVUS, previous studies 
have rendered contradicting results. Nicholls et al (20) demonstrated that smoking was 
a weak independent predictor of percent plaque volume on multivariable analysis in a 
population of 654 patients with a clinical indication for diagnostic coronary angiography 
from the REVERSAL trial. Furthermore, Von Birgelen et al found an association between 
smoking and progression of plaque plus media (P&M) cross-sectional area (CSA)  in 56 
patients with de novo, hemodynamically nonsignificant plaques. In contrast, Kahlon et al 
concluded that smoking was not correlated with plaque burden in 897 consecutive patients 
undergoing IVUS investigation (19). Our findings concur with the latter study. The lack of a 
substantial association between smoking and plaque burden as well as plaque volume in 
our study, may in part be due to the fact that our study population consisted of patients 
who had an indication for coronary angiography. Therefore, in never smokers, other factors 
(not reflected by the ‘established’ risk factors described in the baseline characteristics) 
may potentially have contributed to their burden of atherosclerosis. And as reflected by 
our analyses, the disease burden caused by these factors may have been similar to the 
disease burden caused by smoking, thus potentially obscuring the effect of smoking.  
  Our results do not provide support for the hypothesis that smoking is associated with 
coronary plaque vulnerability. Lack of such an association may in part be explained by 
the possibility that plaque erosion, and not as much vulnerable plaque rupture, is the 
intermediate between smoking and cardiac adverse events, as suggested by earlier, 
histopathological studies. Such studies have shown that luminal thrombosis may result 
from two different pathologies, namely plaque rupture and plaque erosion (8, 22-24). 
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Plaque rupture is highly associated with a lipid-rich atheroma with only a thin fibrous 
layer of intimal tissue covering the necrotic core (a thin-cap fibroatheroma, TCFA) and 
causes thrombotic coronary occlusion. This mechanism is the most common cause of 
myocardial infarction and death from cardiac causes (22). Plaque erosion is characterized 
by an acute thrombus in direct contact with the intimal plaque rich in smooth muscle 
cells with surrounding proteoglycan matrix and minimal inflammation. The lesions 
tend to be eccentric, infrequently calcified and cause less severe narrowing at sites of 
thrombosis (8, 23). Most erosion lesions have an absent or poorly defined necrotic core, 
which, when present, is not in close proximity to the luminal thrombus. The risk factors 
for erosion are poorly understood and are different from those of rupture. The literature 
has shown that plaque erosion is associated with smoking  and frequently causes coronary 
thrombosis (8, 23). This may possibly explain the general absence of an association of 
smoking with coronary plaque composition as assessed by VH-IVUS in the literature, and 
the inconsistent findings with regard to smoking and degree of coronary atherosclerosis 
as assessed by grayscale IVUS. In the present study, we found that current smokers tend 
to have a slightly lower percentage fibrous plaque volume and that they have a somewhat 
higher percentage fibro-fatty plaque volume; however, this trend did not persist with 
regard to percentage necrotic core or presence of TCFA. These findings do not preclude 
plaque erosion as the underlying mechanism. Moreover, histopathological studies examing 
coronary arteries suggest that smoking predisposes patients to coronary thrombosis 
rather than promoting the progression of atherosclerosis (8-11). These investigations are 
supported by clinical patient studies showing that smokers seem to have a more favourable 
response to fibrinolytic therapy compared to nonsmokers, which may be attributed to their 
hypercoagulable state (25-27). In the present study, we did not focus on the influence of 
smoking on blood coagulation. 
Smoking displayed a tendency toward a positive association with negative remodeling, 
as well as a tendency toward a negative association with positive remodeling. A possible 
explanation for these seemingly counterintuitive findings lies in the interpretation of the 
early phases of remodeling. Modest positive lesion remodeling may be considered as a 
physiological, and thus favourable, response to progression of atherosclerotic plaque (also 
known as the Glagov adaptive phenomenon) (28). In this light, smoking may point towards 
a lower adaptive capacity to atherosclerotic burden.
Some aspects of this study warrant consideration. VH-IVUS imaging took place of a 
prespecified single target segment of a single non-culprit coronary artery, under the 
assumption that such a non-stenotic segment would adequately reflect coronary wall 
pathophysiology of the larger coronary tree. Although this assumption may be debated, 
previous studies evaluating IVUS have demonstrated that the coronary wall of comparable 
non-culprit, non-stenotic segments of a single vessel does reflect larger coronary disease 
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burden and is associated with subsequent events (29, 30). Furthermore, it is important to 
note that IVUS is formally not capable of detecting the TCFA according to histopathological 
definitions (31, 32), because the spatial resolution of IVUS is insufficient for thin cap 
detection (31, 32). Nonetheless, a concept of VH-IVUS derived TCFA has been postulated 
for plaques with a plaque burden ≥ 40% and a confluent necrotic core ≥ 10% in direct 
contact with the lumen in at least three VH-IVUS frames (18, 31). Notably, we have recently 
demonstrated that such VH-IVUS derived TCFA lesions are strongly and independently 
predictive of the occurrence of major adverse cardiac events within the current study 
population (33). Another important limitation of this cross-sectional study is that smoking 
status was determined by self-report. To minimize the risk of misclassification, we excluded 
former smokers from our study. Finally, a matching procedure was necessary because of 
differences in baseline characteristics between smokers and never smokers. Since part of 
the smokers (n=29) could not be matched to a never smoker, this study design entailed 
some loss of statistical power.    
In conclusion, we were not able to demonstrate a clear association of cigarette smoking 
with coronary plaque vulnerability as assessed by VH-IVUS in the current study. Additional 
studies, using various intravascular imaging modalities, are needed to further describe the 
association between smoking and in vivo coronary plaque composition, and to herewith 
discern the mechanisms underlying the association between smoking and cardiac adverse 
events.
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ABSTRACT
Aims: Heart failure with normal ejection fraction (HFNEF) is a major and growing 
public health problem, currently representing half of the heart failure burden. 
Although many studies have investigated the diagnostic and prognostic value of 
new biomarkers in heart failure, limited data are available on biomarkers other than 
natriuretic peptides in HFNEF. We performed a systematic review of epidemiologic 
studies on the associations of biomarkers with the occurrence of HFNEF and with the 
prognosis of HFNEF patients. 
Methods and results: Biomarkers examined most extensively in HFNEF include 
biomarkers of myocyte stress, inflammation and extra-cellular matrix remodeling. 
Some biomarkers have been shown to be increased to a different extent in HFNEF 
compared to heart failure with reduced ejection fraction (HFREF). Several biomarkers, 
including biomarkers of myocyte stress, inflammation, extracellular matrix remodeling, 
growth differentiation factor 15 (GDF-15), cystatin C, resistin and galectin-3 were 
associated with development of HFNEF and with clinical outcomes of HFNEF patients 
in terms of morbidity and mortality.  
Conclusion: Several biomarkers, including biomarkers of myocyte stress, inflammation, 
extracellular matrix remodeling, growth differentiation factor 15 (GDF-15), cystatin C, 
resistin and galectin-3 appeared to be promising diagnostic and prognostic tools in 
patients with HFNEF. Investigation of the incremental diagnostic and prognostic value 
of these biomarkers, or a combination thereof, over established clinical covariates and 
imaging techniques in large, prospective studies is warranted.
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INTRODUCTION
Heart failure (HF) is a major and growing public health problem that is associated with 
substantial morbidity and mortality.1, 2 Classically, HF has been considered to be associated 
with impaired cardiac contractility and cardiac dilatation. In the past decade, however, it has 
become evident that a considerable portion of patients presenting with clinical HF have a 
normal left ventricular ejection fraction (LVEF). Some studies report a prevalence as high as 
50%.3 This entity is often termed HF with normal ejection fraction (HFNEF), sometimes also 
referred to as HF with preserved ejection fraction.1, 2  Despite improvements in understanding 
the underlying disease mechanisms, the exact mechanism and the classification of HFNEF 
are still debated.3 In the single syndrome hypothesis, HFNEF and HF with reduced LVEF 
(HFREF) are viewed as two ends of one HF spectrum, the major difference being the degree 
of left ventricular dilatation and shape change or left ventricular remodelling.3 Although 
HFNEF is typically characterized by the presence of diastolic dysfunction, HFREF is found 
to be associated with reduced myocardial tissue doppler velocities as well, which supports 
the single HF syndrome hypothesis. On the other hand, the theory has been proposed 
that clinical HF presents and evolves not as a single syndrome but as two syndromes, one 
with depressed LVEF and the other with normal LVEF and specific mechanisms responsible 
for diastolic LV dysfunction, this theory being supported by structural, functional, and 
molecular biological arguments.3 Regardless of which hypothesis will eventually turn out 
to be appropriate, the prognosis after hospitalization for HFNEF appears to be as ominous 
as that of HFREF with a mortality rate of approximately 65% at 5 years.4 
Although echocardiography is the most useful noninvasive diagnostic method for 
evaluating systolic and diastolic dysfunction, current state-of-the-art echocardiography 
has limited value for prognostication in HF.1, 2 HF results from a complex interplay between 
genetic, neurohormonal, inflammatory and biochemical changes acting on cardiac 
myocytes and the cardiac interstitium. Thus, the sequence of events that lead to overt 
changes in the ventricle begins at cellular level, and assessing these phenomena could be 
of greater value to improve prognostication. Biomarkers, in this context meaning proteins 
measured in blood, may play an important part in this respect. Biomarkers may provide 
important information on the pathogenesis of HF, but may also be a valuable clinical tool 
in the identification of patients at risk for HF, in the diagnosis of HF, in risk stratification and 
in monitoring therapy. Furthermore, reliable non-invasive measures of pre-symptomatic 
worsening of (diastolic) ventricular function, including biomarkers, could aid in prevention 
of ensuing decompensation with its adverse sequels. 
Although many studies have investigated the diagnostic and prognostic value of new 
biomarkers in HF, the majority of these studies included HFREF patients only.5 Limited 
data are available on biomarkers in HFNEF. This review provides a thorough, yet concise, 
overview of clinical and population based studies on the associations of biomarkers with 
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occurrence of HFNEF and with prognosis of HFNEF patients, and of the pathophysiology 
underlying these associations. We summarize research on established biomarkers, such as 
natriuretic peptides, but we mainly focus on biomarkers of myocyte stress, inflammation 
and extra-cellular matrix remodeling since the body of evidence on these markers is less 
elaborate.    
METHODS
Using Medline (Pubmed U.S. National Library of Medicine), we performed a literature 
search from inception to February 2012 using the following search terms: “Heart Failure” 
(MeSH term) and “normal ejection fraction” or “HFNEF” or “preserved ejection fraction” 
or “HFPEF” or “diastolic heart failure” or “DHF” or “diastolic dysfunction” in combination 
with “Biological Markers” (MeSH term) or “cytokine” or “CRP” or “TNF” or “MMP” or 
“TIMP” or “collagen”. We limited our search to studies on human adults. Articles were 
included if they fulfilled the following criteria: a study population that includes patients 
with HFNEF or that has registered incident HFNEF; measurement of biomarkers in blood 
samples (other than natriuretic peptides); and reference to outcome in terms of morbidity 
and mortality. In addition, references of included studies were checked to ensure that no 
potentially eligible studies were missed. 
HFNEF was defined as a reported clinical diagnosis of HF as well as LVEF higher than a cutoff 
value of choice in the specific study, which could range from 40% to 55%. Studies that have 
reported on associations with diastolic dysfunction in general, but not on associations with 
HFNEF, were excluded.
RESULTS
The systematic literature search yielded 198 potential eligible studies. After exclusion of 
the studies that did not fulfill our criteria, 26 original studies were included in this review. 
The study populations and baseline characteristics of these studies are shown in Table 1. 
Additionally, three literature reviews were found on the utility of natriuretic peptides in 
HFNEF.6-8
BIOMARKERS OF MYOCYTE STRESS
Natriuretic peptides
Among biomarkers of myocyte stress, brain natriuretic peptides (BNP) have been 
investigated most extensively.5 Nevertheless, our understanding on the biochemistry of 
natriuretic peptides currently may not be fully complete, as exemplified by the occurrence 
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of the “natriuretic peptide paradox”. Pro-brain natriuretic peptide (proBNP) is synthesized 
by the heart in reaction to cardiac wall distension and stretching, and neurohormonal 
activation.9 During secretion from the cardiomyocytes, the biologically inactive amino-
terminal fragment (NT-proBNP) is split from proBNP. An increased active BNP concentration 
in the plasma leads to natriuresis, vasodilatation, inhibition of the renin-angiotensin 
system, adrenergic activity and improved myocardial relaxation. Herewith, BNP is expected 
to have an important regulatory role in response to acute increases in ventricular volume 
and overload. In HF patients, although levels of serum immunoreactive natriuretic 
peptides are already elevated,  administration of BNP has additional beneficial effects.10 
This “natriuretic peptide paradox” may be explained by the fact that in HF patients, the 
fraction of active BNP in the blood is relatively small. This signifies that HF is characterized 
by altered natriuretic peptide processing with secretion of less biologically active forms, 
while proBNP is the major immunoreactive form that is measured by laboratory assays.10
The associations of the natriuretic peptides with HFNEF have already been evaluated 
extensively in recently published reviews.6-8 As such, we will not evaluate these associations 
in depth in the current paper. In brief, the majority of data show that BNP and NT-proBNP 
levels are increased in both HFREF and HFNEF compared to control subjects. Higher plasma 
NT-proBNP levels are shown to be associated with greater severity of diastolic dysfunction 
in patients with HFNEF.11 However, co-morbidities are major drivers of higher NT-proBNP 
levels in HFNEF as well.12 Several studies have also shown that plasma levels of natriuretic 
peptides are strong predictors of mortality and hospitalizations in both patients with HFREF 
and patients with HFNEF.13 For a given BNP level, the prognosis in patients with HFNEF is 
as poor as in those with HFREF.14
In current clinical guidelines, the recommended natriuretic peptide cutoff values for the 
diagnosis of HF do not differ between HFREF and HFNEF.1, 2 However, there are some 
interesting differences in the epidemiology of natriuretic peptides between the HFREF 
and the HFNEF populations. Firstly, the increase of NT-proBNP levels is less pronounced 
in HFNEF.6-8 NT-proBNP levels have been shown to be lower in HFNEF than HFREF patients 
of a similar NYHA class.15 Furthermore, patients in the Irbesartan in heart Failure with 
Preserved Ejection Fraction Trial (I-PRESERVE) had low overall NT-proBNP levels.16 These 
relatively lower natriuretic peptide levels suggest a lower diastolic wall stress in HFNEF when 
compared to HFREF. In case NT-proBNP is required to be elevated for a definite diagnosis of 
HF, only the higher-risk HFNEF patients will be identified, resulting in a reduced prevalence 
of HFNEF.17 Secondly, the strategy of using elevated natriuretic peptides concentrations as 
a patient selection criterion for HFNEF trials could be questioned because the I-PRESERVE 
trial showed that the use of irbesartan was associated with improved outcomes in patients 
with NT-proBNP below, but not above, the median concentration.16  
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Table 1. Baseline characteristics
 Year Population (n) EF cu-
toff for 
HFNEF
Sample size, n Age, years ± SD Male gender, % DM, % HT, % Ischaemic heart disease, % NYHA III/IV, %
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No HF 
or LVH
HFNEF HFREF
LVH, 
no 
HF
No HF 
or LVH
HFNEF HFREF
Yu et al. (15) 2001 hospitalized HF (77), 
healthy controls (17)
50% 31 46 17 66.5 ± 
8.4
65.7 ± 
12.2
81 72    87.9 84.1 16.7 22.9
Amosova et al. (23) 2004 hospitalized HFNEF (26), 
healthy controls (10)
NR        
Wisniacki et al. (19) 2005 outpatient HF aged 70-90 (52), 
healthy (26)
50% 25 27 26 80.4 ± 
4.5
79.8 ± 
5.2
76,1 ± 
3.5
48 59.3 53.8   52 44
Ahmed et al. (35) 2006 outpatient LVH patients (49), 
healthy controls (53)
50% 26 23 53 59 ± 7  38    
Martos et al. (36) 2007  outpatient HT patients (86) 45% 32 54 72 ± 11 67 ± 9 53 76 12 7 100 100  
Varol et al. (49) 2007 outpatient HCM patients with HF 
(32), healthy controls (30)
NR 32 30 51.3 ± 
18.4
49.6 
±16.1
66 63 13 0   13 0 34
Frantz et al. (37) 2008 hospitalized HF (249), 
healthy controls (74)
45% 102 147 74      
Michowitz et al. (17) 2008 outpatient HF (294), 
healthy controls (7701)
45% 77 217 7701 71 ± 
11.2
72.4 ± 
10.8
61 81.1  40.2 38.2 70.1 57.1  50.6 83.4  
Dunlay et al. (29) 2008 community-based HF patients 
(486)
50% 486  76.7 ± 
13.0
48.6  30.5 80.4  53.7 73.0
Moran et al. (44) 2008 community-based aged ≥65 
(4453)
50%  4453      
Niethammer et al. 
(24)
2008 hospitalized HFNEF (17), hospital-
ized HFPEF (17), healthy controls 
(20)
50% 17 17 20 72 ± 9 70 ± 8 56 ± 5 47 82 45 18 24 0 100 88 13  
Barasch et al. (40) 2009 community-based aged ≥65 (880) 55% 179 131 570 76 ± 5 77 ± 6 77 ± 6 45 63 52 27 30 11 53 48 29 66 83 14  
Butler et al. (46) 2009 community-based aged 70-79 
(2902)
40%  2902 73.6 ± 
2.9
 48.1 14.7  43.5 16.5  
Naito et al. (38) 2009 hospitalized HF (110), hospital-
ized non-HF patients (10)
45% 42 68 10 74 ± 13 71 ± 
16
70 ± 
13
52 0.64 60 33 32 30 48 31 50 17 50 70  
Okuyan et al. (18) 2010 hospitalized HFNEF (68), healthy 
controls (40)
50% 68 40 65.5 ± 
9.6 
65.2 ± 
9.7
43 40 51.47 30 66.17 60  
Stahrenberg et al. 
(42)
2010 community-based HF patients 
(228), healthy elderly controls 
(188)
50% 142 86 188 73 [66-
78]
71 
[66-
75]
56 
[52-
63]
36 83 34 30 37 0 93 91 1 35 52 0  
Gonzales et al. (39) 2010 outpatient hypertensive patients 
with HFNEF (156), healthy con-
trols (20)
50% 156 20 75 ± 9 46  100   
Kalogeropoulos et 
al. (28)
2010 community-based aged 70-79 
(2610)
45%  2610 73.6 ± 
2.9
 48.3 14.8  53.1 19.5  
De Boer et al. (13) 2011 Hospitalized HF (592) 40% 114 368  74 ± 10 69 ± 
12
50 66  29 28 51 40  30 44 47 59
Matsubara et al. (16) 2011 hospitalized HF (181), hospital-
ized non-HF patients (171)
50% 82 70 171 71.2 ± 
10.2
65.5 ± 
13.6
66.5 ± 
11.2
72 67 57 45.1 28.6 37.4 72.0 54.3 67.8 53.7 45.7 55.0 37 63
Carrasco-Sanchez et 
al. (45) 
2011 hospitalized HFNEF (218) 45% 218  75.6 ± 
8.7
39.9  52.8 83.5  18.8 39.4
Wu et al. (25) 2011 hospitalized HFNEF (110), hospi-
talized non-HF patients (55)
NR 110 55 72.22 ± 
9.86
72.16 
± 9.62
52 26 29 36 69 78  
Zile et al. (26) 2011 outpatient LVH patients (205), 
healthy controls (241)
50% 61 144 241 66 ± 8 60 ± 
12
58 ± 
16
41 45 30 31 16 9    
Collier et al. (27) 2011 outpatient HT patients (275) 50% 181 94 73 ± 12 66 ± 
10
54 55 19 14 100 100 38 30  
Krum et al. (41) 2011 outpatient HFNEF aged ≥60 (313) 45% 313    72 ± 7    34    34    96    21    83  
Santhanakrishnan et 
al. (43)
2012 In- and outpatient compensated 
HF patients (101), healthy con-
trols (50)
50% 50 51 50 69 ± 12 59 ± 
11
63 ± 8 58 86 46 40 49 3 88 69 36 32 59 0 16 37
Data are presented as percentage, mean ± standard deviation or as median [interquartile range]. 
DM = diabetes mellitus; EF = ejection fraction; HF = heart failure; HFNEF = heart failure with normal ejection fraction; HFREF = heart failure 
with reduced ejection fraction; HT = hypertension; LVF = left ventricular hypertrophy; NR = not reported; NYHA = New York Heart Association. 
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Table 1. Baseline characteristics
 Year Population (n) EF cu-
toff for 
HFNEF
Sample size, n Age, years ± SD Male gender, % DM, % HT, % Ischaemic heart disease, % NYHA III/IV, %
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No 
HF or 
LVH
HFNEF HFREF
LVH, 
no 
HF
No HF 
or LVH
HFNEF HFREF
LVH, 
no 
HF
No HF 
or LVH
HFNEF HFREF
Yu et al. (15) 2001 hospitalized HF (77), 
healthy controls (17)
50% 31 46 17 66.5 ± 
8.4
65.7 ± 
12.2
81 72    87.9 84.1 16.7 22.9
Amosova et al. (23) 2004 hospitalized HFNEF (26), 
healthy controls (10)
NR        
Wisniacki et al. (19) 2005 outpatient HF aged 70-90 (52), 
healthy (26)
50% 25 27 26 80.4 ± 
4.5
79.8 ± 
5.2
76,1 ± 
3.5
48 59.3 53.8   52 44
Ahmed et al. (35) 2006 outpatient LVH patients (49), 
healthy controls (53)
50% 26 23 53 59 ± 7  38    
Martos et al. (36) 2007  outpatient HT patients (86) 45% 32 54 72 ± 11 67 ± 9 53 76 12 7 100 100  
Varol et al. (49) 2007 outpatient HCM patients with HF 
(32), healthy controls (30)
NR 32 30 51.3 ± 
18.4
49.6 
±16.1
66 63 13 0   13 0 34
Frantz et al. (37) 2008 hospitalized HF (249), 
healthy controls (74)
45% 102 147 74      
Michowitz et al. (17) 2008 outpatient HF (294), 
healthy controls (7701)
45% 77 217 7701 71 ± 
11.2
72.4 ± 
10.8
61 81.1  40.2 38.2 70.1 57.1  50.6 83.4  
Dunlay et al. (29) 2008 community-based HF patients 
(486)
50% 486  76.7 ± 
13.0
48.6  30.5 80.4  53.7 73.0
Moran et al. (44) 2008 community-based aged ≥65 
(4453)
50%  4453      
Niethammer et al. 
(24)
2008 hospitalized HFNEF (17), hospital-
ized HFPEF (17), healthy controls 
(20)
50% 17 17 20 72 ± 9 70 ± 8 56 ± 5 47 82 45 18 24 0 100 88 13  
Barasch et al. (40) 2009 community-based aged ≥65 (880) 55% 179 131 570 76 ± 5 77 ± 6 77 ± 6 45 63 52 27 30 11 53 48 29 66 83 14  
Butler et al. (46) 2009 community-based aged 70-79 
(2902)
40%  2902 73.6 ± 
2.9
 48.1 14.7  43.5 16.5  
Naito et al. (38) 2009 hospitalized HF (110), hospital-
ized non-HF patients (10)
45% 42 68 10 74 ± 13 71 ± 
16
70 ± 
13
52 0.64 60 33 32 30 48 31 50 17 50 70  
Okuyan et al. (18) 2010 hospitalized HFNEF (68), healthy 
controls (40)
50% 68 40 65.5 ± 
9.6 
65.2 ± 
9.7
43 40 51.47 30 66.17 60  
Stahrenberg et al. 
(42)
2010 community-based HF patients 
(228), healthy elderly controls 
(188)
50% 142 86 188 73 [66-
78]
71 
[66-
75]
56 
[52-
63]
36 83 34 30 37 0 93 91 1 35 52 0  
Gonzales et al. (39) 2010 outpatient hypertensive patients 
with HFNEF (156), healthy con-
trols (20)
50% 156 20 75 ± 9 46  100   
Kalogeropoulos et 
al. (28)
2010 community-based aged 70-79 
(2610)
45%  2610 73.6 ± 
2.9
 48.3 14.8  53.1 19.5  
De Boer et al. (13) 2011 Hospitalized HF (592) 40% 114 368  74 ± 10 69 ± 
12
50 66  29 28 51 40  30 44 47 59
Matsubara et al. (16) 2011 hospitalized HF (181), hospital-
ized non-HF patients (171)
50% 82 70 171 71.2 ± 
10.2
65.5 ± 
13.6
66.5 ± 
11.2
72 67 57 45.1 28.6 37.4 72.0 54.3 67.8 53.7 45.7 55.0 37 63
Carrasco-Sanchez et 
al. (45) 
2011 hospitalized HFNEF (218) 45% 218  75.6 ± 
8.7
39.9  52.8 83.5  18.8 39.4
Wu et al. (25) 2011 hospitalized HFNEF (110), hospi-
talized non-HF patients (55)
NR 110 55 72.22 ± 
9.86
72.16 
± 9.62
52 26 29 36 69 78  
Zile et al. (26) 2011 outpatient LVH patients (205), 
healthy controls (241)
50% 61 144 241 66 ± 8 60 ± 
12
58 ± 
16
41 45 30 31 16 9    
Collier et al. (27) 2011 outpatient HT patients (275) 50% 181 94 73 ± 12 66 ± 
10
54 55 19 14 100 100 38 30  
Krum et al. (41) 2011 outpatient HFNEF aged ≥60 (313) 45% 313    72 ± 7    34    34    96    21    83  
Santhanakrishnan et 
al. (43)
2012 In- and outpatient compensated 
HF patients (101), healthy con-
trols (50)
50% 50 51 50 69 ± 12 59 ± 
11
63 ± 8 58 86 46 40 49 3 88 69 36 32 59 0 16 37
Data are presented as percentage, mean ± standard deviation or as median [interquartile range]. 
DM = diabetes mellitus; EF = ejection fraction; HF = heart failure; HFNEF = heart failure with normal ejection fraction; HFREF = heart failure 
with reduced ejection fraction; HT = hypertension; LVF = left ventricular hypertrophy; NR = not reported; NYHA = New York Heart Association. 
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The above considerations suggest that natriuretic peptides may be less useful as a diagnostic 
and prognostic tool in HFNEF than in HFREF. Although NT-proBNP has a better negative 
predictive value than invasive measurement of left ventricular end-diastolic pressure, 
tissue doppler imaging indices and conventional echocardiography measurements in 
HFNEF patients, the overall diagnostic performance of NT-proBNP according to the receiver 
operating characteristic was only similar to that of tissue doppler imaging indices.11 This 
calls for further exploration of other biomarkers which may provide incremental value 
specifically in HFNEF. The value of such other biomarkers will be discussed in this review.   
Other biomarkers of myocyte stress
Another interesting biomarker of myocyte stress is adrenomedullin. Adrenomedullin 
is a hormone that lowers systemic vascular resistance and has natriuretic and diuretic 
effects. It is produced in several organs such as the heart, lungs and kidneys. We found 
one study that examined adrenomedullin in HFNEF (Table 4). Yu et al. showed that plasma 
adrenomedullin concentrations were higher in HFNEF patients than in healthy controls.18 
There was no significant difference in adrenomedullin concentration between HFNEF and 
HFREF patients. Furthermore, the authors concluded that adrenomedullin concentrations 
in patients with HF are especially raised in the presence of a restrictive filling pattern. 
The incremental value of adrenomedullin over natriuretic peptides has not yet been 
investigated.
BIOMARKERS OF INFLAMMATION
Pathophysiology
Biomarkers of inflammation are among the first to have been linked to HF. Early studies 
have focused on tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and C-reactive protein 
(CRP). These proinflammatory cytokines probably contribute to the clinical syndrome of 
HF and to progression of the disease through adverse effects on the vascular endothelium, 
myocyte apoptosis, induction of hypertrophy (e.g. by IL-6) and left ventricular dilatation 
(e.g. by TNF-α).5 CRP has been correlated with the severity and prognosis of HF, as well as 
with response of HF patients to treatment.19-22 
Inflammatory biomarkers may have different meanings in HFREF and HFNEF. In HFREF, 
inflammatory biomarkers may be a measure of heart failure severity. Although the source 
of cytokine production in HFREF is still unknown, it may possibly reside in the failing 
myocardium itself because of hemodynamic overload.23 Alternatively, it may result from 
extramyocardial production in the bowel, because of altered tissue perfusion and tissue 
hypoxia, possibly modulated by bacterial endotoxin release from the gut.23 In contrast, in 
the case of HFNEF, inflammatory biomarkers, particularly those associated with metabolic 
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syndrome, may be a measure of risk for developing HFNEF. Obesity and diabetes mellitus 
are believed to play a major role in the remodeling of the ventricles and in the development 
of HFNEF.24 Both obesity and diabetes mellitus are associated with increased inflammatory 
biomarker levels. As such, inflammatory biomarker levels may be a measure of factors 
driving left ventricular remodeling in HFNEF. 
Moreover, a high body mass index appears to be beneficial in HFREF patients. Explanations 
for this obesity paradox in HFREF include possible protective effects conferred by excess 
body weight on HF mortality - because advanced HF is a catabolic state, obese patients 
with HF may have more metabolic reserve - and protective effects of cytokine and 
neuroendocrine profiles of obese patients.25 However, this obesity paradox is missing in 
HFNEF,24, 26 which further underscores the important role of obesity in the development of 
this condition. 
Biomarker levels in HFNEF
Although many studies have examined the associations of inflammatory biomarkers with 
HF in general, HFNEF has received less attention. Most of the studies that have included 
HFNEF patients have employed cross-sectional or case-control designs, and are summarized 
below (Table 2 and Supplemental Table 1).19-22, 27-31 Several studies have demonstrated 
elevated TNF-α and IL-6 levels in HFNEF patients when compared to a non-HF reference 
group.19, 22, 28, 29, 31 Also, the concentrations of the TNF-α  receptors (sTNFR-1 and sTNFR-2) 
were found to be higher in HFNEF patients.22, 28 Serum levels of CRP and Pentraxin-3 (PTX-3), 
a relatively newly-identified acute phase protein of the pentraxin superfamily which also 
includes CRP, were both found to be significantly higher in HFNEF patients when compared 
to with the non-HF reference group.19-22 Finally, Collier et al. identified IL-8 and monocyte 
chemoattractant protein-1 (MCP-1) as novel inflammatory biomarkers of HFNEF.31 These 
results once again emphasize that inflammatory biomarkers may play an important role in 
the development and progression of HFNEF.  
 
Biomarker levels in HFNEF compared with HFREF
A few of the above mentioned studies also compared inflammatory marker concentrations 
in HFNEF with HFREF. Regarding this comparison, the results were less consistent 
between studies. Wisniacki et al. reported no significant difference in CRP, sTNFR2 and 
IL-6 levels between 25 HFNEF patients and 27 HFREF patients.22 Michowitz et al. did not 
find a significant difference in CRP elevation between HFNEF and HFREF patients either.20 
Niethammer et al. showed that TNF-α and IL-10 were significantly elevated in HFREF 
but not in HFNEF.28 Furthermore, sTNFR1 levels were less highly elevated in HFNEF than 
in HFREF, while sTNFR2 levels were similarly elevated in both groups. Matsubara et al. 
demonstrated less elevation of CRP, PTX3 and IL-6 levels in HFNEF compared to HFREF, 
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while TNF-α concentrations were similarly elevated.19 These findings suggest that several 
inflammatory biomarkers are more pronounced in HFREF, which supports the hypothesis 
that the origin and the meaning of these markers may differ between HFREF and HFNEF.   
 
Association with incidence of HFNEF
Kalogeropoulos et al. examined 2610 persons aged 70-79 years from the Health ABC 
study and found that TNF-α (unadjusted HR per doubling 1.48; 95% CI 1.19-1.86) and IL-6 
(unadjusted HR per doubling 1.81; 95% CI 1.23-2.68) were associated with incident HFNEF 
during follow-up.32 Such associations of TNF-α and IL-6 were less strong for HFREF. CRP 
was not found to be a significant predictor. These findings support the hypothesis that 
inflammatory biomarkers are particularly associated with development of HFNEF.
Association with HFNEF prognosis
Few follow-up studies have been performed on the role of inflammatory biomarkers in 
HFNEF. Michowitz et al. found that CRP was independently associated with hospitalization in 
patients with HFREF, but not in patients with HFNEF.20 These results support the hypothesis 
that inflammatory biomarkers are a measure of heart failure severity, particularly in HFREF. 
Mortality was not predicted by CRP levels in either patient category. 
Within the Olmsted County study, Dunlay et al. performed a prospective study in which 
they examined 486 patients with active HF of whom 54% had HFNEF.33 They found that 
mortality increased with increasing TNFα level (unadjusted HR of highest vs lowest quartile 
2.10; 95% CI 1.30-3.38). No interaction was present between TNFα and ejection fraction, 
thus implying the effect was similar in HFNEF and HFREF. 
BIOMARKERS OF EXTRACELLULAR-MATRIX REMODELING
Pathophysiology
The extracellular matrix provides a skeleton for myocytes and influences their size and 
shape.5 Changes in the extracellular matrix may be causally related to remodeling of 
the ventricles resulting in progression of HF.5 Collagen turnover in the extracellular 
matrix is mainly regulated by matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases (TIMPs). The MMPs are a family of endopeptidases that digest 
interstitial constituents. The various MMPs have different substrates. TIMPs are proteins 
that bind to and inhibit the effects of MMPs. Furthermore, carboxy-terminal propeptide 
of procollagen type I (PICP), amino-terminal propeptide of procollagen type I (PINP) and 
type III (PIIINP) are markers of collagen biosysthesis, while carboxy-terminal telopeptide of 
collagen type I (CITP) is a marker of collagen degradation. 
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Histological research has demonstrated that the nature of fibrosis differs between HFNEF 
and HFREF.34 Fibrosis in HFNEF is mainly interstitial, while fibrosis in HFREF is both interstitial 
and replacement fibrosis.34 Therefore, it may be expected that different pathophysiological 
pathways are activated and that different profiles of collagen biomarkers are expressed in 
HFNEF versus HFREF. Previous studies have shown that interstitial fibrosis is associated with 
increased expression of TIMPs,35 while replacement fibrosis is associated with increased 
expression of MMPs.36 As such, it may be expected that TIMPs are particularly upregulated 
in HFNEF, while several MMPs are particularly upregulated in HFREF. Furthermore, in 
contrast to HFREF, myocardial stiffness may even be more important than extracellular 
fibrosis as a mechanism for diastolic stiffness in HFNEF.37 HFNEF patients with only mild 
elevations of collagen volume fraction may have highly elevated left ventricular end-
diastolic pressures.38 Unfortunately, no biomarkers have been identified yet in order to 
measure this myocardial stiffness.    
 
Biomarker levels in HFNEF
Most studies have applied a cross-sectional or case-control design (Table 3 and Supplemental 
table 2).30, 31, 39-43 Although some of the results were not consistent between studies, most 
of the studies showed that MMP-1, MMP-2, MMP-9, TIMP-1, PICP, PIIINP and CITP were 
elevated in HFNEF patients when compared to a control group consisting of patients 
without HF.30, 31, 39-43 Also MMP-3, MMP-7, TIMP-4 and Osteopontin concentrations might 
be elevated in HFNEF, but these biomarkers are less well investigated.30 Interestingly, lower 
serum concentrations of MMP-8 and MMP-13 were observed in patients with HFNEF.30, 
39 Furthermore, Gonzalez et al. observed that the MMP-1/TIMP-1 ratio was increased 
in HFNEF patients with normal left-sided filling pressures.43 These findings support the 
hypothesis that the balance of collagen turnover is disturbed in patients with HFNEF.
Biomarker levels in HFNEF compared with HFREF
Only two studies compared biomarker levels of HFNEF with HFREF patients. Frantz et al. 
reported similarly elevated TIMP-1 levels in hospitalized HFNEF and HFREF patients. Naito 
et al. found similarly elevated plasma concentration of MMP-2 in hospitalized HFNEF and 
HFREF patients. MMP-1 concentration, however, was significantly higher in HFREF patients. 
The observed difference in MMP-1 concentration supports the hypothesis that different 
profiles of extracellular-matrix biomarkers are expressed in HFREF and HFNEF.      
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Association with incidence of HFNEF
Barasch et al. performed a nested case-control study within the Cardiovascular Health 
study, which has longitudinal follow-up.44 Biomarkers were assessed at 5-year or 9-year 
follow-up in a total of 880 subjects (131 with systolic HF, 179 with HFNEF, 280 controls 
with cardiovascular risk factors and 279 healthy controls). In the total study population, 
elevated CITP (OR per tertile 3.1; 95% CI 2.4 to 4.0) and PIIINP (OR per tertile 2.2; 95% CI 
1.7 to 2.8) were associated with incident HFNEF during follow-up.
Association with HFNEF prognosis
Follow-up studies on the prognostic utility of biomarkers of extracellular matrix remodeling 
are also small in number. Within the Irbesartan in Heart Failure With Preserved Systolic 
Function (I-PRESERVE) trial, Krum et al. investigated the prognostic value of PINP, PICP 
and Osteopontin during follow-up of 4.1 years.45 In univariable analysis, increased levels 
of these biomarkers were all associated with the composite endpoint of mortality and 
hospitalization, all-cause mortality and the composite of HF related death or hospitalization. 
However, none of these biomarkers remained significant as an independent predictor 
when introduced into a multivariable model adjusting for 19 clinical parameters. These 
results are in line with above-mentioned findings suggesting that myocardial stiffness is a 
more important factor of diastolic dysfunction than fibrosis in patients with HFNEF.   
OTHER BIOMARKERS
Homocysteine
Homocysteine is traditionally believed to have pro-oxidative, pro-inflammatory and 
vasoconstrictive properties, and to cause endothelial vascular dysfunction. Experimental 
studies have demonstrated that elevated homocysteine levels may also adversely affect 
the myocardium, leading to pathological hypertrophy of ventricles with disproportionate 
increase in collagen.21 Okuyan et al. measured homocysteine concentrations in 68 
hospitalized HFNEF patients and 40 healthy controls (Table 4 and Supplemental table 3).21 
Homocysteine concentrations were significantly higher in HFNEF patients. The authors 
state that pathologic mechanisms and effects of homocysteine on the natural history of 
HF still need to be clarified.
Growth differentiation factor 15
Growth differentiation factor 15 (GDF-15) is suggested to be a downstream marker 
indicative of different pathways of myocardial stress and inflammation. In animal models, 
GDF-15 was found to attenuate reduction in fractional shortening and to protect the heart 
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from hypertrophy and ischemia-reperfusion injury.46 Stahrenberg et al. measured GDF-15 
in 142 HFNEF patients, 86 HFREF patients and 188 healthy elderly controls.46 They found 
that GDF-15 was higher in HFNEF compared to controls. Serum GDF-15 concentrations 
were equal in HFNEF and HFREF patients. The authors concluded that diagnostic precision 
of GDF-15 was at least as good as that of NT-proBNP, and that a combination significantly 
improved diagnostic accuracy. Similar results were reported by Santhanakrishnan et al.47 
Cystatin C
Renal function is also believed to play a role in the evolvement of HF.48, 49 Cystatin C is 
a marker of renal function. Moran et al examined 4453 subjects aged 65 years or older 
without HF at baseline from the Cardiovascular Health Study.48 They compared the 
association of cystatin C with risk of incident HFNEF and HFREF. 
During 8 years of follow-up, 167 cases of incident HFNEF and 206 cases of incident HFREF 
occurred. Increased risk of HFNEF was apparent only in the highest cystatin C quartile (HR 
2.25; 95% CI 1.33-3.80), while a linear trend was present for HFREF. This study demonstrates 
that kidney dysfunction is a risk factor for occurrence and progression of HF. Carrasco-
Sanchez et al. investigated the prognostic value of cystatin C in HFNEF.49 They included 
218 hospitalized HFNEF patients and collected 1-year follow-up. Cystatin C was a strong 
predictor of the composite of mortality or hospitalization (HR of highest compared to 
lowest quartile 4.85; 95% CI 2.76-8.51) and mortality alone (HR 11.35; 95% CI 4.01-32.14). 
Cystatin C also remained a strong independent predictor with multivariable analysis.  
Resistin
Another potentially interesting biomarker is resistin. Resistin has been found to be 
produced and released from adipose tissue. Although the exact function of resistin is not 
known, it has been associated with insulin resistance and inflammatory response.50 Resistin 
concentrations have previously been correlated with risk of coronary artery disease, renal 
dysfunction and adverse outcomes among stroke patients.50 Butler et al. measured resistin 
in 2902 subjects aged 70-79 years without prevalent HF from the health ABC study, where 
after these patients were followed-up for incident HF.50 Resistin was found to be associated 
with both incident HFNEF (HR per 10ng/mL 1.42; 95% CI 1.27-1.58) and incident HFREF (HR 
per 10ng/mL 1.35; 95% CI 1.20-1.53). The prognostic value of resistin in HFNEF patients 
has not been investigated yet. Another study showed that leptin, which is also a biomarker 
related to adiposity and metabolic syndrome, is associated with incidence of HF.51 A third 
biomarker in this category, adiponectin, was not found to be associated with HF.52 Overall, 
these findings are in line with the hypothesis that obesity and the metabolic syndrome 
drive development of HF. 
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Table 3. Biomarkers of extracellular matrix remodeling
 Index group 
(n)
Reference group 
(n)
Outcome MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-13 TIMP-1 TIMP-2 TIMP-3 TIMP-4 PINP PICP PIIINP CITP Osteopontin
Cross-sectional / case-control studies comparing HFNEF with a non-HF reference group
Ahmed et al. (35) outpatient 
HFNEF (26)
healthy 
without HT (39)
level ns ↑ ↓ ↑ ns
outpatient 
HFNEF (26)
healthy 
with HT (14)
level ns ↑ ↓ ↑ ns
outpatient 
HFNEF (26)
LVH 
without HF (23)
level ns ns ns ↑ ns
Martos et al. (36) outpatient 
HFNEF (32)
HT patients 
without HF (54)
level ns ↑ ↑ ns ns ↑ ↑ ↑
Frantz et al. (37) hospitalized 
HFNEF (102)
healthy (74) level ns ↑
Naito et al. (38) hospitalized 
HFNEF (42)
non-HF patients 
(10)
level ↑ ↑
Gonzales et al. (39) outpatient 
HFNEF (156)
healthy (20) level ↑ ↑ ↑
Zile et al. (26) outpatient 
HFNEF (61)
healthy (241) level ns ↑ ns ↑ ns ↑ ↑ ↑ ns ↑ ns ↑ ↑ ↑
outpatient 
HFNEF (61)
LVH 
without HF (144)
level ns ↑ ↑ ns ↓ ns ns ns ns ↑ ns ↑ ns ns
Collier et al. (27) outpatient 
HFNEF (181)
HT patients 
without HF (94)
level ↑ ↑ ns ns ns ↑ ↑
Cross-sectional / case-control studies comparing HFNEF with HFREF
Frantz et al. (37) hospitalized 
HFNEF (102)
hospitalized 
HFREF (147)
level ns
Naito et al. (38) hospitalized 
HFNEF (42)
hospitalized 
HFREF (68)
level ↓ ns
Follow-up studies
Barasch et al. (40) community-
based 
HFNEF 
(4y follow-up)
ns OR 2.2 OR 3.1
aged ≥65 (880) (1.7-2.8)* (2.4-4.0)*
Krum et al. (41) outpatient 
HFNEF 
mortality or 
hospitalization 
(4.1y follow-up)
HR 1.09 HR 2.47 HR 1.08
aged ≥60 (313) (1.05-1.13)† (0.97-6.33)† (1.03-1.15)‡
all-cause 
mortality 
(4.1y follow-up)
HR 1.06 HR 2.85 HR 1.06
(1.03-1.09)† (1.52-5.36)† (1.02-1.11)‡
HF death or 
hospitalization 
(4.1y follow-up)
HR 1.09 HR 5.91 HR 1.06
             (1.05-1.13)†  (2.94-11.88)†  (0.99-1.14)‡
;a significantly lower biomarker level in the index group compared to the reference group. CITP = carboxy-terminal telopeptide 
of collagen type I; HF = heart failure; HFNEF = heart failure with normal ejection fraction; HFREF = heart failure with reduced 
ejection fraction; HT = hypertension; LVF = left ventricular hypertrophy; MMP = matrix metalloproteinasis; ns = not significant; 
PICP = carboxy-terminal propeptide of procollagen type I; PIIINP = amino-terminal propeptide of procollagen type III; PINP = 
amino-terminal propeptide of procollagen type I; TIMP = tissue inhibitor of metalloproteinasis.
* Unadjusted odds ratio per tertile.
† Unadjusted hazard ratio per 10 μg/L.
‡ Unadjusted hazard ratio per 10 nmol/L.
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Table 4. Other biomarkers
 Index group 
(n)
Reference group 
(n)
Outcome
Adreno-
medullin
Nor-
adrenalin
Homo-
cysteine GDF-15 Cystatin C Resistin Galectin-3 sRAGE CA-125 Troponin-T ST2
Cross-sectional / case-control studies comparing HFNEF with a non-HF reference group
Yu et al. (15) hospitalized HFNEF (31) healthy (17) level ↑
Wisniacki et al. (19)  oupatient HFNEF (25) healthy (26) level ns
Varol et al. (49) outpatient HFNEF (32) healthy (30) level ns
Okuyan et al. (18) hospitalized HFNEF (68) healthy (40) level ↑
Stahrenberg et al. (42) community-based HFNEF (142) healthy (188) level ↑
Zile et al. (26) outpatient HFNEF (61) healthy (241) level ns
outpatient HFNEF (61) LVH without HF (144) level ns
Santhanakrishnan et al. (43) in- and outpatient HFNEF (50) healthy (50) level ↑ ↑ ↑
Cross-sectional / case-control studies comparing HFNEF with HFREF
Yu et al. (15) hospitalized HFNEF (31) hospitalized HFREF (46) level ns
Wisniacki et al. (19) outpatient HFNEF (25) outpatient HFREF (27) level ns
Stahrenberg et al. (42) community-based HFNEF (142) community-based HFREF (86) level ns
De Boer et al. (13) hospitalized HFNEF (114) hospitalized HFREF (368) level ns
Santhanakrishnan et al. (43) in- and outpatient HFREF (51) in- and outpatient HFREF (51) level ns ↓ ns
Follow-up studies
Moran et al. (44) community-based HFNEF 
(8y follow-up)
HR 2.25
aged ≥65 (4453) (1.33-3.80)*
Butler et al. (46) community-based HFNEF 
(9.4y follow-up)
HR 1.42
 aged 70-79 (2902) (1.27-1.58)†
De Boer et al. (13) hospitalized mortality or hospitalization 
(1.5y follow-up)
HR 1.97
 HF (592) (1.62-2.42)‡
Carrasco-Sanchez et al. (45) hospitalized mortality or hospitalization 
(1y follow-up)
HR 4.85
HFNEF (218) (2.76-8.51)§
all-cause mortality 
(1y follow-up)
HR 11.35
       (4.01-32.14)§     
↑ Indicates a significantly higher biomarker level in the index group compared to the reference group. ↓ Indicates a significantly 
lower biomarker level in the index group compared to the reference group. CA-125 = Carbohydrate antigen 125; GDF-15 = growth 
differentiation factor 15; HF = heart failure; HFNEF = heart failure with normal ejection fraction; HFREF = heart failure with 
reduced ejection fraction; LVF = left ventricular hypertrophy; ns = not significant; sRAGE = soluble receptor for advanced glycation 
end-product. 
* Hazard ratio of highest quartile compared to lowest quartile adjusted for age, gender and race.
† Unadjusted hazard ratio per 10ng/mL.
‡ Unadjusted hazard ratio per doubling.
§ Unadjusted hazard ratio of highest quartile compared to lowest quartile. 
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Galectin-3
Galectin-3 is a protein that has a broad biological functionality. It is known to be involved in 
cell adhesion, cell activation, chemo-attraction, cell growth, cell differentiation, fibroblast 
activation and apoptosis.15 Galectin-3 has been proposed as a novel biomarker of HF. It 
was found to be associated with increased risk for incident HF and mortality.15 De Boer et 
al. showed that galectin-3 levels did not differ between 114 hospitalized HFNEF patients 
and 368 HFPEF patients.15 In the overall HF study population, galectin-3 was found to be 
a significant predictor of the composite of mortality and hospitalization (HR per doubling 
1.97; 95% CI 1.62-2.42). The predictive value of galectin-3 was stronger in HFNEF compared 
to HFREF. Furthermore, combined galectin-3 and BNP levels increased prognostic value 
over either biomarker alone. 
Advanced glycation end-products
Advanced glycation end-products (AGEs) are formed through a reaction between proteins 
and sugar residues. AGEs and their soluble receptors (sRAGEs) are known to induce 
intracellular damage and to play a role in chronic inflammation.30 Enhanced accumulation 
of AGE is thought to play a role in the pathophysiology of chronic HF. Zile et al. measured 
sRAGE concentration in HFNEF patients and controls. They could not detect a significant 
sRAGE elevation in HFNEF.30
Carbohydrate antigen 125
Carbohydrate antigen 125 (CA-125) is traditionally known as a tumor marker for ovarian 
cancer. However, non-malignant serosal effusions may display elevated serum CA125 levels 
as well, most likely due to increased CA-125 production by the serosal mesothelium.53 
Previously, CA125 has been shown to be elevated in HF and to be related with HF severity.53 
Varol et al. measured CA-125 concentrations in 32 HFNEF outpatients with hypertrophic 
cardiomyopathy and in 30 healthy controls.53 Although the difference in CA-125 level 
between the groups was not significant, CA-125 levels increased with NYHA class and level 
of diastolic dysfunction.   
Troponin-T
Troponin-T is a well-established marker of myocardial necrosis in acute coronary syndromes, 
but its role in HF is less well defined.47 Santhanakrishnan et al. have evaluated several 
emerging biomarkers, including high sensitivity troponin-T.47 They found that troponin-T 
levels were higher in HF patients compared to healthy control subjects. Furthermore, 
troponin-T concentration was higher in HFREF than in HFNEF, even after adjusting for 
clinical covariates, which suggests that myocyte injury is higher in HFREF.  
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ST2
ST2 is a member of the interleukin-1 receptor family and is involved in the process of 
ventricular remodeling.47 ST2 may be upregulated in cardiac myocytes and fibroblasts 
subjected to mechanical stress. Santhanakrishnan et al. found that HFNEF patients had 
higher serum levels of ST2 compared to healthy control subjects.47 However, this difference 
did not remain statistically significant after adjustment for age, sex and clinical covariates. 
Furthermore, there was no difference in ST2 concentration between HFREF and HFNEF 
patients. Nevertheless, previous studies have demonstrated that ST2 was an independent 
predictor of mortality in patients with acute HF and that ST2 was equally predictive in 
patients with HFREF and HFNEF.54    
DISCUSSION
Although a significant body of research has been generated in the past decade on the 
role of biomarkers in HF, the majority of prognostic studies have included HFREF patients. 
Studies on the prognostic and incremental value of biomarkers, other than BNP and 
NT-proBNP, in HFNEF are scarce or lacking. Most of the studies on biomarkers in HFNEF 
patients are cross-sectional in design and have included limited numbers of patients. Only 
a few prospective studies have been conducted. To the best of our knowledge, this is the 
first review that specifically focuses on the role of biomarkers in HFNEF.
Biomarkers examined most extensively in HFNEF include biomarkers of myocyte stress, 
inflammation and extra-cellular matrix remodeling. Some of these biomarkers have been 
shown to be increased to a different extent in HFNEF and HFREF.19, 28, 42 In general, the degree 
of marker expression in the failing myocardium is likely to depend on the type, degree, and 
duration of the specific extracellular stimuli. As described above, inflammatory biomarkers 
may have different meanings in HFNEF and HFREF. Obesity and the metabolic syndrome, 
associated with increased concentration of several inflammatory and metabolic markers, 
may drive development of HF, particularly in HFNEF.24 On the other hand, inflammatory 
biomarkers may be a measure of severity of HF, particularly in HFREF.23 Furthermore, 
fibrosis and myocardial stiffness occur to a different extent and have a different nature 
in HFNEF versus HFREF.34 In HFNEF, myocyte stiffness may play a more important role 
than myocardial fibrosis.37 This may be reflected by differences in levels of biomarkers of 
extracellular-matrix remodeling between HFNEF and HFREF.   
Specifically, HFREF, typically characterized by volume overload, left ventricular dilatation, 
eccentric left ventricular remodeling and low relative wall thickness, can particularly be 
expected to display upregulation of biomarkers such as NT-proBNP (myocyte stress), GDF-15 
(stress pathway), TNF-α (stimulating MMP expression), several MMPs (proteolytic enzymes) 
and CITP (collagen degradation).28, 46 On the other hand, HFNEF, characterized more often 
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by a non-dilated left ventricle, concentric left ventricular hypertrophy and probably driven 
by metabolic syndrome, may particularly be associated with upregulation of biomarkers 
such as TIMPs (inhibiting collagen proteolysis), Galectin-3 (fibroblast activation), PINP, 
PIIINP (collagen biosynthesis), homocysteine (associated with hypertrophy) and resistin 
(adipose tissue and insulin resistance).15, 21, 50 In this review, we have observed that levels of 
several biomarkers of inflammation, including CRP, PTX-3, TNF-α, IL-6 and IL-10, are higher 
in HFREF compared to HFNEF, although some of these results were not consistent between 
studies. Together with previous data on MMP and TIMP levels in several animal models, 
these observations provide some support for the above-mentioned hypothesis regarding 
the differences between biomarker patterns in HFNEF and HFREF. 
Based on the present review, several biomarkers and biomarker categories, including 
biomarkers of myocyte stress, inflammation, extracellular matrix remodeling, GDF-15, 
cystatin C, resistin and galectin-3, appear to be potentially promising diagnostic tools in 
HFNEF. Some of them, including TNF-α, IL-6, PINP, PIIINP, osteopontin and cystatin C, may 
carry prognostic value as well. Further research may provide additional evidence for the 
value of these biomarkers in improvement of risk stratification of patients with HFNEF. 
Furthermore, the balance between various markers wintin the same category (e.g. MMP/
TIMP ratios and balance between inhibitory and stimulatory cytokines) may also have 
diagnostic and prognostic value, and should be further investigated as well. Applying a 
multiple-biomarker strategy may result in even further improvement of risk stratification 
compared to using one biomarker alone.15, 30 For example, a multiple-biomarker panel 
consisting of increased MMP-2, TIMP-4, PIIINP, and decreased MMP-8 was able to identify 
HFNEF patients with an area under the receiver operating characteristic curve of 0.79, 
which was better than any single biomarker, including NT-proBNP, or clinical covariates 
alone.30 Such results are promising and should be further investigated before such 
biomarkers can be used in clinical practice. 
Some of the studies we reviewed displayed inconsistent results. This may in part be 
explained by the lack of power to detect significant differences in biomarkers levels and 
clinical outcomes, as sample size was modest in many of the studies. Furthermore, various 
definitions of HFNEF were used by the individual studies, and the LVEF cutoff value ranged 
from ≥40% to ≥55%. Moreover, large variations were present in the choice of the reference 
groups. 
 
Future directions
Currently, natriuretic peptides are the only biomarkers routinely used for diagnosis and risk 
stratification in common clinical practice.1, 2 Before other known biomarkers may be used, 
their incremental diagnostic and prognostic value over established clinical covariates and 
imaging techniques, such as echocardiography, should be evaluated. Preferably, this should 
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be done in an epidemiological setting using a gold standard, including measures of cardiac 
structure and function in addition to clinical presentation, to demonstrate the diagnostic 
power of a specific biomarker. Moreover, as mentioned above, a multiple-biomarker 
panel may have higher diagnostic and prognostic value than any single biomarker alone. 
Therefore, large, prospective studies measuring multiple biomarkers are urgently needed 
in order to further elucidate the role and value of biomarkers in HF in general. With regard 
to the diagnostic and prognostic value of biomarkers in HFNEF in particular, evidence is 
much less abundant so far and studies have again mainly focused on natriuretic peptides. 
The other, most promising, biomarkers pertaining specifically to HFNEF at the moment 
include markers of collagen turnover and collagen signaling pathways.   
Meanwhile, it is likely that ongoing fundamental and epidemiologic research will also 
yield new classes of potentially useful HF biomarkers. Several, relatively novel research 
techniques, such as genomics and proteomics, are promising contributors to biomarker 
discovery. New biomarkers may contribute to further improvement of prognostication and 
may improve our understanding of the complex pathophysiology of HF as well. Moreover, 
by comparing biomarker patterns and their prognostic value between patients with 
reduced and normal LVEF, further etiologic insights into the development of HFNEF may 
be obtained. 
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ABSTRACT
Introduction: Several studies have examined the diagnostic value of blood biomarkers 
for acute allograft rejection (AR) after heart transplantation (HTx). However, most of 
them examined only one biomarker and results were generally inconsistent. The aim 
of our study was to investigate the diagnostic value of NT-proBNP, troponin T (TropT) 
and CRP levels for concomitant AR during the first year after HTx.
Methods: From 2005 to 2010, 77 consecutive HTx recipients were included. NT-
proBNP, TropT and CRP were measured at 16±4 (mean±SD) consecutive routine 
endomyocardial biopsy (EMB) surveillance visits during the first year of follow-up. 
AR was defined as ISHLT grade ≥ 2R at EMB. Data were analyzed using generalized 
estimating equations (GEE) and area under the receiver-operating characteristic (ROC) 
curves (AUCs).
Results: Median age of the patients at HTx was 49 years, and 68% were men. During the 
first year of follow up, 56 patients (73%) experienced at least one episode of AR. The 
temporal evolution of NT-proBNP, troponin T and CRP showed a steep decline in the 
first 3 months after HTx and a steady-state level thereafter. CRP level was associated 
with concomitant AR by means of a threshold effect (odds ratio(OR) and 95% CI, 
2.20(1.41-3.44), p=0.001, for the middle vs lowest, and 1.61(1.00-2.60), p=0.050, for 
the highest vs lowest tertile of CRP). Adding CRP to a model containing the clinical 
variables age, gender, diabetes, hypertension, and smoking (AUC= 0.64) resulted in 
higher discriminatory ability during the steady state period, although the difference 
was not statistically significant (AUC= 0.70, p=0.25). NT-proBNP and troponin T were 
not significantly associated with AR.  
Conclusions: CRP level carries limited diagnostic value for concomitant presence 
of AR in the first year after HTx. Discriminative ability of CRP is too poor to replace 
endomyocardial biopsy.  
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INTRODUCTION
Acute allograft rejection (AR) is one of the major causes of cardiac graft loss after heart 
transplantation (HTx).(1) While endomyocardial biopsy (EMB) is currently the gold standard 
for diagnosing allograft rejection in heart transplant recipients, this is an invasive procedure 
that carries potential complications.(2) Non-invasive detection of allograft rejection would 
decrease patient discomfort, lower risk of complications and decrease healthcare costs. 
Although earlier studies suggest a role for biomarkers in the noninvasive diagnosis of AR 
(3-8), the results of these studies are inconsistent.
NT-pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin T and C-reactive protein 
(CRP) are biomarkers which may be expected to be released during allograft rejection. These 
biomarkers reflect several pathophysiological mechanisms that may play a part in allograft 
rejection, and thus the information carried by these biomarkers is complementary.  NT-
proBNP represents systolic and diastolic dysfunction which is induced by allograft rejection 
to some degree, (9) troponin T reflects cardiac myocyte damage, which is the hallmark of 
moderate to severe allograft rejection,(10) and CRP represents the proinflammatory state 
which exists in allograft rejection (i.e., noninfectious myocarditis). 
Existing studies on the value of NT-proBNP, troponin T, or CRP for diagnosis of allograft 
rejection have provided inconsistent results, in part due to differences in methodology.
(3-8, 11-21) Of further note is that the methodology applied by these studies was not 
always appropriate. Transplant recipients generally undergo a large number of repeated 
endomyocardial biopsies according to a standard protocol. Most of the studies examined 
biomarker measurements performed concomitantly with these EMBs, and thus contained 
multiple biomarker measurements and biopsy specimens per patient. However, several 
studies either failed to describe how they accounted for dependence among repeated 
observations in individual patients, or failed to account for this dependence altogether. 
The main objective of this study was to examine the diagnostic value of NT-proBNP, 
troponin T, and CRP for concomitant allograft rejection in heart transplant recipients. We 
aimed to account for correlated data within individual patients in the analysis by using 
appropriate statistical methods.   
METHODS
Study population and baseline characteristics
We included a total of 77 consecutive patients, 18 years of age and older, which successfully 
underwent HTx at the Erasmus MC, Rotterdam, The Netherlands, between September 2005 
and December 2010.  Patients who did not survive the HTx procedure were not included 
in this cohort. From 2005 onwards, we performed routine measurements of NT-proBNP, 
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CRP and troponin T in the context of usual care in post-HTx patients, concomitant with the 
routine endomyocardial biopsy surveillance visits at our centre. For the current study, data 
on these 3 biomarkers were retrieved retrospectively from the medical records, and these 
data were complete in 95, 98 and 96 % of the patients for NT-proBNP, CRP and troponin 
T, respectively. Baseline characteristics were collected from the heart transplantation 
screening records and included diabetes (known history of diabetes or use of antidiabetic 
agents), hypertension (known history of hypertension), hypercholesterolemia (known 
history of hypercholesterolemia), body mass index (BMI) (kg/m2), smoking status (never 
smokers or former smokers (> 1 month)), and indication for transplantation (ischemic or 
non ischemic). Ischemic time and use of immunosuppressive medication were collected 
from the discharge letters and medical records.
This study was approved by the ethical committee of the Erasmus MC. According to Dutch 
law, informed consent was not required, since study specific actions were not implemented. 
All data were readily available in the (electronical and paper-based) medical records of the 
patients and were obtained during routine treatment. Subsequently, data were processed 
in an anonymized manner. 
Biomarker measurement
Concomitant with the endomyocardial biopsy, blood was drawn from the intravascular 
catheter, which was generally placed in the vena jugularis interna dextra.. Plasma NT–
pro-BNP was measured using an electrochemiluminesence assay (Roche Diagnostics, 
Elecsys 2005, Indianapolis, Indiana, USA). This system measures concentrations ranging 
0.6 to 4130 pmol/L. The assay had a total coefficient of variation that ranged between 
2.3 and 3.2%, depending on mean concentration. Cardiac troponin T was measured using 
an immunoassay (Roche Diagnostics, Elecsys 2010 immunoassay analyser, Indianapolis, 
Indiana, USA). This system measures concentrations ranging from 0.01 to 25 ng/mL, with 
a total precision <10 %. CRP was measured using an immunoturbidimetric assay (Roche 
Hitachi 912 chemistry analyzer, Basel, Switzerland). This system measures concentrations 
ranging from 0.3 to 350 mg/L, with a total precision <10 %. 
Follow-up
Patients underwent endomyocardial biopsies according to the standard biopsy protocol, 
which consists of weekly biopsies until week 6, and subsequent biopsies at week 8, 10, 
14, 18, 24, 30, 38, 46 and 52. Exceptions were possible based on individual situations. The 
revised International Society for Heart and Lung Transplantation (ISHLT) grading system 
was applied to classify the endomyocardial biopsies.(22) Allograft rejection was defined as 
the presence of an EMB with an ISHLT grade 2R or greater. 
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Table 1. Baseline characteristics of the 77 heart transplant recipients
Variable Mean±SD, median [IQR] or No. (%)
Age, years 49 [42-55]
Male gender 52 (68)
Diabetes 15 (20)
Hypertension 11 (14)
Hypercholesterolemia 13 (17)
Body Mass Index (kg/m2) 24±3.9
Smoking
       Never 58 (75)
      Former 19 (25)
Indication for transplantation
     Ischemic cardiomyopathy 31 (40)
     Non ischemic cardiomyopathy 46 (60)
Ischemic time, minutes 194±36
Medications
      Tacrolimus 74 (96)
     Prednisone 75 (97)
      Mycophenolate 67 (87)
     Cyclosporine 2 (3)
      Everolimus 4 (5)
 
Statistical analysis
Categorical variables are presented in percentages. We examined the distributions of 
continuous variables for normality by visual examination of the histogram and with the 
Kolmogorov-Smirnov test. Normally distributed continuous variables are presented as 
mean ± standard deviation (SD) while non-normally distributed continuous variables are 
presented as median and interquartile range (IQR). Distributions of NT-proBNP, troponin T 
and CRP were skewed and these variables were ln-tranformed for further analyses. 
Logistic regression was applied to examine whether baseline levels of NT-proBNP, troponin 
T or CRP are associated with the number of allograft rejections in the first year post-
HTx (i.e., remaining free of rejection versus occurrence of one or more rejections; and 
occurrence of zero or one versus two or more rejections). 
Subsequently, generalized estimation equations (GEE) were applied to investigate whether 
repeatedly measured NT-proBNP, troponin T or CRP are associated with concomitant 
allograft rejection in the first year post-HTx. GEE is a method meant for analyzing correlated 
longitudinal data,(23) and may be applied to modeling binary outcomes such as, in this 
case, allograft rejection. GEE consists of two parts, namely, the mean model and a working 
covariance model. The mean model characterizes the mean response and its dependence 
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on selected covariates.(24) The working covariance model describes the pattern of 
associations amongst the repeated measurements within each individual (‘correlation 
structure’).(24, 25) We used an autoregressive (AR) correlation structure for all three 
biomarkers. This correlation structure assumes decreasing correlation as the distance 
between two measurements increases,(24) and thus is appropriate for the current study 
design.(26) We used repeated biomarker measurements available up to one year post-
HTx. Biomarker concentrations were examined as ln-transformed continuous variables in 
order to evaluate linear trends, and as categorical variables (by dividing the variables into 
tertiles) in order to evaluate potential threshold effects. Age and gender were included as 
covariates in the GEE. 
We examined incremental discriminative value of adding NT-proBNP, troponin T or CRP to 
clinical characteristics by calculating area under the receiver operating characteristic curve 
(AUC). AUCs were compared by Medcalc(27).
SPSS statistics version 20.0 was used to perform the analyses. P-values <0.05 were 
considered statistically significant.
RESULTS
Descriptives
Baseline characteristics are summarized in Table 1. Median age was 49 years and 68% were 
men. A total of 1136 biopsies and concurrent blood samples were obtained at different time 
points from the 77 patients. The mean number of measurements was 16 ± 4 (mean±SD), 
and the mean follow-up time was 320 days. During the first year of follow up, 56 patients 
(73%) experienced at least one episode of allograft rejection. The total number of rejection 
episodes in the first year was 121. The numbers of rejection episodes are displayed in 
Figure 1. A total of 21 patients remained free of allograft rejection in the first year post 
HTx. Most patients (n= 23) experienced 1 rejection episode. Fewer patients experienced 2 
or more rejection episodes (figure 1). The number of patients who experienced a rejection 
episode for each week number is displayed in figure 2. Most allograft rejections occurred 
in the first 6 months post-HTx, with a peak in week 3 (16 allograft rejections). 
Baseline biomarker levels and number of allograft rejections during first year 
post-HTx
The associations of NT-proBNP, troponin T and CRP with the number of AR episodes are 
displayed in tables 2a and 2b. No associations were found between any of the three 
biomarkers and occurrence of one or more AR episodes during the first year post HTx 
(table 2a). Similar results were found for patients with zero or one AR episode versus 
patients who experienced two or more AR episodes (table 2b).
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Figure 1. The number of rejection episodes during the first year post-HTx. 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 
Fr
e
q
u
e
n
cy
 
Week number 
Figure 2. Number of patients who experienced a rejection episode for each week number during the 
first year post-HTx. 
Temporal evolution of the biomarkers
The temporal evolutions of NT-proBNP, troponin T and CRP, showed a steep decline in 
approximately the first 3 months after HTx and a steady-state level thereafter (figure 3 a, 
b and c). The biomarker values over time in patients who experienced a rejection episode 
during a particular visit did not show clear differences compared to patients who did not 
experience a rejection episode during that same visit (figure 4 a, b, c, d, e, and f). 
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Table 2 a. Association of baseline (post-HTx) NT-proBNP, troponin T, and CRP levels with the 
occurrence of acute allograft rejection episodes during the first year post-HTx.
Any acute AR  
(vs no acute AR) Unadjusted model Multivariable model*
Odds ratio (95%CI) P Odds ratio (95%CI) P
NT-proBNP# 0.93 (0.84-1.03) 0.17 0.93 (0.84-1.03) 0.18
Troponin T# 0.95 (0.84-1.08) 0.42 0.94 (0.83-1.07) 0.39
CRP# 0.98 (0.89-1.08) 0.68 0.98 (0.89-1.08) 0.75
*adjusted for age and gender; # Ln transformed; AR=allograft rejection
Table 2 b. Association of baseline (post-HTx) NT-proBNP, troponin T, and CRP levels with the 
occurrence of  two or more acute allograft rejection episodes during the first year post-HTx.
Two or more acute ARs
(vs zero or one acute AR) Unadjusted model Multivariable model*
Odds ratio (95%CI) P Odds ratio (95%CI) P
NT-proBNP# 0.90 (0.81-1.02) 0.093 0.90 (0.80- 1.00) 0.047
Troponin T# 0.91 (0.79-1.05) 0.20 0.92 (0.80-1.07) 0.28
CRP# 0.99 (0.89-1.12) 0.94 0.99 (0.89-1.11) 0.88
*adjusted for age and gender; # Ln transformed; AR=allograft rejection 
Diagnostic value of biomarkers for concomitant allograft rejection
Given the observed steep decline of the three biomarkers in the first three months post-
HTx, we corrected all GEE analyses for the time-period in which the biomarkers were 
determined. After visual examination of figures 3 and 4, we chose 3 months post-HTx 
as the boundary between the period of ‘steep decline’ and the period of ‘steady state’. 
The multivariable analyses were additionally adjusted for age and gender. The results are 
shown in table 3. NT-proBNP and troponin T were not associated with allograft rejection: 
p for linear association (ln transformed, continuous biomarkers) was not significant for 
these biomarkers, and analysis of biomarker tertiles did not display statistically significant 
threshold effects. For CRP, higher levels were associated with AR, with a threshold effect 
for CRP values higher than tertile 1 (i.e., 1 mg/L). The age- and sex adjusted ORs and 95% 
CIs  for the presence of allograft rejection were 2.20 (1.41-3.44), p=0.001, for the middle vs 
the lowest tertile of CRP, and 1.61 (1.00-2.60), p=0.050, for the highest vs the lowest tertile 
of CRP. Again, p for linear association was not significant. The OR for the ‘steady state’ time 
period was smaller than 1 in all biomarker models, indicating that the odds of having an 
AR episode after 3 months post-HTx is smaller than the odds of having an AR episode in 
the first 3 months post-HTx. This was in line with our descriptives (figure 2). No interaction 
was present between any of the biomarkers and time period, indicating that associations 
Blood biomarkers for diagnosis of acute allograft rejection  | Chapter 7.1
203
7.1
between the biomarkers and AR was similar in months 0-3 and months 4-12 post-HTx, 
in spite of the steep decline in levels (age- and sex adjusted ORs (95%CIs) of interaction 
term ‘time period’*‘ln (biomarker)’were 0.79 (0.51-1.22), p=0.47, 0.91 (0.70-1.18), p=0.46, 
and 1.11 (0.85-1.45), p=0.44, for NT-proBNP, troponin T and CRP, respectively). When we 
repeated the analysis using data from the steady state period (4-12 months) only, results 
did not change materially (data not shown).    
Table 3. Odds ratios for allograft rejection during week 0-53 post HTx
Variable
OR (95% CI)
Period** adjusted P-value
OR (95% CI)
Period-, age- and sex 
adjusted P-value
NT-proBNP 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.99 (0.59-1.66) 0.96 0.99 (0.59-1.67) 0.97
Tertile 3 0.93 (0.51-1.70) 0.82 0.94 (0.51-1.72) 0.83
NT-proBNP# 1.15 (0.92-1.42) 0.22 1.15 (0.93-1.43) 0.21
Steady state period 0.53 (0.33-0.84) 0.007 0.53 (0.33-0.84) 0.008
Troponin T 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 0.61 (0.37-1.01) 0.055 0.61 (0.37-1.00) 0.051
Tertile 3 0.74 (0.45-1.21) 0.23 0.74 (0.45-1.22) 0.24
Troponin T# 0.99 (0.86-1.13) 0.86 0.99 (0.86-1.14) 0.90
Steady state period 0.53 (0.33-0.84) 0.007 0.53 (0.33-0.84) 0.008
CRP 
Tertile 1 1 (reference) 1 (reference)
Tertile 2 2.18 (1.39-3.42) 0.001 2.20 (1.41-3.44) 0.001
Tertile 3 1.60 (0.99-2.58) 0.057 1.61 (1.00-2.60) 0.050
CRP# 1.09 (0.97-1.23) 0.14 1.10 (0.98-1.23) 0.12
Steady state period 0.53 (0.33-0.84) 0.007 0.53 (0.33-0.84) 0.008
OR (95% CI)= odds ratio, 95% confidence interval; **Period= steady state (4-12 months) versus steep decline (0-3 
months); # Ln transformed
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Figure 3 a, b and c. Absolute values of NT-proBNP, troponin T and CRP, for each week number, during 
the first year post-HTx. 
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Univariable ORs for the available clinical characteristics in relation to allograft rejection are 
displayed in table 4. None of the clinical characteristics we had registered was associated 
with allograft rejection occurring over the entire follow-up period, i.e. month 0-12 post 
HTx. Conversely, in the steady state period of 4-12 months follow-up, ORs for diabetes 
(3.25 (95%CI 0.87-12.08)) and hypertension (2.84 (95%CI 0.59-13.62)) showed to be 
higher, although not statistically significant. The combination of the clinical characteristics 
age, gender, diabetes, hypertension, and smoking displayed the highest discriminatory 
value, with an AUC of 0.61 over the total follow-up period. Adding CRP to these clinical 
characteristics resulted in slightly higher discriminatory ability, although the difference 
was not statistically significant (AUC = 0.63, p = 0.64) (figure 5). Adding NT-proBNP and 
troponin T to the clinical characteristics did not provide any incremental value to the 
clinical characteristics. For the steady state period of 4-12 months of follow-up, the AUC 
for this combination of clinical characteristics was 0.64. Adding CRP resulted in somewhat 
higher discriminatory ability, although again the difference was not statistically significant 
(AUC = 0.70, p = 0.25) (figure 5). Again, adding NT-proBNP and troponin T to the clinical 
characteristics did not provide any incremental value.      
Table 4. Univariable associations of clinical characteristics with presence of AR
Variable
OR (95% CI)
(0-12 months follow-up) P-value
OR (95% CI)
(4-12 months follow-up) P-value
Age 0.99 (0.97-1.02) 0.58 1.01 (0.97-1.05) 0.55
Gender 0.86 (0.54-1.36) 0.52 0.73 (0.34-1.59) 0.43
Diabetes 0.66 (0.36-1.21) 0.18 3.25 (0.87-12.08) 0.079
Hypertension 0.66 (0.30-1.47) 0.31 2.84 (0.59-13.62) 0.19
Hypercholesterolemia 0.57 (0.28-1.18) 0.13 0.74 (0.27-1.99) 0.55
Smoking 1.28 (0.85-1.94) 0.23 0.65 (0.31-1.37) 0.26
OR (95% CI)= odds ratio, 95% confidence interval 
DISCUSSION
In this study we investigated the diagnostic potential of NT-proBNP, troponin T and CRP to 
detect acute allograft rejection in the first year post-HTx in 77 heart transplant recipients. 
We found that biomarker concentrations were elevated directly after HTx, decreased 
during the first three months after HTx, and stabilized thereafter. No associations were 
found between baseline biomarker levels and number of acute allograft rejection in the 
first year post-HTx. When examining repeated biomarker measurements, we found an 
association of CRP level higher than tertile one (i.e., 1 mg/L) and occurrence of concomitant 
acute allograft rejection. However, discriminative ability of CRP was too weak to replace 
endomyocardial biopsy. 
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Figure 4 a, b, c, d, e, and f. Absolute values of NT-proBNP, troponin T and CRP, for each week number, 
in patients with (a, b, and c) and without (d, e, and f) AR, during the first year post-HTx. 
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Figure 4 a, b, c, d, e, and f. Continued.
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Figure 5. Receiver operating characteristic curve displaying additional discriminatory ability of CRP 
for AR during time-period 0-12 months and time period 4-12 months
Repeatedly measured NT-proBNP and troponin T did not show any significant 
associations with concomitant acute rejection. CRP is produced by hepatocytes under 
the influence of cytokines, including IL-6, and is one of the most sensitive markers of 
systemic inflammation.(28) Prior studies in renal transplant patients have shown that 
immunosuppressive therapy with cyclosporine and prednisolone results in suppression of 
CRP response.(29, 30) Nevertheless, changes in CRP levels over time have been found to 
correlate with acute rejection in those patients.(30) In contrast, in HTx recipients there is 
no established consensus about the correlation between CRP levels and acute rejection as 
diagnosed by EMB.(5, 6, 20) Deng et al.(31) investigated the potential role of monitoring 
the immunological status in HTx recipients to differentiate between acute rejection and 
infection in the presence of graft dysfunction. Acute rejection was generally associated 
with under-immunosuppression, but not with CRP levels, whereas infection was associated 
with over-immunosuppression and elevated levels of inflammatory markers, including 
CRP. A recent study of Heikel et al.(32) found the same results and suggested monitoring 
of immune function may have a potential role for individualization of immunosuppressive 
therapy and a minimization of unnecessary EMBs. In contrast, Martinez-Dolz et al.(5) 
found a significant correlation between CRP and acute rejection. However, despite a high 
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specificity of CRP levels below 0.87 mg/dL, the sensitivity was poor. In line with this, we 
found a tendency towards an association of elevated levels of CRP with concomitant acute 
rejection during the first year after HTx, in spite of the fact that part of the patients were 
on immunosuppressive therapy at the time of blood sampling and EMB. However, with an 
AUC of 0.70 in the steady state period of follow-up, discriminative value of CRP was poor.
We did not find an association between NT-proBNP levels and acute rejection. Previous 
studies on the diagnostic value of natriuretic peptides for allograft rejection have 
rendered inconsistent results (12, 15, 21, 33). Moreover, in many of the studies that did 
find positive associations, the specificity of BNP for acute rejection was inadequate to 
replace endomyocardial biopsy.(15, 21) These inconsistent results may in part be due to 
the fact that a large number of parameters are associated with elevated BNP levels. BNP 
is secreted by the heart in response to myocardial stretch(33) to protect the organism 
against pressure and volume overloads, and is generally increased during heart failure.
(13),(34) A substantial decline of NT-proBNP in the initial months after HTx has been found 
in previous studies, (11, 12) however, several studies have shown that these levels do not 
normalize even years after HTx.(33, 34) These observations suggest that BNP should not be 
considered solely as a haemodynamic marker, and have generated much discussion about 
the mechanisms of NT-proBNP release in the transplanted heart. A potential explanation 
is  that BNP may respond to immunological and/or inflammatory stimuli, which may 
induce increased circulating BNP concentrations secreted by cardiomocytes or other 
cell types infiltrating the heart.(33, 35) Torre-Amione et al.(36) examined human cardiac 
allografts, in the absence of histopathological or clinical evidence of rejection and with 
normal LV systolic function, and found an overexpression of TNF-α. A persistently elevated 
TNF-α level may stimulate BNP mRNA and BNP secretion, as demonstrated in neonatal 
rat ventricular cardiocytes.(37) During acute rejection, exacerbation of inflammatory 
processes, and in particular elevated IL-1β or TNF-α levels, may lead to increased secretion 
as well as expression of BNP.(38) Furthermore, a decreased renal clearance in the presence 
of ventricular hypertrophy, systemic or pulmonary hypertension or systolic dysfunction 
is also associated with increased BNP levels.(13, 33) Altogether, a large spectrum of 
parameters may influence natriuretic peptide levels, and this might have obscured a 
potential association of BNP with acute rejection to a certain extent in the current study. 
Troponin T and I are cardiospecific myofibrillar proteins, which are released during myocyte 
damage.(39) Several studies have found a continued release of troponin T over the first 
three months post HTx,(40, 41) although, the pathofysiology of this release is still not fully 
elucidated. Troponin T is not solely a cardiac marker since elevated levels are also found 
in patients with acute pulmonary embolism, sepsis, and end-stage renal disease.(42) In a 
previous study, Mullen et al.(18) investigated the association of both troponin T and I  with 
acute rejection, but concluded that these markers are not useful as indicators of rejection. 
Chapter 7.1 | Blood biomarkers for diagnosis of acute allograft rejection 
210
Similarly, in the current study, we were not able to demonstrate a significant association 
between troponin T and acute rejection. Since the troponin T assay that was available at 
the time of this study was not as sensitive as the currently available high sensitive (hs)-
troponin T assays, minor myocyte damage may have remained undetected. This may in 
part explain the lack of an association. 
Strengths of the present study include the availability and use of a large number of 
biopsies and the consecutive repeated measurement of 3 biomarkers, which represent 
various pathophysiological pathways underlying allograft rejection. Furthermore, 
we have applied appropriate statistical methods, that take into account correlated 
biomarker measurements within each individual, to examine the diagnostic value of 
repeated biomarker measurements for concomitant allograft rejection. Limitations of 
the current study include its retrospective nature. Nevertheless, all data required could 
be collected from the medical records, given that this patient population is under strict 
clinical surveillance. Furthermore, troponin T was measured using an assay which is not as 
sensitive as the currently available hs-troponin T assays.    
In conclusion, we found a positive association between CRP level and concomitant acute 
allograft rejection. However, discriminative ability of CRP was poor and thus unable to 
replace EMB. NT-proBNP and troponin T did not show significant associations with acute 
rejection in the current study. 
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ABSTRACT
Introduction: Studies on the prognostic value of serial biomarker assays for future 
occurrence of allograft rejection (AR) are scarce. We examined whether repeated 
measurements of NT-pro-B-type natriuretic peptide (NT-proBNP), troponin T (TropT) 
and C-reactive protein (CRP) predict AR. 
Methods: In 2005-2010, 77 consecutive HTx recipients were included. NT-proBNP, 
TropT and CRP were measured at 16±4 (mean±SD) consecutive routine endomyocardial 
biopsy (EMB) surveillance visits during the first year of follow-up. AR was defined 
as ISHLT grade ≥2R at EMB. Joint modeling (JM) was used to assess the association 
between repeated biomarker measurements and occurrence of future AR. JM accounts 
for dependence among repeated observations in individual patients. 
Results: The mean age of the patients at HTx was 49±9.2 years, and 68% were men. 
During the first year of follow-up, 1136 biopsies and concurrent blood samples were 
obtained, and 56 patients (73%) experienced at least one episode of AR. All biomarkers 
were elevated directly after HTx and achieved steady-state after ~12 weeks, both in 
patients with or without AR. No associations were present between the repeated 
measurements of NT-proBNP, TropT or CRP and AR both early (weeks 0-12) and late 
(weeks 13-52) in the course after HTx  (hazard ratios for weeks 13-52: 0.96 (95% CI 0.55-
1.68), 0.67 (0.27-1.69), and 1.44 (0.90-2.30), respectively, per ln(unit)). Combining the 
3 biomarkers in one model also rendered null results.
Conclusions: The temporal evolution of NT-proBNP, TropT and CRP prior to AR did 
not predict occurrence of acute AR both in the early and late course of the first year 
post-HTx. 
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INTRODUCTION
Acute allograft rejection (AR) is a common problem after heart transplantation (HTx) and 
is one of the major causes of cardiac graft loss.(1) The gold standard for diagnosing AR in 
heart transplant recipients is endomyocardial biopsy (EMB). This is an invasive procedure 
that carries potential complications and merely confirms the presence of AR.(2) As a result, 
treatment can only start at the moment that rejection is already ongoing. Prognostic 
tools that enable risk stratification of cardiac allograft recipients in an earlier phase could 
potentially facilitate earlier use of therapeutic measures. Unfortunately, such tools are 
currently not available. 
Blood markers of cardiac stress and malfunction may aid in early, noninvasive detection 
of AR, and thus are potential candidates for prognostication of cardiac allograft recipients. 
NT-pro-B-type natriuretic peptide (NT-proBNP) is expected to increase during AR, since 
it is produced in response to increased ventricular pressure, and AR is known to induce 
some degree of systolic and diastolic dysfunction.(3) Cardiac troponin T is a cardiospecific 
myofibrillar protein, which is detectable in the plasma after any cardiac myocyte damage. 
Since myocyte damage is the hallmark of moderate to severe AR, troponin T might also 
be expected to be released during significant AR.(4) Furthermore, a proinflammatory 
state exists in AR (i.e. noninfectious myocarditis) that could be assessed by determining 
plasma levels of inflammatory markers. C-reactive protein (CRP) is an acute phase protein 
produced predominantly by hepatocytes, that rises quickly during inflammation.(5, 6) 
Previous studies on biomarkers in relation to AR have mostly focused on their diagnostic 
value and have examined measurements concurrent to the EMB, which already displayed 
AR. These studies have provided inconsistent results for all 3 biomarkers, in part due to 
differences in methodology. Fewer studies have examined the prognostic value of the 
biomarkers. Positive(7, 8),  as well as negative(9) associations were found between (NT-
pro)BNP and future AR. Studies on CRP and future AR also showed contradicting results.
(9, 10)  All of these studies have examined the value of baseline biomarker measurements 
or the change between two measurements. Since biomarker levels change continuously, 
such approaches do not fully capture the prognostic value of a large number of repeated 
biomarker measurements.   
The main objective of this study was to examine the natural history of NT-proBNP, Troponin 
T, and CRP after HTx and to investigate the prognostic value of repeated measurements of 
these biomarkers for the occurrence of allograft rejection in heart transplant recipients. 
We hypothesized that joint modeling (JM) could potentially better capture prognostic 
information carried by these biomarkers than simpler statistical models used until now. 
JM uses the total number of repeated measurements performed before allograft rejection 
occurs, and accounts for dependence among repeated observations in individual patients.
(11)
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MATERIALS AND METHODS
Study population and baseline characteristics
We included a total of 77 consecutive patients, 18 years of age and older, which successfully 
underwent HTx at the Erasmus MC, Rotterdam, The Netherlands, between September 2005 
and December 2010.  Patients who did not survive the procedure were not included in this 
cohort. From 2005 onwards, we performed routine measurements of NT-proBNP, CRP and 
troponin T in the context of usual care in post-HTx patients concomitant with the routine 
EMB surveillance visits at our centre. For the current study, data on these 3 biomarkers were 
retrieved retrospectively from the medical records. Baseline characteristics were collected 
from the heart transplantation screening records and included diabetes (known history 
of diabetes or use of antidiabetic agents), hypertension (known history of hypertension), 
hypercholesterolemia (known history of hypercholesterolemia), body mass index (BMI) 
(kg/m2), and indication for transplantation (ischemic or non ischemic). Ischemic time 
and use of immunosuppressive medication were collected from the discharge letters and 
medical records.
This retrospective study on anonymized data was approved by the ethical committee of 
the Erasmus MC and does not require informed consent according to Dutch laws (‘WMO’). 
No additional actions involving the study participants were undertaken because of this 
retrospective study.
Biomarker measurement
Concomitant with the EMB, blood was drawn from the intravascular catheter, which was 
generally placed in the vena jugularis interna dextra. Plasma NT–pro-BNP was measured 
using an electrochemiluminesence assay (Roche Diagnostics, Elecsys 2005, Indianapolis, 
Indiana, USA). This system measures concentrations ranging from 0.6 to 4130 pmol/L. The 
assay had a total coefficient of variation that ranged between 2.3 and 3.2%, depending 
on mean concentration. Cardiac Troponin T was measured using an immunoassay (Roche 
Diagnostics, Elecsys 2010 immunoassay analyser, Indianapolis, Indiana, USA). This system 
measures concentrations ranging from 0.01 to 25 ng/mL, with a total precision <10 %. CRP 
was measured using an immunoturbidimetric assay (Roche Hitachi 912 chemistry analyzer, 
Basel, Switzerland). This system measures concentrations ranging from 0.3 to 350 mg/L, 
with a total precision <10 %. 
Follow-up
Patients underwent endomyocardial biopsies according to the standard biopsy protocol, 
which consists of weekly biopsies until week 6 and subsequent biopsies at week 8, 
10, 14, 18, 24, 30, 38, 46 and 52. The revised International Society for Heart and Lung 
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Transplantation (ISHLT) grading system was applied to classify the endomyocardial biopsies.
(6) AR was defined as the presence of an EMB with an ISHLT grade 2R or greater. Patients 
that experienced allograft rejection before a second blood sample could be collected (n=9) 
were excluded from further analyses, since they had no repeated biomarker measurements 
available.
 
Statistical analysis
JM is a modeling framework which combines mixed models (in our case for serial biomarker 
measurements) with Cox proportional hazards models (in our case for the risk of AR), 
and is used to produce valid measures of associations between the two outcomes while 
accounting for dependence among repeated observations in an individual patient.(11) By 
combining mixed models with Cox models, follow-up time until occurrence of the event of 
interest (AR) or until censoring is taken into account, and thus a hazard ratio is computed 
that represents the association between each of the (repeatedly measured) biomarkers 
and the outcome of interest. Fields of medical research that have previously applied this 
method include Human Immunodeficiency Virus research (repeated CD4 cell counts) and 
prostate cancer studies (repeated prostate specific antigen measurements).(12, 13) 
We examined the associations of each of the 3 biomarkers with first AR. While constructing 
the mixed models, we first tested whether the residuals were normally distributed with 
a constant variance, and when deemed necessary, we applied transformations of the 
biomarkers (e.g., taking natural logarithms). We also tested whether quadratic terms 
improved the mixed models by using Akaike’s Information Criterion (AIC) and selected the 
models with the lowest AIC for further use. We used all repeated biomarker measurements 
available up to the occurrence of AR. Subsequently, we combined the mixed models with 
Cox proportional hazards models (‘JM’). Herewith, we obtained hazard ratios for the 
associations of the repeated biomarker measurements with AR. We adjusted the models 
for age and sex. Adjustment for additional confounders was not possible due to the small 
number of events.
JM only allows for one determinant in the model to be repeatedly measured. In order 
to assess the prognostic value of all 3 repeatedly measured biomarkers simultaneously, 
we standardized the biomarkers and combined them into one variable, which was 
subsequently used as the determinant in the JM. 
For standardization, clinical upper reference limits of the biomarker assays were used (14 
pg/mL, 0.02 ng/mL and 9 mg/L for NT-proBNP, Troponin T and CRP, respectively). Each 
biomarker was expressed as a multiple of the doubling relative to its upper reference value 
(for example, for NT-proBNP, a level of 14 pg/mL was coded as 1, a level of 28 pg/mL was 
coded as 2,  a level of 56 pg/mL was coded as 3, etc.). Thus, the right-skewed distribution 
of the biomarkers was accounted for. The 3 re-coded biomarkers were subsequently 
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combined in 2 ways. First, to investigate the presence of an additive effect, they were added 
up. Second, to investigate the presence of a multiplicative effect, they were multiplied.  
R version 2.15.1 was used to perform the analysis, using packages JM (14) and survival.
RESULTS
Baseline characteristics are summarized in Table 1. The mean age of the study population 
was 49 years, and of those 68% were men. A total of 1136 biopsies and concurrent blood 
samples were obtained at different time points from the 77 patients. The average number 
of measurements was 16 ± 4 (mean±SD), during a mean follow-up time of 320 days. 
During the first year of follow up, 56 patients (73%) experienced at least one episode of 
AR. Mean follow-up time until the first episode of AR was 48 days. Figure 1 shows the 
number of patients, per number of AR episodes experienced, during the first year post-
HTx. Furthermore, a total of 5 (6%) patients died during the first year post-HTx and the 
date of death was used for censoring patients when examining allograft rejection as the 
endpoint.
Table 1. Baseline characteristics of the 77 heart transplant recipients
Variable Mean±SD, or No. (%)
Age, years 49±9.2
Male gender 52 (68)
Diabetes 15 (20)
Hypertension 11 (14)
Hypercholesterolemia 13 (17)
Body Mass Index (kg/m2) 24±3.9
Indication for transplantation
     Ischemic cardiomyopathy 31 (40)
     Non ischemic cardiomyopathy 46 (60)
Ischemic time, minutes 194±36
Immunosuppressive regime
      Tacrolimus 74 (96)
     Prednisone 75 (97)
      Mycophenolate 67 (87)
     Cyclosporine 2 (3)
      Everolimus 4 (5)
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Temporal evolution of the biomarkers
At the time of the first routine EMB surveillance visit (week 1), median NT-proBNP, 
Troponin T and CRP was 1081 [507-2702] pg/mL, 0.9 [0.6-1.2] ng/mL, and 14 [8-31] mg/L, 
respectively. The temporal evolution of all three biomarkers, as evaluated by mixed models, 
showed a steep decline in approximately the first 12 weeks after HTx and a steady-state 
level thereafter (figure 2 panel a,b and c). For this reason, we divided the total follow-up 
duration into two time-windows, namely 0-12 weeks and 13-52 weeks, for the remaining 
analyses.
Figure 1. The number of allograft rejection episodes experienced in the first year post-HTx.
Allograft rejection
The results of the analyses for the individual biomarkers for weeks 0-12 are shown in Table 
2. Of note is that JM only takes into account the first AR that occurs during the time window 
of interest (in this case, 0-12 weeks) even if a patient experienced additional AR episodes 
later in time.During weeks 0-12, 47 (61% of 77 patients) ‘first’ AR episodes occurred. Not 
all patients who experienced AR could be taken into account in the JM analyses, since some 
patients had only one biomarker measurement available. These patients experienced 
an early AR episode before a second blood sample could be collected during follow up 
(n= 9 for NT-proBNP, Troponin T, and CRP), or had missing values due to miscellaneous 
reasons resulting in only one available biomarker measurement (n= 5, 5, and 1 for NT-
proBNP, Troponin T, and CRP, respectively). Consequently, of the 77 HTx patients, the total 
numbers of patients available for the JM analyses were 63 (82%), 63 (82%), and 67 (87%) 
for NT-proBNP, Troponin T, and CRP, respectively. Age and sex adjusted hazard ratios for 
developing AR obtained with JM were 1.30 (95% CI 0.91-1.86), 1.03 (0.65-1.63), and 1.25 
(0.91-1.70) per ln(unit)), for NT-proBNP, Troponin T and CRP, respectively. 
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Panel B 
 
Panel C
 
 
Figure 2. Temporal evolution of NT-proBNP, Troponin T, and CRP levels in patients without and with 
rejection during the first year after HTx.
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Table 2. Hazard ratios for allograft rejection during weeks 0-12 and weeks 13-52 post-HTx
Hazard ratio (95% confidence interval)
Variable Week 0-12 post-HTx Week 13-52 post-HTx
NT-proBNP* 1.30 (0.91-1.86) 0.96 (0.55-1.68)
Age 0.98 (0.95-1.01) 1.00 (0.95-1.05)
Gender 0.77 (0.41-1.45) 1.17 (0.48-2.83)
Troponin T* 1.03 (0.65-1.63) 0.67 (0.27-1.69)
Age 0.98 (0.95-1.01) 1.00 (0.96-1.05)
Gender 0.72 (0.38-1.35) 1.16 (0.48-2.81)
CRP* 1.25 (0.91-1.70) 1.44 (0.90-2.30)
 Age 0.98 (0.95-1.01) 0.98 (0.93-1.03)
Gender 0.67 (0.37-1.23) 1.22 (0.50-2.96)
* Ln transformed
The results of the analyses for the individual biomarkers for weeks 13-52 are also shown in 
Table 2. During this time-period, 27 (35% of 77) “first” AR episodes occurred. Some of these 
“first” AR (n=19) were in fact recurrent ARs in persons that had already experienced AR in 
weeks 0-12. The total number of available patients for the JM analyses in this time-window 
was 63 (82%), 63 (82%), and 65 (84%) for NT-proBNP, Troponin T, and CRP, respectively, as 
a result of the reasons described above. Hazard ratios for developing AR obtained with JM 
were 0.96 (95% CI 0.55-1.68), 0.67 (0.27-1.69), and 1.44 (0.90-2.96) per ln(unit)), for NT-
proBNP, Troponin T, and CRP, respectively.  
The results of the analyses that simultaneously incorporated NT-proBNP, Troponin T, and 
CRP are displayed in Table 3. For weeks 0-12, neither an additive effect nor a multiplicative 
effect of the 3 biomarkers could be demonstrated. The same was true for weeks 13-52; all 
hazard ratios were close to unity.
Table 3. Hazard ratios for allograft rejection during weeks 0-12 and weeks 13-52 post-HTx for NT-
proBNP, troponin T and CRP combined.
Hazard ratio (95% confidence interval)
Variable Week 0-12 post-HTx Week 13-52 post-HTx
NT-proBNP, troponin T and CRP combined by 
summation
0.95 (0.84-1.07) 0.93 (0.64-1.33)
Age 0.98 (0.95-1.01) 1.01 (0.97-1.06)
Gender 0.66 (0.36-1.21) 1.01 (0.44-2.34)
NT-proBNP, troponin T and CRP combined by 
multiplication* 
0.79 (0.53-1.18) 1.02 (0.97-1.07)
Age 0.98 (0.36-1.20) 1.00 (0.43-2.30)
Gender 0.65 (0.36-1.20) 0.60 (0.15-2.39)
* Ln transformed
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DISCUSSION
In this study of 77 HTx recipients, we found that high postoperative NT-proBNP, Troponin 
T and CRP values decline progressively, reaching a steady state after approximately 12 
weeks post-HTx. We did not find any association between the temporal evolutions of 
the biomarkers, i.e. repeated measurements of these biomarkers, taken before AR was 
present, and occurrence of clinically significant AR (ISHLT ≥ 2). Such associations were 
absent both in weeks 0-12 post-HTx and in weeks 13-52 post-HTx. 
A substantial decline of NT-proBNP in the initial months after HTx has also been found 
in previous studies. (9, 15, 16) Some studies have shown that plasma NT-proBNP levels 
do not normalize even years after HTx. (17, 18) Other studies have found that despite 
the general decline in NT-proBNP levels after HTx, periodic increase in levels may also be 
present.(15, 19, 20)  It has been suggested that abnormal renal function (15), and high 
pulmonary capillary wedge pressures (20) may contribute to this increase. On the other 
hand, a large study of Bader et al.(15) suggested that a role for these clinical variables is 
less likely in the first 6 months after HTx.  A substantial decline post-HTx has also been 
found for CRP, (9, 21) troponin T, (22-25) and troponin I level(23) in previous studies. In the 
early post-HTx phase, a temporary elevation of IL-6 and other cytokines is seen, caused 
by surgical stress, inflammatory stimuli, infection, or myocardial ischemia.(26) As CRP is 
produced by hepatocytes under the influence of cytokines, including IL-6, it is likely that 
this affects CRP concentrations post-HTx as well.(21) Concerning troponin T, this elevation 
might be due to donor heart ischemia(23),  perioperative ischemic injury and / or trauma 
associated with surgical graft transplantation into the recipient.(22) 
Several existing studies have measured BNP repeatedly and have examined its association 
with AR. However, most of these studies have focused on diagnostic and not prognostic 
value, and have used only the single measurements concomitant to the rejection episodes 
in their analyses.(15, 27-30) These studies have rendered inconsistent results. Few studies 
have examined prognostic value of repeated measurements of NT-proBNP or BNP for 
AR. Arora et al.(9) examined changes in NT-proBNP and did not find any association with 
acute cellular rejection, while Garrido et al.(8), Kittleson et al.(7), Martinez-Dolz et al.(31) 
and Damodaran et al. (32) found positive associations between changes in BNP and NT-
proBNP and AR. None of these prognostic studies have used all the available biomarker 
measurements in their analyses. They examined baseline biomarker values or change in 
biomarkers between two timepoints. 
Studies on repeated measurements of troponin T and AR are less abundant, and these 
studies examined diagnostic, not prognostic, value of troponin T. Some studies (23, 33, 
34)  were negative, while other were positive.(24, 25, 35) Dengler et al.(25) and White 
et al.(16) demonstrated that troponin T was elevated in patients with AR occurring more 
than 3 months postoperatively. Troponin T was only measured in the sample taken at the 
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moment of biopsy in these studies, leaving the abilities of this marker to predict acute 
AR unclear. Subsequently, the same group (35) showed that the diagnostic efficiency of 
troponin T measurement improved markedly when taking into account male recipient 
gender, recipient age < 60 years, female donor gender and donor age ≥ 33 years. Chance et 
al. (22) also found that the troponin concentration was significantly higher in patients with 
rejection than in those without, and concluded that troponin T may have a role to play as 
an adjunct test to EMB in the diagnosis of AR. 
Several studies on the diagnostic value of CRP level for AR have failed to demonstrate 
significant associations.(22, 36, 37) In contrast, Martinez-Dolz et al.(21) found that CRP 
showed significant and sustained differences between patients with and without rejection 
and that low CRP levels ruled out rejection with high specificity. However, they used ROC 
curves which does not account for correlations between intra-patient measurements. 
Studies on the prognostic value of CRP include Eisenberg et al, who found that elevated 
plasma levels of CRP are associated with subsequent allograft failure in cardiac transplant 
recipients.(38) Only one baseline CRP measurement was performed. Arora et al.(9) 
examined absolute and percentage change in CRP, and found no association with AR.  
In our study, we have included all available serial biomarker measurements up to the first 
episode of AR in the analysis. Further strengths of the present study include the availability 
of a large number of biopsies (n=1136) and the consecutive repeated measurement of 
3 biomarkers, which represent various pathophysiological pathways underlying AR. 
Also, we are the first to use JM to examine the prognostic value of repeated biomarker 
measurements for AR. As described above, previous studies have mostly investigated 
diagnostic value and have often applied receiver-operating characteristics (ROC) curves, 
which focus on the biomarker measurement concurrent to the biopsy that shows AR.(21) 
Studies on prognostic value have generally applied regression models, using the difference 
between two biomarker measurements as the determinant.(7, 8) While these methods 
disregard the full temporal evolution of the biomarkers, JM takes into account the total 
number of repeated measurements available.(11) Since biomarker levels may change at 
a certain moment in time when a (subclinical) pathological state sets in, this approach 
results in less bias compared to simplified models.  Moreover, JM makes optimal use of the 
available time-to-event information because it accounts for dependence among repeated 
observations in an individual patient.(11) ROC curves and simple regression models do 
not account for such intra-individual correlations and may provide biased results.(39) JM 
is also appropriate when repeated measurements are performed at varying timepoints 
and when numbers of available repeated measurements are unequal between patients.
(39)  A limitation of JM is that it currently only allows for one determinant to be repeatedly 
measured. Nevertheless, by combining standardized values of NT-proBNP, Troponin T and 
CRP into one variable, we were able to examine their combined prognostic value. To our 
best knowledge, this has not been done before.
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Some issues relating to this study warrant consideration. Seventy-three percent of our 
patients experienced at least one rejection episode in the first year post-HTx. Although 
1-year rejection rates are known to vary among centers, ranging from 4.5%(40) to 
85.6%(41), the rate in our center may be considered as rather high. Such variations in 
rejection rates are inherent to the fact that the centers performing HTx procedures, as 
well as the pathology subspecialists who perform the actual scoring of the biopsies, 
are highly limited in number, and may display center-specific inter-observer variation. 
Nevertheless, the survival rate post-HTx in our center is known to be very high: 69% at 10 
years  (unpublished data), compared to an average of 55% at 10 years  according to the 
International Society of Heart and Lung Transplantation(42). 
The limitations of the current study include its retrospective nature. Nevertheless, all data 
required could be collected from the medical records, given that this patient population 
is under strict clinical surveillance. Furthermore, follow-up was limited to 1 year for the 
present study. This resulted in a relatively low incidence of mortality (n=5), which could 
not be used as an endpoint. 
In conclusion, high postoperative NT-proBNP, Troponin T and CRP values decline 
progressively, reaching a steady state after approximately 12 weeks post-HTx. The temporal 
evolution of these biomarkers does not predict future acute AR both in the early and late 
course of the first year post-HTx.
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Summary and conclusions
Since ‘prevention is better than cure’, predictive thinking plays an important role in 
cardiology. After all, appropriate tools for risk stratification in combination with strategies 
aiming at risk reduction should be available in order to prevent recurrent adverse 
events and mortality in patients with acquired heart disease. The aim of this thesis was 
to explore advanced methods for clinical outcome prediction in acquired heart disease, 
while overarching several methodological, statistical, laboratory and imaging techniques. 
Specifically, this objective was three fold: To perform a critical appraisal of methodological 
aspects of existing prediction models used for patients with coronary artery disease (CAD) 
(Part I); To investigate a wide range of inflammatory biomarkers as potential predictors of 
adverse events in CAD patients, and to examine their value for assessment of extent and 
composition of coronary atherosclerosis as assessed by intravascular ultrasound imaging 
(Part II), and; To evaluate diagnostic and predictive value of several, repeatedly measured, 
biomarkers in patients with heart failure and heart transplant recipients , while making use 
of advanced statistical methods (Part III). 
PART II: METHODOLOGICAL ASPECTS OF PREDICTION MODELS FOR 
CLINICAL OUTCOME IN CORONARY ARTERY DISEASE
In Chapter 2.1, we present an overview of existing models for prediction of cardiovascular 
adverse events in patients with stable, established CAD and discuss (assessment of) model 
performance. Multiple prediction models have been developed in such patients, however, 
large variation was present in classic cardiovascular risk factors, other than age and 
gender, which were included in the different models. Differences in study design, study 
populations and incidence rates may in part account for this heterogeneity. We found that 
the majority of existing studies have paid insufficient attention to model performance and 
validation. Therefore, we set out to develop and validate a series of risk prediction models 
for different endpoints, both fatal and non-fatal, in a prospective cohort consisting of over 
12,000 European patients with established CAD, making use of the EUROPA database 
(chapter 2.2). To provide an extensive framework for cardiovascular disease prediction, 
we chose to also examine PCIs and CABGs as outcomes. Most studies that have developed 
prediction models for CAD patients did not include these outcomes, nor did they examine 
these outcomes separately. While the performance of our models for the prediction of 
cardiovascular and non-cardiovascular mortality was comparable to that of previous 
existing models, we also demonstrated that model performance is considerably worse for 
non-fatal MI, PCI and CABG examined as separate outcomes. 
In Chapter 3, we describe an alternative for prognostic modeling that uses regression 
analyses of isolated patient datasets. Regression models tend to focus on one outcome 
event, and are usually based on just one baseline evaluation of the patient, thus failing 
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to take the disease process in its dynamic nature into account. This approach is only 
suitable to address relatively short-term effects, not long-term predictions. Describing the 
clinical course of a patient with CAD by a (micro-)simulation model may overcome these 
limitations. This method simulates the remaining lifetime of one single virtual patient at a 
time and builds a virtual patient population by repeating the simulation numerous times 
(Chapter 3.1). Micro-simulation models have already been developed for patients requiring 
aortic valve replacement (AVR) in order to assist with the choice of an appropriate type of 
valve, and have been implemented in the software package AVRSim. No such models have 
yet been developed for patients with established CAD. To investigate whether AVRSim can 
also be applied to any given type of disease (or disease related event), we developed a 
new software package, General Microsimulation Toolkit (GMT) (chapter 3.2). This package 
calculates the time-to-event, event-free period and life expectancy. Moreover, it facilitates 
the comparison of the outcomes for each for different treatment choices. The GMT model 
for AVR showed good agreement with the AVRSim package. This implies that GMT may be 
adapted and applied for prognostic modeling in patients with CAD. Obviously, such new 
models will need to be evaluated internally and externally before they can be used in daily 
practice. 
PART III: THE ROLE OF INFLAMMATORY BIOMARKERS IN PREDICTION 
OF CLINICAL OUTCOME IN CORONARY ARTERY DISEASE
In most cases, prediction models for CAD patients are based on established risk factors. 
However, a considerable part of adverse events during follow-up is not fully explained by 
these risk factors. Inflammation has been recognized as an important pathophysiological 
mechanism contributing to CAD. Therefore, insight into the role of inflammatory blood 
biomarkers in CAD may aid in identifying individuals at high risk of adverse events. In 
Part III, we focus on inflammatory blood biomarkers for the prediction of the extent 
and composition of coronary atherosclerosis and major adverse cardiac events (MACE). 
Moreover, we elaborate on the role of smoking, an important inflammatory stimulus. 
The studies described were performed within the ATHEROREMO-IVUS study. This study 
included 581 patients who underwent coronary angiography for acute coronary syndrome 
(ACS) (n=319) or stable angina pectoris (SAP) (n=263) and in whom intravascular ultrasound 
(IVUS) imaging of a non-culprit coronary artery was performed. Using virtual histology (VH) 
IVUS, the extent (plaque volume,  plaque burden) and composition (fibrous, fibro-fatty, 
dense calcium and necrotic core) of coronary atherosclerosis were assessed and high-risk 
lesions were identified (such as VH-IVUS derived thin-cap fibroatheroma (TCFA), lesions 
with plaque burden ≥70%, and lesions with minimal luminal area ≤4.0 mm2). Subsequently, 
these patients were followed-up for MACE for one year. 
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In chapter 4, we investigated whether several circulating cytokines, chemokines, and 
acute phase proteins are associated with IVUS-derived measures of plaque burden and 
features of plaque vulnerability, and whether they are useful for clinical risk stratification 
with regard to cardiovascular outcome. With regard to cytokines (chapter 4.1), we found 
that higher circulating tumor necrosis factor alpha (TNF-α) (pro-inflammatory cytokine) 
and lower circulating interleukin-10 (IL-10) (anti-inflammatory cytokine) are associated 
with higher coronary plaque burden and with presence of VH-TCFA lesions (for IL-10, 
in particular ‘large’ VH-TCFA lesions, i.e. VH-TCFA lesions with a plaque burden ≥ 70%). 
However, these associations did not translate into a higher incidence of MACE. On the 
other hand, in has recently been shown in the same study population that presence of 
lesions with a high plaque burden, and presence of (large) VH-TCFA lesions, are both 
independently associated with a higher MACE rate. Altogether, these findings imply that 
the deleterious effects of high TNF-α and low IL-10 do not translate into a higher MACE 
rate in the current study population. Possible explanations may include the fact that the 
magnitude of the effect of these biomarkers is small in the context of this multifactorial 
disease, or that the current study lacks statistical power to expose such an effect.
With regard to chemokines (chapter 4.2) we concluded that higher circulating monocyte 
chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α (MIP-1α) 
are associated with higher coronary plaque burden and higher percentages of necrotic core 
tissue, as well as the presence of TCFA lesions (for MIP-1α, in particular VH-TCFA lesions 
with a plaque burden ≥ 70%). We did not observe a correlation between MCP-1 and MIP-
1α concentration and occurrence of MACE. In patients who were admitted with ACS, lower 
regulated upon activation normal T cell expressed and secreted (RANTES) concentrations 
were associated with higher plaque burden. In the overall patient population, RANTES 
was also found to be independently predictive of the occurrence of adverse outcomes. Its 
association with acute cardiac events (death or ACS) seemed to be even stronger than with 
all major adverse cardiac events (death, ACS or unplanned coronary revascularization). 
This may indicate that RANTES is especially predictive for plaque rupture rather than 
plaque growth.
In chapter 4.3, we examined acute phase proteins, and demonstrated that higher 
concentrations of ferritin are associated with higher coronary plaque volume as well as 
a higher percentage of fibrofatty tissue in the coronary atherosclerotic plaque, the latter 
only in patients with acute coronary syndrome at baseline. Since serum concentrations 
of ferritin may vary in a wide range of conditions, the interpretation of ferritin level is 
complicated. Furthermore, higher concentrations of Alpha-2-Macroglobulin (α2M) were 
associated with lower percentage of fibrous tissue and higher percentage of dense calcium 
tissue in the coronary atherosclerotic plaque. However, these associations with plaque 
composition could not be further translated into associations with number of VH-TCFA 
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lesions. Finally, Plasminogen Activator Inhibitor 1 (PAI-1) was found to be predictive for the 
occurrence of MACE, which is in line with prior studies.
Altogether, these in-vivo findings suggest that the above-mentioned inflammatory 
biomarkers may play a role in extent, advanced phenotype and vulnerability of coronary 
atherosclerosis. With regard to risk stratification on cardiovascular outcome, lower 
circulating RANTES and higher circulating PAI-1 were the only biomarkers from the panel 
that we investigated, which displayed potential predictive value.  
In Chapter 5.1, we focused on cigarette smoking and its association with the extent and 
vulnerability of coronary atherosclerosis. Smoking showed a tendency towards slightly 
higher coronary plaque burden. However, no associations could be demonstrated with 
percentage necrotic core, nor with VH-IVUS derived TCFA lesions, suggesting that smoking 
has no major influence on plaque vulnerability. Lack of such an association may in part 
be explained by the possibility that plaque erosion, and not as much vulnerable plaque 
rupture, is the intermediate between smoking and cardiac adverse events, as suggested by 
earlier, histopathological studies. 
PART IV: THE ROLE OF BIOMARKERS IN PREDICTION OF CLINICAL 
OUTCOME IN HEART FAILURE AND AFTER HEART TRANSPLANTATION 
CAD remains by far the most common cause of heart failure. Due to improved treatment, 
CAD mortality rate has declined, but survivors are often left with damaged myocardium 
resulting in left ventricular dysfunction and, potentially, clinical heart failure. Blood 
biomarkers may potentially be a valuable tool in risk stratification of these patients. 
Although many studies have investigated the diagnostic and predictive value of new 
biomarkers in heart failure, the majority of these studies included patients with heart failure 
with reduced ejection fraction (HFREF) only. Limited data are available on biomarkers in 
heart failure with normal ejection fraction (HFNEF), in spite of its ominous prognosis. In 
Chapter 6.1, we provide an overview of blood biomarkers that have been found to be 
associated with the occurrence and prognosis of HFNEF. Several biomarkers and biomarker 
categories, including biomarkers of myocyte stress, inflammation, extracellular matrix 
remodeling, growth differentiation factor  15 (GDF-15), cystatin C, resistin, and galectin-3, 
appear to be potentially promising diagnostic tools in HFNEF. Some of them, including 
TNF-a, interleukin-6, amino-terminal propeptide of procollagen type I (PINP), amino-
terminal propeptide of procollagen type III (PIIINP), osteopontin, and cystatin C, may carry 
predictive value as well. 
In patients with end stage heart failure, treatment options have improved in recent years 
and include a combination of drugs, mechanical devices and surgical procedures which may 
improve symptoms and survival. Nevertheless, for some patients these treatment options 
are not sufficient, and these patients might benefit most from heart transplantation. 
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Acute allograft rejection (AR) is a common problem after heart transplantation (HTx) and 
is one of the major causes of cardiac graft loss. In Chapter 7, we examine diagnostic and 
predictive value of the biomarkers NT-pro-B-type natriuretic peptide (NT-proBNP), cardiac 
troponin T and C-reactive protein (CRP) for AR. Existing studies on this topic have provided 
inconsistent results, in part due to differences in methodology. Of further note is that the 
methodology applied by these studies was not always appropriate.
We found that CRP level carries diagnostic value for concomitant presence of AR in the 
first year after HTx (chapter 7.1). However, discriminative ability of CRP was too poor to 
replace endomyocardial biopsy. To assess the prognostic value (chapter 7.2), we used so-
called Joint Modeling (JM), with combines mixed models (in our case for serial biomarker 
measurements) with Cox proportional hazards models (in our case for the risk of AR). 
Joint modeling makes optimal use of the available time-to-event information because it 
accounts for dependence among repeated observations in an individual patient. We found 
that none of the three biomarkers we investigated were able to predict future AR during 
the first year after HTx. 
CONCLUSIONS 
The main conclusions of this thesis may be summarized as follows:
- Existing prediction models for adverse cardiac events in patients with CAD have mostly 
used regression analyses and have paid limited attention to model performance and 
validation. Micro-simulation is a promising method that could improve prediction 
models by taking into account the dynamic nature of the disease process.
- Several cytokines (TNF α, IL-10), chemokines (MCP-1, MIP-1α, RANTES) and acute phase 
proteins (ferritin, α2M) are associated with various aspects of extent and composition 
of coronary atherosclerosis, and RANTES and PAI-1 are associated with occurrence 
of MACE. Thus, these inflammatory biomarkers are potential candidates whose 
incremental value should be evaluated for prediction models of recurrent events in 
CAD patients
- Several biomarkers and biomarker categories, including biomarkers of myocyte stress, 
inflammation, extracellular matrix remodelling, GDF-15, cystatin C, resistin, and 
galectin-3, appear to be potentially promising diagnostic tools in HFNEF. Some of them, 
including TNF-a, IL-6, PINP, PIIINP, osteopontin, and cystatin C, may carry predictive 
value as well.
- CRP level carries diagnostic value for concomitant presence of AR in the first year after 
heart transplantation. However, discriminative ability of CRP is too poor to replace 
endomyocardial biopsy. None of the repeatedly measured biomarkers which were 
investigated (NT-proBNP, troponin T nor CRP) was able to predict future AR during the 
first year after heart transplantation.
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FUTURE DIRECTIONS
The above findings illustrate that combining advanced laboratory, imaging and statistical 
techniques may lead to additional insights into prediction of adverse cardiovascular 
events in patients with acquired heart disease. As such, further research combining 
these aspects is warranted. An example of an ongoing study that covers a wide range of 
sophisticated, multidisciplinary  methods is the ‘Serial Biomarker meaSurements and new 
echocardiographic techniques in chronic Heart Failure patients result in Tailored prediction 
of prognosis’ (Bio-SHiFT) study. In this study, patients with chronic heart failure are included, 
blood samples are drawn every 3 months during a follow-up period of up to 2,5 years and 
stored for future biomarker determination, and echocardiography (including TDI, Speckle 
tracking and 3D-echocardiography) is performed repeatedly. The results of this study are 
expected to provide information on individual patterns of change in biomarker levels and 
cardiac structure and function, and may thus carry potential to improve individual risk 
prediction and to herewith contribute to personalized medicine. 
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SAMENVATTING EN CONCLUSIES
Omdat voorkomen gewoonlijk beter is dan genezen, speelt voorspellend denken een 
belangrijke rol in de cardiologie. Veelal worden daarbij schema’s of ‘modellen’ gebruikt die 
kenmerken van patiënten met hart- en vaatziekten koppelen aan het risico op medische 
(nood)situaties, zoals hartinfarct, herseninfarct of overlijden (engelse afkorting: MACE). 
De behandeling wordt vervolgens afgestemd op de individuele situatie van de patiënt, 
rekening houdend met de hoogte van genoemd risico.
Het is evident dat de kwaliteit van de risico-voorspelling en daarmee (indirect) die van de 
behandeling afhankelijk is van de prestatie van het gebruikte model. Dit proefschrift had 
zowel ten doel de prestaties in kaart te brengen van bestaande risico-voorspellingsmodellen 
voor patiënten met verworven hart- en vaatziekten, als ook om deze, waar mogelijk, 
te verbeteren. Daarbij is gebruik gemaakt van geavanceerde statistische methoden, 
intravasculaire beeldvorming en laboratorium technieken voor het bepalen van 
zogenaamde bloed biomarkers. 
Deel I van dit proefschrift bevat een kritische beoordeling van methodologische aspecten 
van bestaande risico-voorspellingsmodellen die gebruikt worden voor patiënten met 
coronaire hartziekte (CAD). In deel II wordt een  breed scala aan inflammatoire biomarkers 
onderzocht als mogelijke voorspellers van het beloop van coronaire atherosclerose, zowel 
als van het ontstaan van medische (nood)situaties bij CAD patiënten. Deel III beschrijft 
de diagnostische en voorspellende waarde van verschillende, herhaaldelijk gemeten, 
biomarkers bij patiënten met hartfalen en bij patiënten die een harttransplantatie hebben 
ondergaan.
DEEL II: METHODOLOGISCHE ASPECTEN VAN VOORSPELLENDE 
MODELLEN VAN KLINISCHE UITKOMST BIJ CORONAIRE HARTZIEKTE 
In hoofdstuk 2.1 presenteren we een overzicht van de bestaande risico-
voorspellingsmodellen voor cardiovasculaire (nood)situaties bij stabiele CAD patiënten. 
Tevens bespreken en beoordelen we de model prestaties. Voor deze patiëntengroep zijn 
er meerdere risico-voorspellingsmodellen ontwikkeld. Leeftijd en geslacht worden in alle 
modellen als risicofactor gebruikt, maar er bestaat grote variatie in het gebruik van de 
overige klassieke cardiovasculaire risicofactoren. Deze heterogeniteit kan deels verklaard 
worden door verschillen in onderzoeksopzet, onderzoekspopulatie en incidentie. We 
vonden dat het merendeel van de bestaande studies onvoldoende aandacht hebben 
besteed aan model prestatie en validatie. Om deze reden hebben we besloten een reeks 
risico-voorspellingsmodellen te ontwikkelen en te valideren voor verschillende, zowel 
fatale als niet-fatale, eindpunten. Om deze modellen te ontwikkelen hebben we een 
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prospectief cohort gebruikt, bestaande uit meer dan 12.000 Europese CAD patiënten, 
geselecteerd uit de EUROPA-database (hoofdstuk 2.2).  
Om de risico-voorspellingsmodellen voor hart- en vaatziekten zo optimaal mogelijk te 
kunnen onderzoeken hebben we ervoor gekozen om ook de PCI’s en CABG’s als uitkomsten 
mee te nemen. De meeste studies die risico-voorspellingsmodellen hebben ontwikkeld 
voor CAD patiënten hebben deze uitkomsten niet onderzocht als gecombineerd eindpunt, 
noch afzonderlijk van elkaar. We hebben aangetoond dat de prestatie van onze modellen 
voor het voorspellen van cardiovasculaire en niet-cardiovasculaire doodsoorzaken 
vergelijkbaar zijn met die van eerdere bestaande modellen. Daarnaast hebben we 
laten zien dat de model prestaties voor de niet-fatale uitkomsten MI, PCI en CABG als 
afzonderlijke uitkomsten, aanzienlijk slechter zijn.
In hoofdstuk 3 beschrijven we zogenaamd micro-simulatie als een alternatieve benadering 
voor risico-schatting bij CAD patiënten. Regressiemodellen hebben de neiging zich te 
richten op slechts één uitkomstmaat, terwijl zij meestal gebaseerd zijn op slechts één 
evaluatiemoment van de patiënt, namelijk aan het begin van de studie. Hierdoor slagen 
deze modellen er niet in om rekening te houden met het veranderingen die tijdens het 
ziekteproces kunnen optreden. Bijvoorbeeld, een patiënt die aan het begin van de studie 
geen diabetes had kan dit tijdens de studie wel ontwikkelen. Dit zorgt ervoor dat deze 
benadering alleen geschikt is voor het voorspellen van relatief korte termijn effecten, 
en niet voor lange termijn voorspellingen. Een (micro-) simulatiemodel, die het klinisch 
verloop van een patiënt met CAD beschrijft kan dan uitkomst bieden. Dit model is namelijk 
in staat om het klinisch verloop te simuleren. Van een individuele patiënt kan de resterende 
levensduur worden gesimuleerd. Door deze simulatie vele malen te herhalen kan een 
virtuele patiëntenpopulatie worden gecreëerd van (bij aanvang) identieke patiënten 
(hoofdstuk 3.1). Op deze wijze kan het klinisch verloop van een individuele patiënt worden 
ingeschat, waarbij rekening wordt gehouden met medische situaties die zich ‘onderweg’ 
voordoen. Voor patiënten die aortaklepvervanging (AVR) moeten ondergaan waren al 
micro-simulatiemodellen ontwikkeld. Deze modellen helpen met de keuze van de meest 
geschikte type klep en zijn in het softwarepakket AVRSim geïmplementeerd en gevalideerd. 
Voor het bouwen van micro-simulatie modellen bij CAD patiënten ontwikkelden we een 
nieuw, generiek softwarepakket, “General Microsimulatie Toolkit” (GMT) (hoofdstuk 3.2). 
Dit pakket is in staat om de time-to-event, event-free period en de levensverwachting 
te berekenen. Verder kan het op een eenvoudige wijze een vergelijking maken van de 
resultaten voor verschillende behandelkeuzes. Wij hebben het AVR probleem uitgewerkt 
met het GMT pakket en het vergeleken met AVRSim. Beide resultaten kwamen goed 
overeen. . Bij vervolgonderzoek kan GMT gebruikt worden voor risico-voorspelling bij 
patiënten met CAD.
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DEEL III: DE ROL VAN INFLAMMATOIRE BIOMARKERS BIJ HET 
VOORSPELLEN VAN DE KLINISCHE UITKOMST VAN CORONAIRE 
HARTZIEKTE 
In de meeste gevallen worden risico-voorspellingsmodellen voor het optreden van MACE 
bij CAD patiënten ontwikkeld op basis van bekende risicofactoren, zoals bijvoorbeeld roken, 
suikerziekte en hoge bloeddruk. Veel MACEs die zich tijdens de follow-up voordoen kunnen 
echter niet voorspeld worden op basis van bekende risicofactoren. Er is dus ruimte voor 
verbetering van risico-voorspellingsmodellen. Wij hebben die gezocht bij verschillende 
pathofysiologische concepten. Inflammatie is een erkend pathofysiologisch mechanisme 
dat een bijdrage levert aan het ontstaan van CAD. Daarom kan het verkrijgen van inzicht 
in de rol van inflammatoire biomarkers helpen bij het identificeren van mensen met CAD 
die een hoog risico hebben op het optreden van MACEs. In deel III richten we ons op 
inflammatoire biomarkers bij het voorspellen van het optreden en de ernst van een MACE. 
Daarnaast onderzoeken we een belangrijke stimulus die aanzet tot een inflammatoire 
respons, namelijk roken.
Voor de onderzoeken uit deel III hebben we gebruik gemaakt van de data uit de 
ATHEROREMO-IVUS studie. Deze studie omvatte 581 patiënten die coronaire beeldvorming 
ondergingen middels angiografie vanwege een “acuut coronair syndroom” (ACS) (n = 
319) of “stabiele angina pectoris” (SAP) (n = 263) en bij wie intravasculaire beeldvorming 
(IVUS) was uitgevoerd van een kransslagader. Met behulp van virtuele histologie (VH) 
IVUS, werd de mate (plaque volume, plaque burden) en samenstelling (fibrous, fibro-fatty, 
dense calcium and necrotic core) van coronaire atherosclerose beoordeeld en werden 
hoog-risico laesies geïdentificeerd (zoals “thin-cap fibroatheroma” (TCFA) laesies, plaque 
burden van ≥ 70%, en letsels met minimale luminale oppervlakte ≤ 4,0 mm2). Vervolgens 
werd bij deze patiënten gekeken of er een MACE optrad in het eerste jaar na de ingreep. 
In hoofdstuk 4 hebben we onderzocht of een aantal circulerende biomarkers, namelijk 
cytokines, chemokines en acute fase eiwitten, kunnen worden geassocieerd met metingen 
verricht met IVUS. Voor cytokinen (hoofdstuk 4.1), vonden we dat hogere waardes 
van circulerend tumor necrose factor alfa (TNF-α) (een pro-inflammatoire cytokine) en 
lagere waardes van circulerend interleukine-10 (IL-10) (een anti-inflammatoire cytokine) 
geassocieerd waren met hogere coronaire plaque burden en de aanwezigheid van VH-TCFA 
laesies. Bij  IL-10 betrof het voornamelijk “grote” VH-TCFA laesies, namelijk VH-TCFA leasies 
met een plaque burden van ≥ 70%. Echter, de hoge waardes van TNF-α en lage waardes IL-
10 lieten zich echter niet vertalen in hogere percentages MACE in de huidige studiegroep. 
Mogelijke verklaringen kunnen zijn dat de grootte van het effect van deze biomarkers 
slechts klein is in de context van deze multifactoriële ziekte ofwel dat de huidige studie 
statistische power mist om een dergelijk effect aan te tonen.
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Wat de door ons onderzochte chemokinen betreft (hoofdstuk 4.2), vonden wij dat 
hogere waardes van circulerend monocyt chemoattractant eiwit-1 (MCP-1) en macrofaag 
inflammatoir proteïne-1α (MIP-1α) geassocieerd zijn met hogere coronaire plaque burden, 
hogere percentages necrotic core, en de aanwezigheid van TCFA laesies (voor MIP-1α 
betreft het vooral VH-TCFA letsels met een plaque burden van ≥ 70%). We hebben geen 
associatie gevonden tussen de concentratie van MCP-1 en MIP-1α en het optreden van 
MACE. 
Bij patiënten die werden opgenomen met ACS, waren lagere concentraties van regulated 
upon activation normal T cell expressed and secretes (RANTES) geassocieerd met de 
aanwezigheid van hogere plaque burden. ACS en niet-ACS patiënten samengenomen, 
bleek de RANTES concentratie ook een onafhankelijke voorspeller voor het optreden van 
MACE. De associatie met acute cardiale gebeurtenissen (overlijden of ACS) leek nog sterker 
te zijn dan bij alle andere belangrijke cardiovasculaire gebeurtenissen (overlijden, ACS of 
ongeplande coronaire revascularisatie). Dit kan erop wijzen dat de RANTES concentratie 
vooral voorspellend is voor een plaque ruptuur in plaats van plaque groei.
In hoofdstuk 4.3 onderzochten we de acute fase eiwitten. Hogere concentraties van 
ferritine waren geassocieerd met een hoger coronair plaque volume alsmede, in ACS 
patiënten, een hoger percentage van fibrofatty weefsel in de coronaire atherosclerotische 
plaque  Aangezien de concentraties van ferritine in het serum verhoogd kunnen zijn bij 
verschillende medische omstandigheden, bijvoorbeeld bij een acute infectie of bij patiënten 
met chronische nierfalen, is de interpretatie van een verhoogde ferritine concentratie niet 
triviaal. Een hogere concentratie van alfa-2-Macroglobuline (a2M) was geassocieerd met 
een lager percentage bindweefsel en een hoger percentage calcium tissue in de coronaire 
atherosclerotische plaque. 
Samenvattend, deze resultaten suggereren dat de hierboven genoemde inflammatie 
biomarkers een rol spelen in de fenotypering (verzameling van waarneembare kenmerken) 
en kwetsbaarheid van coronaire atherosclerose. Met betrekking tot de risico inschatting van 
MACE, waren lagere waardes van het circulerend RANTES en hogere waardes van circulerend 
PAI-1 de enige onderzochte biomarkers die potentiële voorspellende waarde hadden. 
In hoofdstuk 5.1, hebben we ons gericht op de relatie tussen het rookgedrag van patiënten 
en de met behulp van VH-IVUS in beeld gebrachte coronaire atherosclerose. Rokers lieten 
een trend zien naar hogere coronaire plaque burden. Er kon echter geen associatie worden 
aangetoond met het percentage van nectrotic core, noch met VH-IVUS gemeten TCFA 
laesies, wat suggereert dat roken geen grote invloed heeft op de kwetsbaarheid van de 
plaque. Het ontbreken van een dergelijk verband kan deels worden verklaard doordat de 
plaque mogelijk eerder wordt aangetast, maar niet zozeer scheurt. 
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DEEL IV: DE ROL VAN BIOMARKERS IN HET VOORSPELLEN VAN DE 
KLINISCHE UITKOMST BIJ HARTFALEN EN NA HARTTRANSPLANTATIE 
Het acute hartinfarct de meest voorkomende oorzaak van hartfalen. Als gevolg van 
betere behandelingen tijdens de acute fase, is het sterftecijfer na een hartinfarct gedaald. 
Helaas hebben mensen die overleven vaak een beschadigde hartspier. Dit leidt tot een 
verslechterde linkerkamerfunctie en klinisch hartfalen. Bloed biomarkers kunnen mogelijk 
een waardevol instrument zijn bij de risico inschatting van deze patiënten.
De meeste studies die de diagnostische en voorspellende waarde van biomarkers 
bij hartfalen hebben onderzocht, richtten zich op patiënten met een verminderde 
ejectiefractie (HFREF). Er zijn slechts beperkte gegevens beschikbaar over biomarkers in 
patiënten met hartfalen met normale ejectiefractie (HFNEF). In hoofdstuk 6.1, geven we 
een overzicht van de bloed biomarkers die worden geassocieerd met het optreden en 
de prognose van HFNEF. Verscheidene biomarkers en biomarker categorieën, waaronder 
biomarkers voor myocyten stress, ontstekingen, extracellulaire matrix remodelering,  groei 
differentiatiefactor 15 (GDF-15), cystatine C, resistin en galectine-3, lijken veelbelovend 
voor diagnostische toepassingen. De biomarkers  TNF-a, interleukine-6, “amino-terminale 
propeptide van het type I procollageen” (PINP), “amino-terminale propeptide van type III 
procollageen” (PIIINP), osteopontine en cystatine C kunnen ook prognostisch van belang zijn.
De afgelopen jaren zijn de behandelopties voor patiënten met eindstadium hartfalen 
verbeterd. Symptomen kunnen worden verlicht, en overleving verbeterd door een 
combinatie van medicijnen, mechanische ondersteuning van het hart en chirurgische 
behandelingsopties. Helaas zijn deze behandelingen niet voor alle patiënten toereikend. 
Deze ‘uitbehandelde’ patiënten zouden profijt kunnen hebben van een harttransplantatie 
(HTx). Acute allograft afstoting (AR) is een veel voorkomend probleem na HTx en is een 
van de belangrijkste oorzaken van verlies van het harttransplantaat. In hoofdstuk 7 
onderzoeken we diagnostische en voorspellende waarde van de biomarkers NT-pro-B-
type natriuretisch peptide (NT-proBNP), troponine T en C-reactief proteïne (CRP) voor AR. 
Bestaande studies over dit onderwerp bevatten inconsistente resultaten, mede als gevolg 
van verschillen in methodologie. Daarnaast was bij deze studies niet altijd duidelijk welke 
methodologie was toegepast.
Wij vonden dat het optreden van AR in het eerste jaar na HTx samenging met een 
hogere concentratie van CRP(hoofdstuk 7.1). Echter, het diagnostisch vermogen van CRP 
was te gering om endomyocardiale biopsie te vervangen. Om de prognostische waarde 
(hoofdstuk 7.2) te beoordelen, gebruikten we een geavanceerde statistische techniek 
die  Joint Modeling (JM) wordt genoemd. Deze methode houdt rekening met herhaalde 
metingen in een individuele patiënt, maar ook met verschillen tussen de patiënten in de 
database. We vonden dat geen van de onderzochte biomarkers gebruikt konden worden 
voor het voorspellen van AR gedurende het eerste jaar na HTx.
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CONCLUSIES
De belangrijkste conclusies van dit proefschrift zijn de volgende: 
- Bestaande risico-voorspellingsmodellen voor ongunstige cardiale uitkomsten 
bij patiënten met CAD gebruiken veelal regressie-analyses en besteden slechts 
beperkte aandacht aan de prestatie en validatie van de modellen. Micro-simulatie 
houdt rekening met de dynamische aard van het ziekteproces en is daarom een 
veelbelovende methode die risico-voorspellingsmodellen zou kunnen verbeteren. 
- Verschillende cytokinen (TNF α, IL-10), chemokinen (MCP-1, MIP-1α, RANTES) en 
acute fase eiwitten (ferritine, a2M) zijn geassocieerd met verschillende aspecten 
van de omvang en samenstelling van coronaire atherosclerose (gemeten met VH-
IVUS), terwijl RANTES en PAI -1 geassocieerd zijn met het optreden van MACE. 
Deze inflammatoire biomarkers zijn daarom potentiële kandidaten om te worden 
opgenomen in voorspellingsmodellen voor het optreden van MACE bij CAD patiënten. 
Verder onderzoek in dit verband is nuttig en nodig.
- Verschillende biomarkers en biomarker categorieën, waaronder biomarkers voor 
myocyte stress, inflammatie, extracellulaire matrix remodelering, GDF-15, cystatine 
C, resistin en galectin-3, lijken veelbelovende diagnostische hulpmiddelen in HFNEF. 
Sommige, waaronder TNF-a, IL-6, PINP, PIIINP, osteopontine en cystatine C kunnen ook 
als hulpmiddel dienen bij het voorspellen van prognose.
- Het optreden van van AR in het eerste jaar na harttransplantatie gaat samen met 
een verhoogde CRP concentratie. Echter, het diagnostisch vermogen van CRP is 
te gering om endomyocardiale biopsie te vervangen. Geen van de herhaaldelijk 
gemeten biomarkers die werden onderzocht (NT-proBNP, troponine T of CRP) kon 
voorspellen of er gedurende het eerste jaar na harttransplantatie AR zou optreden. 
TOEKOMSTIGE RICHTINGEN
De bovenstaande bevindingen illustreren dat het combineren van geavanceerde 
laboratorium technieken, beeldvorming en statistische technieken kunnen leiden tot 
aanvullende inzichten in de voorspelling van een medische (nood)situatie bij patiënten 
met verworven hart- en vaatziekten. Daarom is verder onderzoek, die deze aspecten 
combineert, wenselijk. Een voorbeeld van een lopend onderzoek dat een breed scala van 
geavanceerde, multidisciplinaire methoden gebruikt, is de Serial Biomarker meaSurements 
and new echocardiographic techniques in chronic Heart Failure patients result in Tailored 
prediction of prognosis’ (Bio-shift) studie. In deze studie worden patiënten met chronisch 
hartfalen geїncludeerd. Bloedmonsters worden tijdens een follow-up periode van maximaal 
2,5 jaar elke 3 maanden verzameld en opgeslagen voor toekomstig biomarker onderzoek, 
tevens wordt er herhaaldelijk echografisch onderzoek uitgevoerd.  De verwachting is dat de 
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resultaten van deze studie informatie  zullen geven over individuele veranderingspatronen 
betreft biomarkers en de structuur en functie van het hart, en hiermee potentie heeft 
om de individuele risicovoorspelling te verbeteren en bijdraagt aan geneeskunde die zich 
specifiek richt op de patiënt in kwestie.
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